Stable aqueous formulations of anti-adrenomedullin (adm) antibodies or anti-adm antibody fragments
By adding arginine, trehalose and surfactant to the antibody preparation, combined with the appropriate pH range, the denaturing and aggregation of antibodies during storage and transportation is solved, and high concentration of biological activity and stability is achieved. It is suitable for Anti-adrenal medullin antibody preparations with multiple injection routes.
Patent Information
- Application Number
- CN202380036069.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-15
- Filing Date
- 2023-03-15
- Publication Date
- 2024-12-03
AI Technical Summary
Existing antibody preparations are prone to denature, oxidation or aggregation during storage and transportation, resulting in the loss of protein activity and structural integrity, especially when used at high concentrations, making it difficult to maintain biological activity and antigen binding efficacy, limiting their application pathway.
Develop an aqueous pharmaceutical preparation containing human or humanized anti-adrenal medullin (ADM) antibodies or anti-adrenal medullin antibody fragments that combine arginine, trehalose and surfactants to develop appropriate pH ranges to enhance Stability and anti-aggregation of antibodies.
It realizes the stable and high-concentration biological activity of the antibody in solution, and is suitable for parenteral administration, including intravenous, intramuscular, intraperitoneal, intradermal or subcutaneous injection, prolongs the half-life of the antibody, reduces side effects, and improves the stability of the drug. and security.
Smart Images

Figure BDA0005099751150000381 
Figure BDA0005099751150001211 
Figure BDA0005099751150001221
Abstract
Description
[0001] The present invention relates to the field of pharmaceutical preparations of antibodies. Specifically, the subject matter of the present invention relates to a stable liquid antibody preparation comprising arginine, trehalose, a surfactant and histidine, and a pharmaceutical preparation and use thereof. Background Art
[0002] Antibody preparations for treatment or prevention purposes require stabilizers to prevent the loss of protein activity or structural integrity caused by the influence of denaturation, oxidation or aggregation during storage and transportation before use. These problems are aggravated by the presence of high levels of antibodies generally required for disease treatment. The main purpose of antibody preparation development is to maintain the antibody, its solubility, stability and antigen binding efficacy. It is particularly important to avoid particles from aggregating in solution, which requires aseptic filtration before intravenous or subcutaneous administration and limits the route of administration. The preparation of antibody preparations especially requires careful selection of these factors to avoid protein denaturation and loss of antigen binding activity. Therefore, a stable aqueous antibody preparation is needed, which supports stable high concentrations of biologically active antibodies in solution and is suitable for parenteral administration, including intravenous, intramuscular, intraperitoneal, intradermal or subcutaneous injection.
[0003] In addition, multiple diseases or ailments can have common, partially non-specific symptoms that are unpleasant to unbearable for the individual suffering from them. Usually, individuals experiencing more than one symptom need to take several drugs to experience the relief of these symptoms. There is a constant demand for new treatments or prevention forms of symptoms associated with many different potential diseases or ailments. Specifically, providing a drug or medicament that can be used to treat or prevent more than one symptom associated with a potential disease or ailment will be helpful.
[0004] The peptide adrenomedullin (ADM) was first described in 1993 ( Kitamura K. et al., 1993. Biochemicaland BiophysicalResearchCommunications Vol.192(2):553-560 ) is a novel antihypertensive peptide consisting of 52 amino acids, which was isolated from human pheochromocytoma.
[0005] In the same year, a cDNA encoding a precursor peptide comprising 185 amino acids and the complete amino acid sequence of the precursor peptide were also described.
[0006] The precursor peptide which comprises, among other things, a signal sequence of 21 amino acids at the N-terminus is referred to as "pre-pro-adrenomedullin" (pre-proADM). In the present description, all designated amino acid positions are generally related to pre-proADM comprising 185 amino acids. The peptide adrenomedullin (ADM) is a peptide comprising 52 amino acids (SEQ ID NO: 13) and comprises amino acids 95 to 146 of pre-proADM, which is formed from pre-proADM by proteolytic cleavage. To date, only a few of the peptide fragments formed in the cleavage of pre-proADM have been more accurately characterized, in particular the physiologically active peptide adrenomedullin (ADM) and "PAMPs", which are peptides comprising the 20 amino acids (22-41) following the 21 amino acids of the signal peptide in pre-proADM. The discovery and characterization of ADM in 1993 triggered an intensive research campaign, the results of which have been summarized in various review articles, in the context of this specification, particular reference is made to the article in the issue of the journal "Peptides" devoted to ADM ( Editor-in-Chief, Takahashi K. 2001. Peptides 22: 1691) and (Eto T. 2001. Peptides 22: 1693-1711 A further review is (Hinson et al., 2000. Endocrine Reviews 21(2):138-167 In scientific studies to date, it has been found, among other things, that ADM can be considered a multifunctional regulatory peptide. It is released into the circulation in an inactive form extended by glycine ( Kitamura K. et al., 1998. Biochem. Biophys. Res. Commun.2 44(2):551-555 There is also a binding protein ( Pio R. et al., 2001. The Journal of Biological Chemistry 276(15):12292-12300 ), which is specific for ADM and may also regulate the effects of ADM. The most important physiological effect of ADM and PAMPs studied so far is the effect on blood pressure.
[0007] ADM is a potent vasodilator and it is possible to associate the hypotensive effect with a specific peptide segment in the C-terminal portion of ADM. It has also been found that the physiologically active peptide PAMP formed from pre-proADM mentioned further above also exhibits a hypotensive effect, even though it appears to have a different mechanism of action from ADM.
[0008] It has also been found that the ADM concentrations that can be measured in the circulation and other biological fluids are significantly higher in many pathological conditions than those found in healthy controls. Thus, ADM levels are significantly increased in patients with congestive heart failure, myocardial infarction, renal disease, hypertensive disorders, diabetes, in the acute phase of shock, and in sepsis and septic shock, although to varying degrees. In some of these pathological conditions, PAMP concentrations are also increased, but plasma levels are lower relative to ADM (Eto, T., supra).
[0009] It is also known that abnormally high concentrations of ADM are observed in sepsis, and the highest concentrations of ADM are observed in septic shock (references (Eto, T., supra) and ( Hirata et al., Journal of ClinicalEndocrinologyandMe tabolism1996.81(4):1449-1453; Ehlenz K. et al., 1997. Exp Clin Endocrinol Diabetes 105:156-162); Tomoda Y. et al., 2001. Peptides 22: 1783-1794; Ueda S. et al., 1999. Am. J. Res pir. Crit. Care Med. 160:132-136; and Wang P. Peptides 2001. 22:1835-1840 ).
[0010] WO-A1 2004 / 097423 describes the use of antibodies against adrenomedullin in the diagnosis, prognosis and treatment of cardiovascular disorders. Treatment of diseases by blocking ADM receptors has also been described in the art (e.g. WO-A1 2006 / 027147, PCT / EP2005 / 012844), the diseases may be sepsis, septic shock, cardiovascular disease, infection, skin disease, endocrine disease, metabolic disease, gastrointestinal disease, cancer, inflammation, blood disease, respiratory disease, musculoskeletal disease, nervous system disease, urinary system disease.
[0011] It is reported that in the early stages of sepsis, ADM improves cardiac function and blood supply in the liver, spleen, kidney and small intestine. ADM neutralizing antibodies neutralize the above effects in the early stages of sepsis (Wang, P., "Adrenomedullin and cardiovascular responses in sepsis", Peptides, Vol. 22, pp. 1835-1840 (2001).
[0012] For other diseases, blocking ADM may be beneficial to a certain extent. However, if ADM is completely neutralized, it may also be harmful, because several physiological functions may require a certain amount of ADM. In many reports, it is emphasized that the administration of ADM may be beneficial in certain diseases. In contrast, in other reports, ADM is reported to be life-threatening when administered in certain conditions.
[0013] The art describes the use of ADM in combination with ADM binding protein 1 to treat sepsis and septic shock. It is speculated that treating septic animals with ADM and ADM binding protein 1 prevents the transition to late sepsis. It must be noted that in living organisms, ADM binding protein (complement factor H) is present in high concentrations in the circulation of the organism (Pio et al.: Identification, characterization, and physiological actions of factor H as an Adrenomedullin binding Protein present in Human Plasma, Microscopy Res. and Technique, 55: 23-27 (2002); and Martinez et al., Mapping of the Adrenomedullin-Binding domains in Human Complement factor H, Hypertens Res Vol. 26, Suppl (2003), S56-59).
[0014] In a survival study in CLP-induced septic mice, the efficacy of a non-neutralizing antibody targeting the N-terminus of ADM was investigated. Pre-treatment with the non-neutralizing antibody resulted in a reduction in catecholamine infusion rates, renal dysfunction, and ultimately improved survival ( Struck et al., 2013. Intensive Care Med Exp 1(1):22; Wagner et al., 2013.IntensiveCareMed Exp1(1):21 ).
[0015] As a result of these positive results, an N-terminally humanized version of the anti-ADM antibody, named Adrecizumab, was developed for further clinical development. The beneficial effects of Adrecizumab on vascular barrier function and survival were recently demonstrated in preclinical models of systemic inflammation and sepsis ( Geven et al., 2018.Shock50(6):648-654). In this study, pretreatment with Adrecizumab attenuated renal vascular leakage in endotoxemic rats and CLP-induced septic mice, which coincided with increased renal expression of the protective peptide Ang-1 and decreased expression of the harmful peptide vascular endothelial growth factor. In addition, pretreatment with Adrecizumab increased 7-day survival from 10% to 50% (single dose administration) and from 0% to 40% in CLP-induced septic mice. Of particular interest is the proposed mechanism of action of Adrecizumab. Both animal and human data revealed an effective dose-dependent increase in circulating ADM after administration of the antibody. Based on pharmacokinetic data and the lack of increase in MR-proADM (an inactive peptide fragment derived from the same prohormone as ADM), the higher circulating ADM levels cannot be explained by increased production.
[0016] A mechanistic explanation for this increase may be that the excess of circulating antibodies may expel ADM from the interstitium into the circulation, because ADM is small enough to cross the endothelial barrier, while antibodies cannot (Geven et al., 2018. Shock. 50(2):132-140; and Voors et al., J. Eur J Heart Fail. 2019 Feb; 21(2):163-171). In addition, the binding of antibodies to ADM results in an increase in the half-life of ADM. Although NT-ADM antibodies partially inhibit ADM-mediated signaling, the large increase in circulating ADM leads to an overall "net" increase in ADM activity in the blood compartment, where it exerts beneficial effects on EC (mainly barrier stabilization), while the deleterious effects of ADM in the interstitium on VSMC (vasodilation) are reduced.
[0017] WO2013 / 072510 describes a non-neutralizing anti-ADM antibody for use in treating a serious chronic or acute disease or acute condition in a patient to reduce the risk of death in the patient.
[0018] WO2013 / 072511 describes a non-neutralizing anti-ADM antibody for use in treating a chronic or acute disease or acute condition in a patient to prevent or alleviate organ dysfunction or organ failure.
[0019] WO2013 / 072512 describes a non-neutralizing anti-ADM antibody, which is an ADM stabilizing antibody that prolongs the half-life (t 1 / 2 Half retention time). This ADM stabilized antibody blocked the biological activity of ADM to less than 80%.
[0020] WO2013 / 072513 shows that in patients with chronic or acute diseases or acute conditions requiring stabilization of circulation, anti-adrenomedullin (ADM) antibodies or anti-adrenomedullin antibody fragments or anti-ADM non-Ig scaffolds stabilize the patient's blood circulation and reduce the patient's need for vasopressors such as catecholamines.
[0021] WO2013 / 072514 shows that anti-adrenomedullin (ADM) antibodies or anti-adrenomedullin antibody fragments or anti-ADM non-Ig scaffolds can be effectively used to regulate fluid balance in patients with chronic or acute diseases or acute diseases, especially patients with fluid imbalance in the ICU (intensive care unit).
[0022] WO2017 / 182561 describes a method for determining the total amount of DPP3 or active DPP3 in a patient sample to diagnose a disease associated with a necrotic process. It further describes a method for treating a necrosis-related disease by an antibody against DPP3.
[0023] The inventors have now discovered that treatment with anti-adrenomedullin (ADM) antibodies or anti-adrenomedullin antibody fragments may be particularly effective in treating patients suffering from diseases associated with impaired vascular integrity.
[0024] Therefore, there is a need to provide stable aqueous formulations of anti-adrenomedullin (ADM) antibodies. Summary of the invention
[0025] Although the invention will be described with respect to specific embodiments, this description should not be construed in a limiting sense.
[0026] As used in this specification and claims, singular forms include the corresponding plural forms unless the context clearly dictates otherwise.
[0027] In the context of the present invention, the terms "about" and "approximately" represent an interval of accuracy that a person skilled in the art will understand still ensures the technical effect of the feature in question. The terms generally represent a deviation of ±20%, preferably ±15%, more preferably ±10%, and even more preferably ±5% from the indicated numerical value.
[0028] It should be understood that the term "comprising" is not limiting. For the purposes of the present invention, the term "consisting of" is considered a preferred embodiment of the term "comprising". If a group is defined hereinafter as comprising at least a certain number of embodiments, this is also meant to encompass a group that preferably consists only of these embodiments.
[0029] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the claims.
[0030] Embodiments of the invention are provided below. It should be noted that generally an embodiment can be combined with any other embodiment of the same category (product, process, use, method).
[0031] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the antibody or fragment binds to the N-terminal portion (aa 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1), wherein the antibody or antibody fragment is present in a concentration of 1 mg / ml to 100 mg / ml, 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, most preferably 20 mg / ml, and wherein the aqueous pharmaceutical formulation further comprises:
[0032] Arginine in the range of 1 g / L to 100 g / L, and
[0033] Trehalose in the range of 1 g / L to 100 g / L, and
[0034] - a surfactant selected from polysorbates and poloxamers in the range of 0.01 g / L to 5 g / L, and
[0035] Histidine in the range of 0.1 g / L to 6.4 g / L, and
[0036] wherein the pH of the formulation is in the range of 4.0 to 8.0.
[0037] A preferred embodiment of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the antibody or fragment binds to the N-terminal portion of ADM (aa 1-21): YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1), wherein the antibody or antibody fragment is present in a concentration of 1 mg / ml to 100 mg / ml, preferably 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, most preferably 20 mg / ml, and wherein the aqueous pharmaceutical formulation further comprises:
[0038] ● arginine or a salt thereof in the range of 1 g / L to 100 g / L in terms of the content of arginine zwitterion, and
[0039] Trehalose in the range of 1 g / L to 100 g / L, and
[0040] a surfactant in the range of 0.01 g / L to 5 g / L selected from polysorbates such as ethoxylated sorbitan esterified with fatty acids (including polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80) and poloxamers such as copolymers based on ethylene oxide and propylene oxide, and
[0041] Histidine in the range of 0.1 g / L to 6.4 g / L, and
[0042] wherein the pH of the formulation is in the range of 4.0 to 8.0.
[0043] In a specific embodiment of the present invention, the ADM antibody or ADM antibody fragment can be administered at a dose of at least 0.5 mg / kg body weight, particularly at least 1.0 mg / kg body weight, more particularly 1.0 to 20.0 mg / kg body weight, for example 1.0 to 10 mg / kg, 2.0 to 10 mg / kg body weight, 2.0 to 8.0 mg / kg body weight or 3.0 to 5.0 mg / kg body weight.
[0044] In a specific embodiment of the present invention, the ADM antibody or ADM antibody fragment is present in a concentration of at least 1 mg / ml to 100 mg / ml, preferably 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, and most preferably 20 mg / ml.
[0045] In another embodiment of the invention, the ADM antibody or ADM antibody fragment is present in a total amount of at least 5 mg, particularly at least 10 mg, more particularly 10 mg to 1000 mg, more particularly 50 mg to 700 mg, more particularly 100 mg to 500 mg, most particularly 200 to 480 mg relative to a 10 ml vial. The total amount of the ADM antibody or ADM antibody fragment can be used, for example, to prepare a ready-to-use solution by diluting the total amount of the ADM antibody or ADM antibody fragment to the desired concentration in a suitable buffer comprising phosphate buffered saline solution, water and an emulsion such as an oil / water emulsion. In an embodiment of the present invention, the ADM antibody or ADM antibody fragment is present in a total amount of at least 5 mg, particularly at least 10 mg, more particularly 10 mg to 1000 mg, more particularly 50 mg to 700 mg, more particularly 100 mg to 500 mg, most particularly 200 to 480 mg relative to a 10 ml vial and can be diluted to 10 ml to 200 ml, preferably 20 ml to 180 ml, more preferably 30 ml to 150 ml, most preferably 50 ml to 100 ml in a suitable buffer comprising phosphate buffered saline solution, water and emulsions such as oil / water emulsions.
[0046] In another embodiment of the present invention, the ADM antibody or ADM antibody fragment is present in a ready-to-use solution at a concentration of at least 1 mg / ml to 100 mg / ml, preferably 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, most preferably 20 mg / ml, and is diluted to 10 ml to 200 ml, preferably 20 ml to 180 ml, more preferably 30 ml to 150 ml, most preferably 50 ml to 100 ml in a suitable buffer comprising phosphate buffered saline solution, water and emulsions such as oil / water emulsions.
[0047] The skilled person will then know from the instructions for use how to prepare a ready-to-use solution from the provided aqueous pharmaceutical formulation, which can then be administered to the patient via known routes of administration.
[0048] In other embodiments, the aqueous pharmaceutical preparation is further diluted in an infusion solution and applied to the patient by infusion. In another embodiment, a physician as a person skilled in the art will prepare a ready-to-use solution from the aqueous pharmaceutical preparation according to the needs of the patient, and then the ready-to-use solution is directly applied to the patient. In an embodiment of the present invention, the ADM antibody or ADM antibody fragment can be administered with a dosage of at least 0.5 mg / Kg body weight, particularly at least 1.0 mg / kg body weight, more particularly 1.0 to 20.0 mg / kg body weight, for example 2.0 to 10 mg / kg body weight, 2.0 to 8.0 mg / kg body weight or 3.0 to 5.0 mg / kg body weight.
[0049] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, wherein the antibody or fragment is a human monoclonal antibody or fragment thereof that binds to the N-terminal region (aa 1-21) of ADM (SEQ ID No. 1), wherein the heavy chain comprises the following sequence:
[0050] CDR1: SEQ ID NO: 2
[0051] GYTFSRYW
[0052] CDR2: SEQ ID NO: 3
[0053] ILPGSGST
[0054] CDR3: SEQ ID NO: 4
[0055] TEGYEYDGFDY
[0056] And wherein the light chain comprises the following sequence:
[0057] CDR1: SEQ ID NO: 5
[0058] QSIVYSNGNTY
[0059] CDR2: SEQ ID NO: 6
[0060] RVS
[0061] CDR3: SEQ ID NO: 7
[0062] FQGSHIPYT.
[0063] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, comprising an anti-adrenomedullin antibody directed against the N-terminal end of adrenomedullin, said antibody comprising as a heavy chain the following sequence or a sequence having >95% identity thereto:
[0064] SEQ ID NO: 8
[0065] QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0066] and comprising as a light chain the following sequence or a sequence having >95% identity thereto:
[0067] SEQ ID NO: 9
[0068] DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLE IKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
[0069] In another embodiment of the present invention, an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment comprises an anti-adrenomedullin antibody directed against the N-terminal end of adrenomedullin, said antibody comprising as a heavy chain the following sequence or a sequence having >95%, preferably >98%, preferably >99% identity thereto:
[0070] SEQ ID NO: 8
[0071] QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0072] and comprising as a light chain the following sequence or a sequence having >95%, preferably >98%, preferably >99% identity thereto:
[0073] SEQ ID NO: 9
[0074] DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLE IKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
[0075] To assess the identity between two amino acid sequences, a pairwise alignment is performed. The identity is defined as the percentage of amino acids that have direct matches in the alignment.
[0076] Surfactants disclosed in the present invention can be used to change the surface tension of liquid antibody preparations. In a particular embodiment, the surfactant reduces the surface tension of liquid antibody preparations. In another embodiment, the surfactant can help improve the stability of any antibody in the preparation. The surfactant can also reduce the aggregation of the antibody prepared (e.g., during transportation and storage) and / or minimize the formation of particles in the preparation and / or reduce adsorption (e.g., adsorption on a container). For example, the surfactant can also improve the stability of the antibody during and after the freeze-thaw cycle. The surfactant can be, for example, but not limited to, polysorbate, poloxamer, triton, sodium dodecyl sulfate, sodium lauryl sulfate, sodium octyl glucoside, lauryl sulfobetaine, myristyl sulfobetaine, linoleyl sulfobetaine, stearyl sulfobetaine, lauryl sarcosine, myristyl sarcosine, linoleyl sarcosine, stearyl sarcosine, linoleyl betaine, myristyl betaine, cetyl betaine, lauramidopropyl betaine, cocamidopropyl betaine, linoleamidopropyl betaine, myristamidopropyl betaine, palmitamidopropyl betaine, isostearamidopropyl betaine, myristamidopropyl dimethylamine, palmitamidopropyl dimethylamine, isostearamidopropyl dimethylamine, sodium methyl cocoyl taurate, disodium methyl oleyl taurate, dihydroxypropyl PEG 5. Linoleyl ammonium chloride, polyethylene glycol, polypropylene glycol and mixtures thereof.
[0077] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the surfactant is a poloxamer. In another embodiment, the poloxamer is selected from copolymers based on ethylene oxide and propylene oxide, including but not limited to L64, P65, P84, P85, F88, P103, P104, P105, F108, P123 or F127.
[0078] In some embodiments, the surfactant is selected from polysorbates and poloxamers, wherein the polysorbate is derived from ethoxylated sorbitan esterified with fatty acids and is selected from polyoxyethylene (20)-sorbitan monolaurate, polyoxyethylene (4)-sorbitan monolaurate, polyoxyethylene (20)-sorbitan monopalmitate, polyoxyethylene (20)-sorbitan monostearate, polyoxyethylene (4)-sorbitan monostearate, polyoxyethylene (20)-sorbitan tristearate, polyoxyethylene (20)-sorbitan monooleate, polyoxyethylene (5)-sorbitan monooleate, polyoxyethylene (20)-sorbitan trioleate or polyoxyethylene (20)-sorbitan monoisostearate, polyoxyethylene derivatives, Tween, PEG3350 and mixtures thereof.
[0079] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment, wherein the formulation is substantially free of NaCl and / or glycine.
[0080] In some embodiments, the aqueous formulation comprises, for example, but not limited to, acetate, succinate, gluconate, citrate, histidine, acetic acid, phosphate, phosphoric acid, ascorbate, tartaric acid, maleic acid, glycine, lactate, lactic acid, ascorbic acid, imidazole, bicarbonate and carbonic acid, succinic acid, sodium benzoate, benzoic acid, gluconate, edetate, acetate, malate, imidazole, tris, phosphate, and mixtures thereof. Preferably, the aqueous formulation comprises histidine, wherein the histidine may comprise L-histidine or D-histidine, a solvated form of histidine, a hydrated form of histidine (e.g., a monohydrate, including L-histidine hydrochloride monohydrate), a salt of histidine (e.g., histidine hydrochloride), or an anhydrous form of histidine or a mixture thereof.
[0081] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, wherein arginine is present in a range of 1 g / L to 100 g / L, preferably 13.1 g / L to 52.2 g / L, more preferably 26.1 g / L. Preferably, the aqueous formulation comprises histidine, wherein the histidine may include L-histidine or D-histidine, a solvated form of histidine, a hydrated form of histidine (e.g., a monohydrate, including L-histidine hydrochloride monohydrate), a salt of histidine (e.g., histidine hydrochloride) or an anhydrous form of histidine or a mixture thereof.
[0082] In one aspect of the invention, the aqueous formulation comprises an isotonicity regulator, which protects the antibody or protein in the formulation from freeze-thaw induced aggregation and aggregation during storage. The isotonic agent can be a polyol having a molecular weight such as but not limited to less than about 600kD (e.g., in the range of about 120 to about 400kD) and comprising multiple hydroxyls, including sugar (e.g., reducing sugar and non-reducing sugar or its mixture, sugar or carbohydrate), sugar alcohol, sugar acid or its salt or mixture. The example of non-reducing sugar includes but is not limited to sucrose, trehalose and its mixture. In some embodiments, the polyol is mannitol, trehalose, sorbitol, erythritol, isomalt, lactitol, maltitol, xylitol, glycerol, lactitol, propylene glycol, polyethylene glycol, inositol or its mixture. In other embodiments, the polyol can be such as but not limited to monosaccharide, disaccharide or polysaccharide, or a mixture of any of the above substances. The sugar or carbohydrate can be, for example, but not limited to, fructose, glucose, mannose, sucrose, sorbose, xylose, lactose, maltose, sucrose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch, water-soluble dextran or a mixture thereof. In a preferred embodiment of the present invention, the polyol is trehalose.
[0083] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment, wherein trehalose is present in the range of 1 g / L to 100 g / L, preferably 28.4 g / L to 85.1 g / L, more preferably 56.7 g / L.
[0084] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the poloxamer is present in the range of 0.01 g / L to 5 g / L, preferably 0.1 g / L to 1.0 g / L, more preferably 0.5 g / L.
[0085] In some embodiments, the aqueous formulation comprises a chelating agent, which may be selected from aminopolycarboxylic acids, hydroxyaminocarboxylic acids, N-substituted glycine, 2-(2-amino-2-oxoethyl)aminoethanesulfonic acid (BES), deferoxamine (DEF), citric acid, nicotinamide and deoxycholate and mixtures thereof. In some embodiments, the chelating agent is selected from ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid 5 (DTPA), nitrilotriacetic acid (NTA), N-2-acetamido-2-iminodiacetic acid (ADA), bis(aminoethyl)ethylene glycol ether, N,N,N',N'-tetraacetic acid (EGTA), trans-diaminocyclohexanetetraacetic acid (DCTA), glutamic acid and aspartic acid, N-hydroxyethyliminodiacetic acid (HIMDA), N,N-bishydroxyethylglycine (bici ne) and N-(trihydroxymethylmethyl) 10 glycine (tricine), glycylglycine, sodium deoxycholate, ethylenediamine, propylenediamine, diethylenetriamine, triethylenetetramine (trien), disodium edetate dihydrate (or disodium EDTA dihydrate or disodium EDTA salt), calcium EDTA oxalate, malate, citric acid, citric acid monohydrate and trisodium citrate dihydrate, 8-hydroxyquinoline, amino acids, histidine, cysteine, methionine, peptides, polypeptides and proteins and mixtures thereof. In some embodiments, the chelating agent is selected from salts of EDTA, including dipotassium edetate, disodium edetate, calcium disodium edetate, sodium edetate, trisodium edetate and potassium edetate; and a suitable salt of deferoxamine (DEF) is deferoxamine mesylate (DFM) or a mixture thereof. The chelating agent used in the present invention may exist as the free acid or free base form or salt form of the compound, or as the anhydrous, solvated or hydrated form of the compound or the corresponding salt, where possible. In the most preferred embodiment of the present invention, the chelating agent is histidine.
[0086] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein histidine is present in the range of 0.1 g / L to 6.4 g / L, preferably 0.8 g / L to 3.2 g / L, more preferably 1.6 g / L.
[0087] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment, wherein the pH of the formulation is in the range of 4.0 to 8.0, preferably 5.0 to 7.0, more preferably 6.0.
[0088] According to the present invention, the aqueous formulation is provided with a pH close to physiological pH to reduce the risk of pain or anaphylactoid side effects upon injection, and also provides enhanced antibody stability and resistance to aggregation, oxidation and fragmentation.
[0089] In some embodiments, the formulation may contain a preservative. Preferably, the preservative is selected from phenol, m-cresol, benzyl alcohol, benzalkonium chloride, benzalkonium chloride, phenoxyethanol and methyl paraben.
[0090] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the formulation comprises an anti-adrenomedullin antibody directed against the N-terminal end of adrenomedullin (which comprises the following sequence: SEQ ID No. 1), arginine at a concentration of 26.1 g / L, trehalose at a concentration of 56.7 g / L, poloxamer at a concentration of 0.5 g / L, histidine at a concentration of 1.6 g / L, and wherein the formulation exhibits a pH of 6.0.
[0091] In another embodiment of the present invention, the aqueous pharmaceutical formulation comprises a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the formulation comprises an anti-adrenomedullin antibody directed against the N-terminal end of adrenomedullin (which comprises the following sequence: SEQ ID No. 1), arginine at a concentration of 1 g / L to 100 g / L, trehalose at a concentration of 1 g / L to 100 g / L, poloxamer at a concentration of 0.01 g / L to 5 g / L, histidine at a concentration of 0.1 g / L to 6.4 g / L, and wherein the formulation exhibits a pH in the range of 4.0 to 8.0.
[0092] Another aspect of the present invention relates to an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the formulation comprises an anti-adrenomedullin antibody directed against the N-terminal end of adrenomedullin (which comprises the following sequence: SEQ ID No. 1), arginine at a concentration of 13.1 g / L to 52.2 g / L, trehalose at a concentration of 28.4 g / L to 85.1 g / L, poloxamer at a concentration of 0.1 g / L to 1 g / L, histidine at a concentration of 0.8 g / L to 3.2 g / L, and wherein the formulation exhibits a pH of 5.0 to 7.0.
[0093] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, wherein the formulation is stable after storage for at least 4 weeks at 2 to 8° C. and less than 5 wt / wt-%, preferably 4 wt / wt-%, more preferably 3 wt / wt-%, more preferably 2 wt / wt-%, more preferably 1 wt / wt-%, more preferably 0.05%-mol or most preferably 0.01 wt / wt-% of total antibody aggregation when measured, for example, by size exclusion high performance liquid chromatography (SEC-HPLC), and wherein the antibody is present in a concentration of 1 mg / ml to 100 mg / ml, preferably 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, most preferably 20 mg / ml. Other methods for characterizing the molecular weight distribution of biomacromolecules are, for example, micellar liquid chromatography or ion exchange chromatography.
[0094] A preferred embodiment of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, wherein the formulation is stable after storage at 2 to 8° C. for at least 4 weeks, and wherein less than 5 wt / wt-%, preferably 4 wt / wt-%, more preferably 3 wt / wt-%, more preferably 2 wt / wt-%, more preferably 1 wt / wt-%, more preferably 0.05%-mol or most preferably 0.01 wt / wt-% of total antibody aggregation when measured, for example, by size exclusion high performance liquid chromatography (SEC-HPLC), and wherein the antibody can be administered at a dose of 1 mg / kg body weight to 10 mg / kg body weight, more preferably 2 mg / kg body weight to 8 mg / kg body weight, most preferably 3 mg / kg body weight to 5 mg / kg body weight. Other methods for characterizing the molecular weight distribution of biomacromolecules are, for example, micellar liquid chromatography or ion exchange chromatography.
[0095] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the formulation is stable after storage for at least 4 weeks at 2 to 8° C., and wherein less than 5 wt / wt-%, preferably 4 wt / wt-%, more preferably 3 wt / wt-%, more preferably 2 wt / wt-%, more preferably 1 wt / wt-%, more preferably 0.05%-mol or most preferably 0.01 wt / wt-% of total antibody aggregation when measured, for example, by size exclusion high performance liquid chromatography (SEC-HPLC), and wherein the antibody is present in a total amount of 10 mg to 1000 mg, more preferably 50 mg to 700 mg, most preferably 100 mg to 500 mg relative to a 10 ml vial. Other methods for characterizing the molecular weight distribution of biomacromolecules are, for example, micellar liquid chromatography or ion exchange chromatography.
[0096] In an embodiment of the present invention, SEC-HPLC is capable of separating protein species with an apparent molecular weight of 150 kDa from other protein species with a molecular weight of 300 kDa or higher.
[0097] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the activity of the antibody or antibody fragment in the formulation is stable after stress, and wherein the stress is induced by storing the formulation at 45°C, preferably 42°C, more preferably 38°C, more preferably 36°C, most preferably 40°C and 85% rH, preferably 80 rH, preferably 70% rH, most preferably 75% rH for at least 4 weeks, and / or by storing the formulation at 29°C, preferably 27°C, more preferably 22°C, more preferably 20 ℃, most preferably 25℃ and / or 70% rH, preferably 65% rH, preferably 55% rH, more preferably 50% rH, most preferably 60% rH for at least 3 months, and / or by storing the formulation at 9℃, preferably 7℃, more preferably 2℃, more preferably 0℃, most preferably 5℃ for at least 6 months, and / or by subjecting the formulation to at least 5 freeze-thaw cycles, and / or by subjecting the formulation to mechanical stress including orbital shaking and overhead rotation, and wherein the stability is determined by evaluating the visual appearance of the formulation after stress, including color, clarity and visible particles.
[0098] The abbreviation "rH" stands for "relative humidity" and refers to a measure of the water vapor content in a water-air mixture compared to the maximum possible amount. In addition, rH is the ratio of the moisture content of a particular water-air mixture to the saturated moisture content (dry bulb) at a given temperature. The term relative humidity "rH" is used according to the ICH Q1A guide "Stability Testing of new Drug Substances and Products". Since relative humidity is temperature dependent, accurate air temperature control is required to achieve tight relative humidity control. It is known to those skilled in the art that humidity is typically measured by a hygrometer such as a gravimetric hygrometer, a chilled mirror hygrometer or an electrolytic hygrometer.
[0099] According to the present invention, "stable" means that all critical quality attributes of the formulation remain within the specification limits of the quality specification, in particular the absence of any visible particles after application of stress conditions, such as subjecting the formulation to 45°C, preferably 42°C, more preferably 38°C, more preferably 36°C, most preferably 40°C and / or at 29°C, preferably 27°C, more preferably 22°C, more preferably 20°C, most preferably 25°C and / or 70% rH, preferably 65% rH, preferably 55% rH, more preferably 50% rH, most preferably 60% rH and / or at 45°C, preferably 42°C, more preferably 38°C, more preferably 36°C, most preferably 40°C. 0°C and / or 85% rH, preferably 80 rH, preferably 70% rH, most preferably 75% rH for at least 2 weeks, or by storing the formulation at 29°C, preferably 27°C, more preferably 22°C, more preferably 20°C, most preferably 25°C and / or 70% rH, preferably 65% rH, preferably 55% rH, more preferably 50% rH, most preferably 60% rH, or by storing the formulation at 9°C, preferably 7°C, more preferably 2°C, more preferably 0°C, most preferably 5°C, and / or by subjecting the formulation to at least 5 freeze-thaw cycles, and / or by subjecting the formulation to mechanical stress including orbital shaking and overhead rotation.
[0100] In another embodiment of the present invention, the aqueous pharmaceutical formulation comprises a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the activity of the antibody or antibody fragment in the formulation is stable after stress, and wherein the stress is induced by storing the formulation at 45°C, preferably 42°C, more preferably 38°C, more preferably 36°C, most preferably 40°C for at least 2 weeks and / or by subjecting the formulation to at least 5 freeze-thaw cycles and / or by subjecting the formulation to mechanical stress including orbital shaking and overhead rotation, and wherein the stability is determined by evaluating the visual appearance of the formulation after stress, including color, clarity and visible particles.
[0101] In some embodiments of the invention, the aqueous pharmaceutical formulation comprises a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the activity of the antibody or antibody fragment in the formulation is stable after stress, and wherein the stress is induced by storing the formulation at 29°C, preferably 27°C, more preferably 22°C, more preferably 20°C, most preferably 25°C and / or 70% rH, preferably 65% rH, preferably 55% rH, more preferably 50% rH, most preferably 60% rH for at least 2 months and / or by subjecting the formulation to at least 5 freeze-thaw cycles and / or by subjecting the formulation to mechanical stress including orbital shaking and overhead rotation, and wherein the stability is determined by evaluating the visual appearance of the formulation after stress, including color, clarity, and visible particles.
[0102] Another embodiment of the present invention relates to an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the activity of the antibody or antibody fragment in the formulation is stable after stress, and wherein the stress is induced by storing the formulation at 45°C, preferably 42°C, more preferably 38°C, more preferably 36°C, most preferably 40°C and / or 85% rH, preferably 80 rH, preferably 70% rH, most preferably 75% rH for at least 2 weeks, or by storing the formulation at 29°C, preferably 27°C, more preferably 22°C , more preferably 20°C, most preferably 25°C and / or 70% rH, preferably 65% rH, preferably 55% rH, more preferably 50% rH, most preferably 60% rH, or by storing the formulation at 9°C, preferably 7°C, more preferably 2°C, more preferably 0°C, most preferably 5°C, and / or by subjecting the formulation to at least 5 freeze-thaw cycles, and / or by subjecting the formulation to mechanical stress including orbital shaking and overhead rotation, and wherein the stability is determined by evaluating the visual appearance of the formulation after stress (including color, clarity and visible particles). Those skilled in the art will also consider storing the formulation under the above conditions for less than two weeks.
[0103] In another aspect, the present invention relates to performing at least 5 freeze-thaw cycles, wherein 1 freeze-thaw cycle comprises first freezing the formulation to -80°C, followed by thawing to 25°C at a rate of 1°C per minute. In some embodiments, 1 to 50, preferably 1 to 30, more preferably 1 to 20, more preferably 1 to 10, more preferably 2 to 8, and most preferably 5 freeze-thaw cycles are performed.
[0104] In other embodiments, the aqueous pharmaceutical formulation comprises a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the activity of the antibody or antibody fragment in the formulation is stable after stress, and wherein the stress is induced by subjecting the formulation to mechanical stress including orbital shaking and overhead rotation. In some embodiments, the stress is applied by overhead rotation at 30 rpm for 24 h and / or with 400 rpm orbital shaking. In another aspect of the invention, the stress is applied by overhead rotation at 30 rpm for 24 h, preferably 36 h, more preferably 48 h, most preferably 72 h and / or with 200 rpm, preferably 400 rpm, more preferably 600 rpm, more preferably 800 rpm, most preferably 1000 rpm orbital shaking.
[0105] Micron-sized protein aggregates and particles (sub-visible particles, SVP) are important quality attributes of therapeutic protein formulations due to the risk of enhancing immunogenic responses. Therefore, the pharmacopoeia requires that sub-visible particles greater than 10 μm and 25 μm be quantified, and light obscuration (LO) technology is generally used for this purpose. In an embodiment of the present invention, the stability is determined by evaluating the visual appearance (including color, clarity and visible particles) of the formulation after stress. In some embodiments of the present invention, sub-visible particles greater than 1 μm, more preferably 5 μm, more preferably 10 μm, more preferably 15 μm, more preferably 20 μm, and most preferably 25 μm are quantified. In another embodiment, particles greater than 25 μm are quantified. In some embodiments, visual and color inspections are performed. Appearance tests of the formulation in terms of color (according to European Pharmacopoeia Method 2.2.2, visible particles, European Pharmacopoeia Method 2.9.20), clarity and opalescence (European Pharmacopoeia Method 2.2.) are generally analyzed according to European Pharmacopoeia Methods 2.9.20 and 2.2.1, respectively. In one aspect of the invention, visible particles, appearance, color and clarity are assessed visually.
[0106] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the formulation is stable after storage at 2 to 8°C for at least 4 weeks, and wherein stable means that the formulation remains free of visible particles.
[0107] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the formulation is stable after storage at 2 to 8°C for at least 4 weeks, and wherein stable means that the formulation remains free of subvisible particles.
[0108] Those skilled in the art will be aware that micron-sized protein aggregates and particles (subvisible particles, SVPs) are important quality attributes of therapeutic protein formulations due to the risk of enhancing immunogenic responses. Therefore, pharmacopoeias require quantification of subvisible particles greater than 10μm and 25μm, and this is typically performed using light obscuration (LO) techniques. Currently, the acceptance criteria for SVPs are 6000NMT ≥ 10μm / container and 600NMT ≥ 25μm / container. SVPs <10μm must be monitored and acceptance criteria have not yet been determined. However, quantification and characterization of particles less than 10μm in size is gaining interest and is a regulatory expectation.
[0109] The subject matter of the present invention is an aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment, wherein the antibody is present in a concentration of 1 mg / ml to 100 mg / ml, preferably 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, most preferably 20 mg / ml.
[0110] In some embodiments of the present invention, the aqueous pharmaceutical formulation comprises a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the antibody or the fragment can be administered at a dose of at least 0.5 mg / kg body weight, particularly at least 1.0 mg / kg body weight, more particularly 1.0 to 20.0 mg / kg body weight, for example 2.0 to 10 mg / kg body weight, 2.0 to 8.0 mg / kg body weight or 2.0 to 5.0 mg / kg body weight.
[0111] The subject matter of the present invention is a lyophilized pharmaceutical formulation that can be obtained from an aqueous pharmaceutical formulation. In some embodiments, a formulation is provided that is lyophilized and / or has undergone lyophilization. In another aspect of the present disclosure, the pharmaceutical formulation is provided in a lyophilized form, which is referred to as a "cake" or "powder", is physically stable, and is compatible with a pharmaceutically acceptable solvent mixture. In some embodiments, a composition that is not lyophilized and has not yet undergone lyophilization is provided.
[0112] In some embodiments, the aqueous formulations disclosed herein have a shelf life at 5°C of at least or more than about 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, or 48 months (e.g., at 5°C, 25°C, or 40°C). In another embodiment, the formulation of the invention has a shelf life of at least about 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months, 34 months, 35 months, 36 months, 37 months, 38 months, 39 months, 40 months, 41 months, 42 months, 43 months, 44 months, 45 months, 46 months, 47 months, 48 months, 49 months, 50 months, 51 months, 52 months, 53 months, 54 months, 55 months, 56 months, 57 months, 58 months, 59 months, or 60 months.
[0113] In some embodiments, the aqueous formulations disclosed herein have a shelf life at 25°C of at least or more than about 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, or 48 months (e.g., at 5°C, 25°C, or 40°C). In another embodiment, the formulation of the invention has a shelf life of at least about 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months, 34 months, 35 months, 36 months, 37 months, 38 months, 39 months, 40 months, 41 months, 42 months, 43 months, 44 months, 45 months, 46 months, 47 months, 48 months, 49 months, 50 months, 51 months, 52 months, 53 months, 54 months, 55 months, 56 months, 57 months, 58 months, 59 months, or 60 months.
[0114] In some embodiments, the aqueous formulations disclosed herein have a shelf life at 40°C of at least or more than about 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, or 48 months (e.g., at 5°C, 25°C, or 40°C). In another embodiment, the formulation of the invention has a shelf life of at least about 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months, 34 months, 35 months, 36 months, 37 months, 38 months, 39 months, 40 months, 41 months, 42 months, 43 months, 44 months, 45 months, 46 months, 47 months, 48 months, 49 months, 50 months, 51 months, 52 months, 53 months, 54 months, 55 months, 56 months, 57 months, 58 months, 59 months, or 60 months.
[0115] The subject matter of the present invention is a method for preparing a ready-to-use solution, the method comprising the steps of:
[0116] a. Provide aqueous pharmaceutical preparations
[0117] b. conditioning the aqueous pharmaceutical preparation from step a) in a physiologically acceptable solution by optionally diluting the volume of the pharmaceutical preparation from step a) with a physiologically acceptable solution and by optionally dividing the pharmaceutical preparation from step a) into aliquots, wherein the diluted or adjusted aqueous pharmaceutical preparation is suitable for administration in a patient.
[0118] The subject matter of the present invention is a method for preparing a ready-to-use solution, the method comprising the steps of:
[0119] a. providing a lyophilized formulation obtained from said aqueous formulation by freeze drying and optionally without adding any other bulking agent;
[0120] b. reconstitute the lyophilisate from step a) in water and / or a physiologically acceptable solution for injection;
[0121] c. conditioning the reconstituted formulation from step b) in a physiologically acceptable solution by optionally diluting the volume of the reconstituted formulation from step b) with a physiologically acceptable solution and by optionally dividing the reconstituted formulation from step b) into aliquots, wherein the diluted or conditioned aqueous pharmaceutical formulation is suitable for administration in a patient.
[0122] A preferred embodiment of the present invention is a method for preparing a ready-to-use solution, the method comprising the steps of:
[0123] a. Provide aqueous pharmaceutical preparations
[0124] b. conditioning the aqueous pharmaceutical preparation from step a) in a physiologically acceptable solution by optionally diluting the volume of the pharmaceutical preparation from step a) with a physiologically acceptable solution and by optionally dividing the pharmaceutical preparation from step a) into aliquots, wherein the diluted or conditioned aqueous pharmaceutical preparation is suitable for administration in a patient,
[0125] And wherein the solution is selected from Ringer's lactate, glucose solution, electrolyte solution, isotonic sodium chloride solution, and wherein the infusion solution is present in a volume of 10 ml to 200 ml, preferably 20 ml to 180 ml, more preferably 30 ml to 150 ml, most preferably 50 ml to 100 ml.
[0126] Another preferred embodiment of the present invention is a method for preparing a ready-to-use solution, the method comprising the steps of:
[0127] a. providing a lyophilized formulation obtained from said aqueous formulation by freeze drying and optionally without adding any other bulking agent;
[0128] b. reconstitute the lyophilisate from step a) in water and / or a physiologically acceptable solution for injection;
[0129] c. conditioning the reconstituted formulation from step b) in a physiologically acceptable solution by optionally diluting the volume of the reconstituted formulation from step b) with a physiologically acceptable solution and by optionally dividing the reconstituted formulation from step b) into aliquots, wherein the diluted or conditioned aqueous pharmaceutical formulation is suitable for administration in a patient,
[0130] And wherein the solution is selected from Ringer's lactate, glucose solution, electrolyte solution, isotonic sodium chloride solution, and wherein the infusion solution is present in a volume of 10 ml to 200 ml, preferably 20 ml to 180 ml, more preferably 30 ml to 150 ml, most preferably 50 ml to 100 ml.
[0131] The antibody administration route is well known in the art and may include, for example, injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes or by sustained release system injection or infusion. Sustained release parenteral injection can be divided into several types: oil-based injection solution, injection drug suspension, polymer-based microspheres and polymer-based in situ formation. The antibody can be continuously administered by infusion or push injection. Physiologically acceptable solutions are supplementary fluids used in, for example, intravenous therapy to restore or maintain normal fluid volume and electrolyte balance. Those skilled in the art will know that there are different physiologically acceptable solutions, and different physiologically acceptable solutions can be classified, for example, according to their osmotic pressure or purpose. Typically, the osmotic pressure of a physiologically acceptable solution can be isotonic, hypotonic or hypertonic. In an embodiment of the present invention, the physiologically acceptable solution may be selected from Ringer's lactate, glucose solution, electrolyte, isotonic sodium chloride solution. In another embodiment of the present invention, the physiologically acceptable solution is also suitable for use with commercially available infusion or injection carrier solutions for supplying electrolytes without carbohydrates, such as isotonic NaCl solution, isotonic glucose solution, Ringer's lactate, etc. (Rote Liste 2004, List of finished medicinal products of the members of the Federation of the Pharmaceutical Industry, eV, Editio Cantor, Aulendorf / Wuertt, main groups 52.1 and 52.2.1) to the desired concentration or dosage without exhibiting physical or chemical incompatibility.
[0132] A subject of the present invention is a device comprising the above-described preparation.
[0133] The aqueous pharmaceutical composition according to the present invention can be stored in a device such as a medical container. The medical container according to the present invention is any container suitable for storing the aqueous pharmaceutical composition. Typical medical containers according to the present invention are made of glass or plastic and can be selected from vials, prefilled syringes and cartridges. The medical container can have a different set of closures: rubber stoppers for vials; plungers, needles and needle shields (or Luer connectors and caps) for prefilled syringes; and plungers and seals for cartridges. Those skilled in the art will know how to choose a suitable medical container.
[0134] The subject matter of the present invention is a ready-to-use aqueous pharmaceutical formulation obtainable by the process according to the invention, comprising said human or humanized anti-Adrenomedullin (ADM) antibody or anti-Adrenomedullin antibody fragment in a dose of 1 to 10 mg / kg body weight.
[0135] The subject matter of the present invention is a ready-to-use aqueous pharmaceutical formulation obtainable by the process according to the invention, comprising said human or humanized anti-Adrenomedullin (ADM) antibody or anti-Adrenomedullin antibody fragment in a dose of 2 to 8 mg / kg body weight, preferably 2 or 4 or 8 mg / kg body weight.
[0136] In an embodiment of the present invention, the ready-to-use aqueous pharmaceutical formulation comprises a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the antibody or the fragment is present in a concentration of at least 0.5 mg / kg body weight, particularly at least 1.0 mg / kg body weight, more particularly 1.0 to 20.0 mg / kg body weight, for example 2.0 to 10 mg / kg body weight, 2.0 to 8.0 mg / kg body weight or 2.0 to 5.0 mg / kg body weight.
[0137] The subject matter of the present invention is a pharmaceutical preparation for the treatment or prevention of an acute disease or condition selected from the group consisting of SIRS, severe infection, sepsis, shock such as septic shock, acute vascular disease such as heart failure, congestion, in particular diuretic-resistant congestion, inflammatory conditions, autoimmune diseases, metabolic diseases, brain diseases, cardiovascular diseases, and drug-induced disease symptoms or conditions characterized by such symptoms, wherein the disease symptoms are selected from the group consisting of nausea, headache, muscle pain, back pain, tremors, vomiting and / or migraine.
[0138] The acute disease or acute condition may be selected from, but is not limited to, severe infections such as meningitis, systemic inflammatory response syndrome (SIRS) or sepsis, other diseases such as diabetes, cancer, acute and chronic vascular diseases such as heart failure, myocardial infarction, stroke, atherosclerosis, shock such as septic shock, and organ dysfunction such as renal dysfunction, liver dysfunction, burns, surgery, trauma, poisoning, injury caused by chemotherapy.
[0139] The pharmaceutical preparation according to the invention is used to reduce the risk of death during sepsis and septic shock, ie the advanced stages of sepsis.
[0140] Septic shock is a potentially fatal medical condition that occurs when sepsis, which is organ injury or damage in response to infection, leads to dangerously low blood pressure and abnormalities in cellular metabolism. The Third International Consensus Definition of Sepsis and Septic Shock (Sepsis-3) defines septic shock as a subset of sepsis in which particularly severe circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone. Patients with septic shock can be clinically identified by the need for the use of vasopressors to maintain a mean arterial pressure of 65 mmHg or higher and a serum lactate level greater than 2 mmol / L (>18 mg / dL) in the absence of hypovolemia. This combination is associated with a hospital mortality rate of over 40% ( Singer et al., 2016.JAMA.315(8):801–10 ). The primary infection is most often caused by bacteria, but can also be caused by fungi, viruses, or parasites. It can be located anywhere in the body, but is most commonly in the lungs, brain, urinary tract, skin, or abdominal organs. It can lead to multiple organ dysfunction syndrome (formerly known as multiple organ failure) and death. Often, people with septic shock are cared for in an intensive care unit. It most commonly affects children, immunocompromised individuals, and the elderly because their immune systems cannot respond to infection as effectively as healthy adults. The mortality rate of septic shock is about 25-50%.
[0141] In the following clinical criteria for SIRS, sepsis, severe sepsis, and septic shock will be defined.
[0142] 1) Systemic inflammatory host response (SIRS), characterized by at least two of the following symptoms:
[0143] Patients present with hypotension (mean arterial pressure < 65 mmHg)
[0144] Elevated serum lactate level, >4mmol / L
[0145] Blood sugar >7.7mmol / L (in the absence of diabetes)
[0146] Central venous pressure is not within the range of 8-12 mmHg
[0147] Urine output < 0.5 mL x kg -1 x hr -1
[0148] Central venous (superior vena cava) oxygen saturation <70% or mixed venous oxygen saturation <65%
[0149] Heart rate > 90 beats / min
[0150] Temperature < 36°C or > 38°C
[0151] Respiratory rate > 20 / min
[0152] White blood cell count <4 or >12 x 10 9 / L (leukocytes); >10% immature neutrophils
[0153] 2) Sepsis
[0154] After at least two of the symptoms mentioned under 1), additional clinical suspicion of a new infection, i.e.:
[0155] Cough / sputum / chest pain
[0156] Abdominal pain / bloating / diarrhea
[0157] ·Hematogenous infection
[0158] Endocarditis
[0159] Difficulty urinating
[0160] Headache with stiff neck
[0161] Cellulitis / wound / joint infection
[0162] Any microbiologically positive infection
[0163] 3) Severe sepsis
[0164] The prerequisite is that sepsis is present in the patient and any organ dysfunction is clinically suspected, i.e.:
[0165] Systolic blood pressure <90 / mean; <65 mmHG
[0166] Lactate>2mmol / L
[0167] Bilirubin>34μmol / L
[0168] Urine output < 0.5 mL / kg / h in 2 hours
[0169] Creatinine>177μmol / L
[0170] Platelets 100x10 9 / L
[0171] Unless provided O 2 , otherwise SpO 2 >90%
[0172] 4) Septic shock
[0173] Exhibits at least one sign of end-organ dysfunction as mentioned under 3).
[0174] Administration of a pharmaceutical formulation according to the invention is also provided if there is refractory hypotension that is unresponsive to treatment and intravenous systemic fluid administration alone is insufficient to maintain the patient's blood pressure from becoming hypotensive, indicating septic shock.
[0175] In a specific embodiment of the present invention, the pharmaceutical preparation is provided for use in treating an acute disease or an acute condition, wherein the acute disease or acute condition may be headache, preferably primary headache, and most preferably migraine.
[0176] Thus, the acute disease or acute condition may be selected from, but is not limited to, severe infections such as meningitis, systemic inflammatory response syndrome (SIRS) or sepsis, other diseases such as diabetes, cancer, acute and chronic vascular diseases such as heart failure, myocardial infarction, stroke, atherosclerosis, shock such as septic shock and organ dysfunction such as renal dysfunction, liver dysfunction, burns, surgery, trauma, poisoning, injury caused by chemotherapy.
[0177] In one embodiment of the invention, the patient does not suffer from SIRS, severe infection, sepsis, shock such as septic shock. The severe infection means, for example, meningitis, systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and shock such as septic shock. In this regard, severe sepsis is characterized by the presence of sepsis in the patient and in addition the presence of any clinical suspicion of organ dysfunction, i.e.:
[0178] Systolic blood pressure <90 / mean; <65 mmHG
[0179] Lactate>2mmol / L
[0180] Bilirubin>34μmol / L
[0181] Urine output < 0.5 mL / kg / h in 2 hours
[0182] Creatinine>177μmol / L
[0183] Platelets 100x10 9 / L
[0184] Unless provided O 2 , otherwise SpO 2 >90%
[0185] The term "nausea" as used herein refers to a feeling of uneasiness and discomfort in the upper abdomen, accompanied by an involuntary urge to vomit (Metz A. 2017. Australian Family Physician Vol. 36(92): 688-692). It can occur before vomiting, but a person can have nausea without vomiting.
[0186] When it lasts for a prolonged period, it can be a debilitating symptom. Nausea is a nonspecific symptom, which means it has many possible causes. Some common causes of nausea are motion sickness, dizziness, migraines, fainting, low blood sugar, gastroenteritis (stomach infection), or food poisoning. Nausea is a side effect of many medications including chemotherapy or morning sickness in early pregnancy. Nausea can also be caused by anxiety, disgust, and depression.
[0187] The term "headache" as used herein is a painful symptom anywhere in the head or neck region. It occurs in migraines (severe or throbbing pain), tension headaches, and cluster headaches (Waldman et al., 2014. J Yoga Phys Ther 2014. 4: 1). The risk of depression is also increased in people with severe headaches. Headaches can be the result of many conditions, whether severe or not. There are a large number of different classification systems for headaches. It is well known that the causes of headaches can include fatigue, lack of sleep, stress, the effects of medications, the effects of recreational drugs, viral infections, loud noises, the common cold, head injuries, rapid intake of very cold food or drinks, and dental or sinus problems.
[0188] Headaches are broadly classified as either "primary" or "secondary" (Oleson 2005. Functional Neurology 20(2):61-68). Primary headaches are benign, recurrent headaches that are not caused by an underlying disease or structural problem. For example, migraine is a primary headache. Although primary headaches can cause significant daily pain and disability, they are not dangerous. The four categories of primary headaches are: migraine, tension-type headaches (TTH), cluster headaches and other trigeminal autonomic headaches, and other primary headaches.
[0189] Secondary headaches of organic, metabolic or drug-induced origin are caused by underlying diseases such as infection, head injury, vascular disorders, brain hemorrhage or tumors. Secondary headaches can be harmless or dangerous. Migraine is a primary headache disorder characterized by recurrent headaches of moderate to severe severity (reviewed in: Diener et al., 2012. Nat Rev Neurol. 8(3):162-71). Typically, the headaches affect half of the head, are pulsating in nature, and last for 2 to 72 hours. Associated symptoms may include nausea, vomiting, and sensitivity to light, sound or smell. Physical activity often makes the pain worse. Up to one-third of people have an aura: usually a brief visual disturbance that indicates that the headache will soon occur. Occasionally, an aura occurs with little or no headache afterwards.
[0190] As used herein, the term "muscle pain" or "muscle pain", also known as "myalgia", refers to a symptom of many diseases and disorders (for review, see Kyriakides et al., 2013, European Journal of Neurology 20:997-1005).
[0191] The most common cause is overuse or overstretching of a muscle or muscle group. Myalgia without a history of trauma is often caused by a viral infection. Long-term myalgia may indicate a metabolic myopathy, certain nutritional deficiencies, or chronic fatigue syndrome.
[0192] The term "back pain" as used herein refers to the pain sensation in any part of the back. Depending on the duration, the onset of back pain can be acute, subacute or chronic. The pain can be characterized as dull pain, flashing pain or tingling or burning sensation. The pain can radiate to the arms and hands and legs or feet, and can include paresthesia (tingling sensation without obvious reason), weakness or numbness in the legs and arms. The anatomical classification of back pain follows each segment of the spine: neck pain (neck), mid-back pain (chest), lower back pain (waist) or coccygeal pain (coccyx or sacrum pain), wherein lumbar regional pain is the most common. The pain can originate from other structures in muscles, nerves, bones, joints or spine (vertebrae), however, internal structures such as gallbladder and pancreas can also cause referred pain in the back (Cohen et al., 2008, BMJ.337.'ü2 718).
[0193] The term "shivering" (also called "shivering") as used herein is a bodily function of warm-blooded animals in response to incipient hypothermia or simply feeling cold. When the core body temperature drops, the shivering response is triggered to maintain homeostasis. Skeletal muscles begin to shiver in small movements, generating warmth by expending energy. Shivering can also be a response to a fever, as a person may feel cold. During a fever, the hypothalamic temperature set point increases. The increased set point causes an increase in body temperature (fever), but also makes the patient feel cold until the new set point is reached. Severe chills accompanied by violent shivering are called shivers. Shivers occur because the patient's body physiologically tries to shiver in an attempt to raise the body temperature to the new set point. Shivers can also occur after surgery and are called post-anesthetic shivers.
[0194] The term "vomiting" as used herein, also known as emesis and throwing up, etc., refers to the involuntary forced expulsion of a person's gastric contents through the mouth and sometimes through the nose (Metz A., 2017, Australian Family physician Vol. 36 (9): 688-692). Vomiting can be caused by a variety of different conditions; it can occur as a specific response to disease such as gastritis or poisoning or as a nonspecific sequelae of disorders ranging from brain tumors, increased intracranial pressure to excessive exposure to ionizing radiation.
[0195] As used herein, in a patient in need of treatment and / or prevention of symptoms of an illness or disease, such symptoms are selected from a group of disease indications including inflammatory disorders, autoimmune diseases, metabolic diseases, brain diseases, cardiovascular diseases and drug-induced diseases.
[0196] Below, the types of symptoms and ailments associated therewith are provided in the form of a non-limiting list. It should be noted that the treatment or prevention described herein can be directed to more than one type of symptom. In addition, it is worth noting that a given medical indication, ailment or disease can be associated with more than one symptom.
[0197] The symptom of "nausea" can be related to intra-abdominal diseases, such as obstructive disorders (e.g., pyloric obstruction, small bowel obstruction, colonic obstruction, superior mesenteric artery syndrome), intestinal infections (e.g., viral or bacterial infections), inflammatory diseases (e.g., cholecystitis, pancreatitis, appendicitis, hepatitis), sensorimotor dysfunction (e.g., gastroparesis, intestinal pseudo-obstruction, gastroesophageal reflux disease, chronic idiopathic nausea, functional vomiting, cyclic vomiting syndrome, rumination syndrome), or biliary colic; extra-abdominal diseases, such as cardiopulmonary disorders (e.g., cardiomyopathy, myocardial infarction), inner ear diseases (e.g., motion sickness, labyrinthitis, malignant tumors), brain disorders (e.g., hemorrhage, abscess, hydrocephalus, malignant tumors), psychiatric pain (e.g., anorexia and bulimia nervosa, depression), postoperative vomiting, nausea associated with drugs and medications (e.g., chemotherapy and biologic therapy, antibiotics, antiarrhythmic drugs, digoxin, oral hypoglycemic drugs, oral contraceptives), nausea associated with endocrine / metabolic diseases (e.g., pregnancy, uremia, ketoacidosis, thyroid and parathyroid diseases, adrenal insufficiency), nausea due to poisoning due to liver failure, alcoholism, etc.
[0198] "Back pain" symptoms can be associated with conditions caused by inflammation, especially in the acute phase, which usually lasts two weeks to three months, and can be associated with low back pain, trauma, injury, infection, cancer (especially cancers known to spread to the spine such as breast cancer, lung cancer and prostate cancer), etc.
[0199] Symptoms of "myalgia" or "muscle pain" may be related to injury or trauma, including sprains, hematomas, or overuse, where a muscle is used too much, too often, including protection from isolated injuries, chronic strain, muscle pain caused by rhabdomyolysis, associated with, for example, viral infections, compression injuries, drug-related, such as those caused by fibrates and statins, ACE inhibitors, cocaine, certain antiretroviral drugs, severe potassium deficiency, fibromyalgia, Ehlers-Danlos syndrome, autoimmune disorders (including, for example, mixed connective tissue disease, systemic lupus erythematosus, polymyalgia rheumatica, myositis such as polymyositis, dermatomyositis, and inclusion body myositis, multiple sclerosis, myalgic encephalomyelitis (chronic fatigue syndrome), family history of myalgic encephalomyelitis, ... Familial Mediterranean fever, polyarteritis nodosa, Devic disease, morphea, sarcoidosis), metabolic diseases (e.g., carnitine palmitoyltransferase II deficiency, Conn syndrome, adrenal insufficiency, hyperthyroidism, hypothyroidism, diabetes, hypogonadism, and ion channelopathies, Stickler syndrome, hypokalemia, hypotonia (low muscle tone), exercise intolerance, mastocytosis, peripheral neuropathy, eosinophilia-myalgia syndrome, Barcoo fever, herpes, hemochromatosis (also known as iron overload disorder), delayed onset muscle soreness, AIDS, HIV infection, tumor-induced osteomalacia, vitamin D deficiency, myocardial infarction.
[0200] The symptom "headache" can be associated with a primary headache. 90% of headaches are primary headaches. Primary headaches usually start between the ages of 20 and 40. The most common types of primary headaches are migraines and tension-type headaches. They have different characteristics. Migraines usually present with pulsating headaches, nausea, photophobia (sensitivity to light) and phonophobia (sensitivity to sound). Tension-type headaches usually present as non-pulsating "band-like" pressure on both sides of the head, without other symptoms. Other very rare types of primary headaches include cluster headaches: short attacks (15-180 minutes) of severe pain, usually around one eye, accompanied by autonomic symptoms (tears, red eyes, nasal congestion), occurring at the same time every day. Cluster headaches can be treated with triptans and prevented with prednisone, ergotamine, or lithium. Trigeminal or occipital neuralgia, which is characterized by flashes of facial pain, hemicranial pain, which is continuous, unilateral pain, with sharp attacks of pain. Primary stabbing headaches, for example, stabbing "icepick pain" or "jabs and jolts" that come and go for 1 second to several minutes without autonomic symptoms (watery eyes, red eyes, nasal congestion). Primary cough headaches, which start suddenly and last for several minutes after coughing, sneezing, or straining (any event that can increase pressure inside the head). Serious causes must be ruled out (see the Secondary Headache Red Flags section) before a diagnosis of a "benign" primary cough headache can be made. Primary exertional headaches, which are characterized by throbbing, pulsating pain that begins during or after exercise and lasts from 5 minutes to 24 hours. The mechanism behind these headaches is unclear, but they may be caused by tension causing the veins in the head to dilate, causing pain; primary sex headaches, which are characterized by a dull, bilateral headache that begins during sexual activity and becomes worse during orgasm; hypnic headaches; and secondary headaches, which can be caused by problems elsewhere in the head or neck. Some of these are harmless, such as cervicogenic headache (pain arising from the neck muscles), overmedication headache in people who use too many analgesics to treat headaches, meningitis characterized by inflammation of the meninges (which presents with fever and meningitis) or neck stiffness; intracerebral hemorrhage (bleeding in the brain); subarachnoid hemorrhage (acute, severe headache, stiff neck, no fever); ruptured aneurysm, arteriovenous malformation, intraparenchymal bleeding; temporal arteritis, an inflammatory disease of the arteries common in the elderly (average age 70 years), polymyalgia rheumatica; acute angle-closure glaucoma (increased pressure inside the eye); postictal headache that occurs after a seizure or other type of epileptic seizure as part of the postictal period (postictal state); gastrointestinal disorders that may cause headaches, including Helicobacter pylori infection, celiac disease, non-celiac gluten sensitivity, irritable bowel syndrome, inflammatory bowel disease, gastroparesis, and hepatobiliary disorders. Treatment of gastrointestinal disorders can lead to relief or improvement of headaches. The term headache is defined as either primary or secondary. Primary headaches were defined as migraine, tension-type headache (TTH), cluster headache and other trigeminal autonomic headaches and other primary headaches.The diagnosis or assessment of headache is well established in the art. Assessment can be based on subjective measures such as patient characterization of symptoms. For example, migraine can be diagnosed according to the following criteria: 1) headache attack lasts 4 to 72 hours; 2) has two of the following symptoms: unilateral pain, throbbing, aggravation after movement, and moderate or severe pain; and 3) one of the following symptoms: nausea or vomiting, photophobia or phonophobia. Goadsby et al., N.Engl.J.Med.346:257-270, 2002 ).
[0201] "Children" symptoms can be associated with fever, cold sensitivity, menopause, panic attacks, anxiety, bacterial infections, rickettsial infections, viral infections, medication withdrawal, etc.
[0202] "Vomiting" symptoms can be associated with the following diseases: gastritis (inflammation of the stomach lining), gastroenteritis, gastroesophageal reflux disease, celiac disease, non-celiac gluten sensitivity, pyloric stenosis, intestinal obstruction, overeating, acute abdomen and / or peritonitis, intestinal obstruction, food allergies (usually accompanied by hives or swelling); cholecystitis, pancreatitis, appendicitis, hepatitis; food poisoning, allergic reaction to milk protein such as milk allergy or lactose intolerance; motion sickness, Meniere's disease, concussion, cerebral hemorrhage, migraine, brain tumor, benign intracranial hypertension and hydrocephalus, metabolic disorders such as hypercalcemia, uremia adrenal insufficiency, hypoglycemia, hyperglycemia, drug reaction, alcoholism, opioid ingestion, selective serotonin reuptake inhibitors; use of chemotherapy drugs; stomach inflammation caused by various viruses and bacteria such as norovirus, influenza; or psychiatric / behavioral disorders such as bulimia nervosa and elimination disorders.
[0203] Another embodiment of the present invention relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold according to any of the preceding embodiments, for use in treating or preventing symptoms of a disease selected from nausea, headache, muscle pain, back pain, tremor, vomiting in a subject in need thereof, or for treating or preventing a disease characterized by such symptoms, such as migraine, in combination with known drugs for nausea.
[0204] Another embodiment of the present invention relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold according to any of the preceding embodiments, for use in treating or preventing symptoms of a disease selected from nausea, headache, muscle pain, back pain, tremor, vomiting in a subject in need thereof, or for treating or preventing a disease characterized by such symptoms, such as migraine, in combination with known drugs for headache.
[0205] Another embodiment of the present invention relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold according to any of the preceding embodiments, for use in treating or preventing symptoms of a disease selected from nausea, headache, muscle pain, back pain, tremor, vomiting in a subject in need thereof, or for treating or preventing a disease characterized by such symptoms, such as migraine, in combination with known drugs for myalgia.
[0206] Another embodiment of the present invention relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold according to any of the preceding embodiments, for use in treating or preventing symptoms of a disease selected from nausea, headache, muscle pain, back pain, tremor, vomiting in a subject in need thereof, or for treating or preventing a disease characterized by such symptoms, such as migraine, in combination with known drugs for tremor.
[0207] Another embodiment of the present invention relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold according to any of the preceding embodiments, for use in treating or preventing symptoms of a disease selected from nausea, headache, muscle pain, back pain, tremor, vomiting in a subject in need thereof, or for treating or preventing a disease characterized by such symptoms, such as migraine, in combination with known drugs for vomiting.
[0208] Another embodiment of the present invention relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold according to any of the preceding embodiments, for use in treating or preventing symptoms of a disease selected from nausea, headache, muscle pain, back pain, tremor, vomiting in a subject in need thereof, or for treating or preventing a disease characterized by such symptoms, such as migraine, in combination with known drugs for back pain.
[0209] The subject matter of the present invention is a pharmaceutical preparation for treating or preventing an acute disease or acute condition in a patient to prevent or alleviate organ dysfunction or prevent organ failure in said patient, wherein said acute disease or acute condition is selected from, for example, severe infection, diabetes, cancer, acute and chronic vascular diseases such as heart failure, myocardial infarction, stroke, atherosclerosis, shock and organ dysfunction, renal dysfunction, liver dysfunction, burns, surgery, trauma, poisoning and injury caused by chemotherapy, and wherein said disease is not SIRS, sepsis or septic shock.
[0210] "Organ dysfunction" is a condition or health state in which an organ fails to perform its intended function. "Organ failure" is organ dysfunction that has progressed to the point where normal homeostasis cannot be maintained without external clinical intervention.
[0211] The patient group targeted by the present invention can be defined as follows.
[0212] In the following, clinical criteria of the respective organs prone to dysfunction or failure are mentioned, thus representing the group of patients suffering from chronic or acute diseases or acute conditions according to the invention:
[0213] The criteria are based on the clinical SOFA score.
[0214] The SOFA system was created in 1994 at a consensus conference of the European Society of Intensive Care Medicine and further revised in 1996.
[0215] SOFA is a six-organ dysfunction / failure score that measures multiple organ failure on a daily basis. Each organ is graded from 0 (normal) to 4 (most abnormal), providing a daily score of 0 to 24. The purpose of SOFA is to create a simple, reliable, and continuous score for clinical staff.
[0216] Sequential assessment of organ dysfunction during the first few days of intensive care unit (ICU) or hospitalization is a good indicator of prognosis. Both the mean and maximum SOFA scores are particularly useful predictors of outcome.
[0217]
[0218] MAP, mean arterial pressure; CNS, central nervous system; SaO 2 , peripheral arterial oxygen saturation. a Prioritize PaO 2 / FIO 2 If not available, use SaO 2 / FIO 2 ratio; b Vasoactive drugs were administered for at least 1 hr (dopamine and norepinephrine, μg / kg / min).
[0219] References for SOFA scores
[0220] 1. Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med. 2009 May;37(5):1649-54.
[0221] 2. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001 Oct 10; 286(14): 1754-8.
[0222] 3.Vincent JL,Moreno R,Takala J,Willatts S,De A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction / failure. On behalf of the European Society of Intensive Care Medicine Working Group on Sepsis-Related Issues. Intensive Care Med. 1996 Jul;22(7):707-10.
[0223] In a specific embodiment, the patient group according to the present invention has at least one SOFA score of the lower threshold, i.e. one of the respiratory, or liver, or coagulation, or cardiovascular, or CNS or renal clinical criteria of 1 on the day of admission to the hospital or intensive care unit (ICU). Therefore, said patient group is in need of a therapeutic intervention according to the present invention and is therefore in need of preventing or alleviating organ dysfunction or organ failure.
[0224] In another specific embodiment, the patient group according to the present invention has at least two SOFA scores at the lower threshold on the day of admission to the hospital or intensive care unit (ICU), i.e. respiratory, and / or liver, and / or coagulation, and / or cardiovascular, and / or CNS and / or renal clinical criteria each being 1. Therefore, said patient group is in need of a therapeutic intervention according to the present invention and therefore in need of preventing or alleviating organ dysfunction or organ failure.
[0225] In another specific embodiment, the patient group according to the present invention has at least three SOFA scores at the lower threshold on the day of admission to the hospital or intensive care unit (ICU), i.e. respiratory, and / or liver, and / or coagulation, and / or cardiovascular, and / or CNS and / or renal clinical criteria each being 1. Therefore, said patient group is in need of a therapeutic intervention according to the present invention and therefore in need of preventing or alleviating organ dysfunction or organ failure.
[0226] In another specific embodiment, the patient group according to the present invention has at least four SOFA scores at the lower threshold on the day of admission to the hospital or intensive care unit (ICU), i.e. respiratory, and / or liver, and / or coagulation, and / or cardiovascular, and / or CNS and / or renal clinical criteria each being 1. Therefore, said patient group is in need of a therapeutic intervention according to the present invention and therefore in need of preventing or alleviating organ dysfunction or organ failure.
[0227] Patient groups – Renal dysfunction / failure
[0228] In the following, the clinical criteria represent the patient groups with renal dysfunction / failure:
[0229] Patients at risk for renal dysfunction / failure: GFR decline > 25%, serum creatinine increase 1.5-fold, or urine output < 0.5 ml / kg / hr for 6 hours
[0230] Patients with renal impairment: GFR decrease > 50%, doubling of creatinine, or urine output < 0.5 ml / kg / hr for 12 hours
[0231] Renal failure: GFR decrease > 75%, creatinine tripled or creatinine > 355 μmol / l (increase > 44) (> 4 mg / dl) or urine output less than 0.3 ml / kg / hr for 24 hours
[0232] Patients with renal loss: Persistent acute kidney injury (AKI) or complete renal loss for more than 4 weeks
[0233] End-stage renal disease: Complete loss of kidney function for more than 3 months.
[0234] Patient groups – Liver dysfunction / failure
[0235] The group of patients with liver dysfunction / failure is characterized by a lower threshold of bilirubin > 1.2 mg / dL, preferably > 1.9 mg / dL, more preferably > 5.9 mg / dL.
[0236] The pharmaceutical preparation can also be administered prophylactically before the patient shows any signs of organ dysfunction or failure. This may be the case if the patient suffers from a chronic or acute disease or acute condition where dysfunction or failure problems may be expected, for example, including severe infections such as meningitis, systemic inflammatory response syndrome (SIRS), sepsis; other diseases such as diabetes, cancer, acute and chronic vascular diseases such as heart failure, myocardial infarction, stroke, atherosclerosis; shock such as septic shock and organ dysfunction such as renal dysfunction, liver dysfunction, burns, surgery, trauma, poisoning. The pharmaceutical preparation can also be administered prophylactically or therapeutically before, during or after chemotherapy. The same applies to surgeries where ischemic damage may occur to certain organs, which can lead to organ dysfunction or failure. Prophylactic means before organ damage occurs, and therapeutic means that organ damage has already occurred. Particularly useful are antibodies or fragments or scaffolds according to the present invention, which are used to reduce the risk of organ dysfunction or failure during sepsis and septic shock (i.e., the late stage of sepsis).
[0237] The subject matter of the present invention is a pharmaceutical preparation for treating or preventing an acute disease or acute condition in a patient to stabilize the systemic circulation of the patient, wherein the patient suffers from a disease selected from SIRS, sepsis, diabetes, cancer, acute vascular disease such as heart failure, shock such as septic shock and organ dysfunction such as renal dysfunction.
[0238] In another embodiment of the present invention, a pharmaceutical preparation is used to treat an acute disease or acute condition in a patient to stabilize the patient's circulation, especially the systemic circulation. Specifically, the subject matter of the present invention is a pharmaceutical preparation for treating an acute disease or acute condition in a patient to stabilize the patient's systemic circulation, wherein the patient needs to stabilize the circulation.
[0239] Systemic circulation refers to the part of the circulatory system where blood leaves the heart, serves the body's cells, and then re-enters the heart. Blood leaves the left ventricle and flows to the aorta, the body's largest artery. The aorta leads to smaller arteries, arterioles, and finally capillaries. Waste products and carbon dioxide diffuse from the cells into the blood, and oxygen from the blood diffuses into the cells. The blood then flows to the venous capillaries and then to the vena cava: the inferior and superior vena cava, through which blood re-enters the heart at the right atrium.
[0240] Throughout this specification, stabilizing circulation means stabilizing systemic circulation. The term systemic circulation does not encompass microcirculation phenomena. Microcirculation is the smallest blood vessel that fresh blood is transported to the vascular system that is embedded in the organ tissue. This is in sharp contrast to the macrocirculation that transports blood to and from the organ. The state of systemic circulation can be measured by parameters such as mean arterial pressure, blood pressure (other parameters are shown above). Therefore, patients who need stable circulation can be patients with heart rate>100 times / min and / or mean arterial pressure<65mmHg. If circulation is stabilized by administering anti-adrenomedullin (ADM) antibodies or anti-ADM antibody fragments that are combined with adrenomedullin or anti-ADM non-Ig scaffolds that are combined with adrenomedullin, this can be measured and characterized by increasing mean arterial pressure to more than 65mmHg and / or reducing heart rate to less than 100 times / min.
[0241] It should be emphasized that the pharmaceutical preparations provided by the present invention are intended to be applied for the purpose of stabilizing systemic circulation and are therefore not necessarily intended for any primary treatment or first-line treatment of acute diseases or acute conditions which must be considered as underlying diseases per se. This means that the present invention does not provide a therapy for healing / curing, for example, cancer, diabetes, meningitis, multiple injuries, etc. Therefore, within the scope of the present invention, the therapy for acute diseases or acute conditions in patients involves any type of systemic circulation deficiency or poor systemic circulation of blood as an acute event.
[0242] The subject matter of the present invention is a pharmaceutical preparation,
[0243] a) for the treatment of an acute disease or acute condition in a patient in order to stabilize the patient's systemic circulation, wherein the patient requires systemic circulation stabilization and exhibits a heart rate > 100 beats / min and / or a mean arterial pressure < 65 mmHg, and wherein stabilization of systemic circulation means increasing the mean arterial pressure to more than 65 mmHg, or
[0244] b) For prophylactic use in the treatment of an acute disease or acute condition in a patient to prevent an increase in heart rate to >100 beats / min and / or a decrease in mean arterial pressure to <65 mmHg.
[0245] In all of the above acute diseases and conditions, it may be necessary to stabilize the patient's circulation by administering a pharmaceutical preparation. Pharmaceutical preparations may also be administered prophylactically in patients with acute diseases or conditions to prevent an increase in heart rate to >100 beats / min and / or a decrease in mean arterial pressure to <65 mmHg.
[0246] In one embodiment, the pharmaceutical formulation according to the present invention reduces the patient's vasopressor requirement, such as catecholamine requirement. The patient's vasopressor requirement, such as catecholamine requirement, is an indicator of the patient's circulatory status. Therefore, the pharmaceutical formulation can be administered at a time point when the patient requires a vasopressor, such as a catecholamine.
[0247] In one embodiment of the present invention, the patient is a patient in need of increased blood pressure.
[0248] A patient who needs stabilization of circulation may be one with low cardiac output and / or low blood pressure (hypotension). This may be a patient with a heart rate >100 beats / min. This may be a patient with a mean arterial pressure <65 mmHg or even <60 mmHg. Mean arterial pressure is defined as MAP = (CO x SVR) + CVP, where CO is cardiac output, SVR is systemic vascular resistance, and CVP is central venous pressure, and is usually so small that it can be ignored in this formula. A patient who needs stabilization of circulation may also be one with a respiratory rate >20 / min in addition to the above symptoms.
[0249] In a particular embodiment of the invention, the patient in need of stabilization of circulation may be a patient with low cardiac output and / or low blood pressure (hypotension). This may be a patient with a heart rate > 90 beats / min. This may be a patient with a mean arterial pressure < 65 mmHg or even < 60 mmHg.
[0250] Despite adequate fluid replacement, some sepsis-induced hypoperfusion patients may remain hypotensive. In these cases, vasopressors are required to increase MAP. Therefore, in one embodiment of the present invention, patients with chronic or acute diseases or acute conditions are patients who require vasopressors to increase MAP. Catecholamines, such as dopamine, epinephrine, norepinephrine, and phenylephrine, have traditionally been used to increase blood pressure in patients with, for example, septic shock. Recently, vasopressin has also been suggested as a potential vasopressor in patients with chronic or acute diseases or acute conditions who require circulatory stabilization.
[0251] Vasopressors such as catecholamines can stabilize the circulation of patients with chronic or acute diseases or acute conditions. In cases where the patient's condition (hypotension) is very critical, the administration of vasopressors such as catecholamines alone may not prevent the collapse of the circulation. The additional administration of the pharmaceutical preparation together with the administration of, for example, catecholamines can help stabilize the circulation of patients whose condition is so critical that the administration of catecholamines without the administration of the pharmaceutical preparation would not be sufficient to stabilize the patient's circulation.
[0252] In addition, vasopressors can have serious side effects. Dopamine stimulates D1 receptors in the local circulation of the kidney, producing vasodilation and increasing blood flow. This is one reason clinicians use low doses of dopamine to protect renal function. In addition, for other vasopressors, it has been proposed that the use of certain drugs to increase blood pressure, although intuitively appealing because of certain benefits, may be associated with worse outcomes.
[0253] The subject of the present invention is therefore a pharmaceutical preparation for use in the treatment of an acute disease or acute condition in a patient to completely or partially replace the administration of a vasopressor. This means that the patient according to the present invention can be a patient in need of vasopressor therapy or a patient receiving vasopressor therapy.
[0254] The pharmaceutical preparation can also be administered prophylactically before the patient shows any signs of severe circulatory problems. This may be the case if the patient suffers from a chronic or acute disease or acute condition where circulatory problems may be expected, including severe infections such as meningitis, systemic inflammatory response syndrome (SIRS) or sepsis; other diseases such as diabetes, cancer, acute and chronic vascular diseases such as heart failure, myocardial infarction, stroke, atherosclerosis; shock such as septic shock and organ dysfunction such as renal dysfunction, liver dysfunction, burns, surgery, trauma, poisoning, injury caused by chemotherapy.
[0255] Particularly useful are antibodies or fragments or scaffolds according to the invention for reducing the risk of death during sepsis and septic shock (i.e., the late stage of sepsis). It is known to those skilled in the art that, according to the present invention, the reduced risk of death is related to the stabilization of circulation. An acute disease or acute condition may be a disease or condition in which the patient is characterized by the need for stable circulation. The need for stable circulation is characterized as summarized above, i.e., this may be a patient with a heart rate preferably >90 beats / min or even a heart rate >100 beats / min. This may be a patient with a mean arterial pressure <65 mmHg or even <60 mmHg. Mean arterial pressure is defined as MAP=(COxSVR)+CVP, where CO is cardiac output; SVR is systemic vascular resistance, CVP is central venous pressure, and is usually so small that it can be ignored in this formula. Patients who need stable circulation may also be patients with a respiratory rate >20 / min.
[0256] In some embodiments of the present invention, a pharmaceutical formulation is also provided, which is used in combination with another active drug, for example, used as a main drug, wherein the combination is used to treat or prevent a chronic or acute disease or acute condition in a patient to stabilize the patient's circulation, in particular the patient's systemic circulation.
[0257] In one embodiment of the invention, said patient having a chronic or acute disease or acute condition requiring circulatory stabilization is characterized in that said patient requires access to intravenous fluids.
[0258] Therefore, in a specific embodiment, the subject matter of the present invention is the pharmaceutical preparation combined with ADM binding protein and / or other active ingredients for the treatment or prevention of patients who need intravenous fluids. This means that the patient needs intravenous fluids to regulate the body fluid balance.
[0259] The pharmaceutical preparations and ADM binding proteins and / or other active ingredients can be used in combination with vasopressors such as catecholamines and / or intravenously administered fluids for chronic or acute diseases or acute conditions in patients to stabilize circulation, particularly systemic circulation.
[0260] The antibodies, antibody fragments and combinations of the present invention can be used to treat or prevent chronic or acute diseases in patients:
[0261] for the prevention of organ dysfunction or failure, particularly renal dysfunction or failure, and / or
[0262] To stabilize circulation, e.g., to reduce the patient's need for vasopressors, e.g., catecholamines, and / or
[0263] for regulating fluid balance in said patient,
[0264] To reduce the risk of death in said patient.
[0265] The subject matter of the present invention is a pharmaceutical preparation for treating or preventing an acute disease or acute condition in a patient to regulate fluid balance, wherein the patient is a patient in need of regulating fluid balance and suffering from a disease selected from systemic inflammatory response syndrome (SIRS), sepsis, diabetes, cancer, heart failure, shock and renal dysfunction.
[0266] In the context of the present invention, the expression "regulating fluid balance" refers to any correction of a significant imbalance in a patient's fluid balance due to an underlying chronic or acute disease or acute condition. Said correction contributes to reestablishing normal blood pressure in said patient. A person skilled in the art is fully aware that blood pressure, as well as hypertension and hypotension in general, are closely related to a patient's fluid balance.
[0267] Fluid balance is the balance of fluid input and output in the body to allow metabolic processes to function. Dehydration is defined as a loss of 1% or more of body weight as a result of fluid loss.
[0268] The three elements of assessing fluid balance and hydration status are: clinical assessment, weight and urine output; review of fluid balance charts, and review of blood chemistry.
[0269] All of this is well known to the person skilled in the art (Alison Shepherd, Nursing Tomes 19.07.11 / Vol 107 No 28, pages 12 to 16).
[0270] Therefore, in one embodiment, the person who needs to adjust the fluid balance of such patients and / or improve the fluid balance is a person who loses 1% or more of body weight as a result of fluid loss. Fluid balance can be assessed according to Scales and Pilsworth, (2008), Nursing Standard 22:47,50-57. For example, normal urine output is within the range of 0.5 to 2 ml / kg body weight per hour. The minimum acceptable urine output for patients with normal renal function is 0.5 ml / kg per hour. All of these criteria can be used to assess whether a patient needs to adjust the fluid balance and / or improve the fluid balance.
[0271] Patients in a state of fluid imbalance can receive intravenous fluids as standard care measures, particularly in an ICU setting. However, due to the occurrence of possible complications such as edema (acral edema), it is desirable to reduce or avoid additional fluid administration. Edema refers to swelling caused by fluid in body tissues. It can occur in the feet and legs, but can involve the entire body and can involve organs such as the lungs, heart, and eyes. Therefore, the pharmaceutical preparation can be administered at a time point when the patient needs fluid administration. According to the present invention, the patient is a patient who needs to adjust fluid balance.
[0272] Therefore, the subject of the present invention is also a pharmaceutical preparation for use in the treatment of an acute disease or acute condition in a patient, which is used to regulate the balance of body fluids, including but not limited to preventing or reducing edema.
[0273] Fluid balance / fluid therapy
[0274] In acute hospital settings such as those in the ICU, clinical staff often monitor fluid balance carefully, as this provides specific information about the patient's actual hydration status, and therefore renal and cardiovascular function.
[0275] However, if the acute fluid loss is greater than the fluid gain, the patient is said to be in a negative fluid balance. In this case, doctors usually give physiological fluids intravenously to make up for the loss.
[0276] In contrast, a positive fluid balance, where fluid gains are greater than fluid losses, can provide information about problems with the kidneys or cardiovascular system.
[0277] In cases such as SIRS, sepsis, severe sepsis and septic shock, this means, among other things, that the blood pressure is also low (often referred to as hypotension) and the filtration rate of the kidneys will be reduced, leading to reduced fluid reabsorption and reduced urine output.
[0278] The term "fluid therapy" generally refers to the therapeutic administration of fluids (e.g., saline solution or water for injection (WFI)) to a patient as a treatment or preventive measure. It can be administered by intravenous, intraperitoneal, intraosseous, subcutaneous, and oral routes.
[0279] Fluid therapy is indicated when there is fluid loss or there is a risk of fluid loss due to an underlying disease or condition. The severity of the fluid loss and the compartment into which it is lost influences the choice of fluid and how quickly it needs to be administered. If fluid therapy is to be administered as a treatment, then it is necessary to diagnose and treat the underlying disease or condition. Fluid therapy is often indicated in cases of hypotension, hypovolemia, metabolic disorders, decreased oxygen delivery, SIRS, sepsis, severe sepsis, shock, and septic shock.
[0280] However, it should be emphasized that the drugs provided by the present invention, i.e. the pharmaceutical preparations, are intended only for the purpose of regulating fluid balance and are therefore not used in any primary treatment methods for chronic or acute diseases or conditions per se. This means that the present invention does not provide a therapy for healing / curing, for example, meningitis, systemic inflammatory response syndrome (SIRS) or sepsis or severe sepsis within the scope of the present invention, other diseases such as diabetes, cancer, acute and chronic vascular diseases such as heart failure, myocardial infarction, stroke, atherosclerosis, shock such as septic shock and organ dysfunction such as renal dysfunction, liver dysfunction, burns, surgery, trauma, poisoning or damage caused by chemotherapy.
[0281] Thus, the fluid regulating effect of the pharmaceutical preparation supports the primary therapy of the chronic or acute disease or acute condition. In the case of chronic or acute diseases or acute diseases such as severe infections such as meningitis, systemic inflammatory response syndrome (SIRS), sepsis, etc., the primary therapy is, for example, the administration of antibiotics. The pharmaceutical preparation will regulate fluid balance and help prevent the patient's critical condition from worsening until, for example, antibiotic administration takes effect. As previously mentioned, the pharmaceutical preparation can be administered in a prophylactic or therapeutic manner, which means for preventing fluid imbalance problems or for alleviating fluid imbalance when there are fluid imbalance problems in the patient. Edema is included in the term fluid imbalance problems.
[0282] In one embodiment of the invention, the patient suffering from a chronic or acute disease or condition requiring regulation of fluid balance is characterized in that the patient requires administration of a vasopressor, such as a catecholamine.
[0283] Thus, in a particular embodiment of the invention, the subject matter of the invention is said pharmaceutical preparation for use in the therapy of patients in need of treatment with vasopressors such as catecholamines.
[0284] Patients who need to improve fluid balance may have features of capillary leak and may have an hourly urine output < / =0.5–1cc / kg。
[0285] The subject matter of the present invention is a pharmaceutical preparation for treating or preventing congestion in a patient suffering from a disease or condition selected from congestive hypertension, swelling or water retention (edema), heart failure (particularly acute heart failure), kidney disease or liver disease.
[0286] In a specific embodiment, the pharmaceutical formulation may be administered to a patient suffering from vascular barrier dysfunction or endothelial dysfunction that may lead to congestion.
[0287] Vascular barrier dysfunction or endothelial dysfunction is a systemic pathological state of the endothelium (the inner lining of blood vessels) and can be broadly defined as an imbalance between vasodilatory and vasoconstrictive substances produced by (or acting on) the endothelium ( Deanfield et al., 2005, J Hypertens 23(1):7–17 ). Normal functions of endothelial cells include mediating coagulation, platelet adhesion, immune function, and controlling the volume and electrolyte content of the intravascular and extravascular spaces. The endothelium is a cell monolayer that lines the entire cardiovascular system and regulates many processes, including vascular tone, thrombosis, angiogenesis, and inflammation. Endothelial cells have been shown to be phenotypically dynamic and are able to switch between quiescent and activated states in response to a variety of local and systemic stimuli ( Colombo et al., 2015, CurrHeart Fail Rep. 12(3):215–222 In recent years, emerging research has demonstrated that endothelial dysfunction is a major contributing factor to cardiovascular diseases including hypertension, atherosclerosis, and congestive heart failure ( Gutierrez et al., 2013, EuropeanHeart Journal 34:3175–3181 ).
[0288] The endothelium tightly controls the exchange of fluid from the circulation to the peripheral tissues, and dysfunction of this barrier results in uncontrolled extravasation of fluid, which can lead to congestion and / or edema. A common feature of edema (e.g., pulmonary edema) is increased permeability to water and low molecular weight solutes ( Rocker et al., 1987, Thorax 42: 620-23 ).
[0289] Endothelial dysfunction can be caused by and / or contribute to a variety of disease processes, as occurs in hypertension, hypercholesterolemia, diabetes, or septic shock. Endothelial dysfunction is an important pathophysiological mechanism leading to coronary artery disease and other atherosclerotic diseases.
[0290] From preclinical experiments in sepsis / septic shock models, it is known that administration of anti-ADM antibodies induces increases in plasma bio-ADM concentrations, and this is consistent with improved survival ( Struck et al., 2013, IntensiveCare MedExp1(1):22 ). The mechanism behind this effect is thought to be as follows:
[0291] When the pharmaceutical preparation is administered iv, it cannot enter the interstitial tissue by crossing the endothelial barrier due to its size, but stays in the blood circulation. In contrast, ADM as a small peptide can freely diffuse across the endothelial barrier. Therefore, when administered in a molar excess greater than that of endogenous ADM, the antibody almost combines all ADM in the plasma, and as a simple result of reaching a binding equilibrium, causes ADM to translocate from the interstitial tissue to the blood circulation. The interstitial localized ADM can combine with vascular smooth muscle cells and induce relaxation, leading to vasodilation. This is reduced by the administration of the antibody. On the other hand, the ADM in the plasma combines with endothelial cells, thereby stabilizing or even restoring vascular integrity. Therefore, when the plasma ADM level increases due to the administration of the antibody (which is a non-neutralizing antibody), this function is enhanced. Finally, the combination of the antibody with ADM reduces the proteolytic attenuation of ADM.
[0292] Surprisingly, we observed in the PROTECT study and the BIOSTAT study (see, e.g., WO2018 / 109228) that in subjects with heart failure, despite their diuretic treatment, bio-ADM concentrations increased with the presence and severity of congestion. Therefore, the increase in bio-ADM in these patients is the body's counter-regulation of tissue congestion. However, the natural increase is not enough to effectively achieve this counter-regulation. Tissue congestion also occurs in sepsis. For example, it can be demonstrated in WO2018 / 109228 that the administration of anti-ADM antibodies in animal models of sepsis leads to the restoration of impaired vascular integrity. Due to the parallel mechanisms of tissue congestion in both sepsis and heart failure, experts in the field believe that, similar to sepsis / septic shock, the administration of anti-ADM antibodies must be beneficial in treating congestion in heart failure.
[0293] In a specific embodiment of the invention, the pharmaceutical formulation is used for intervention and treatment of congestion in a patient according to any embodiment of the invention, wherein the patient is diuretic resistant or unresponsive to diuretic therapy.
[0294] Another particular embodiment of the invention relates to said pharmaceutical preparation for use in the intervention and treatment of congestion in a patient in need thereof, wherein said patient is resistant to diuretics or unresponsive to diuretic therapy.
[0295] The term "diuretic resistance" is generally defined as the inability to reduce extracellular fluid volume despite liberal use of diuretics ( Ravnan et al., 2002, CHF 8:80-85 Epstein et al defined diuretic resistance as the failure to excrete at least 90 mmol of sodium within 72 hours of a 160 mg oral furosemide dose twice daily ( Epstein et al., 1977, Curr Ther Res.21:656-667 ).
[0296] Adaptation to diuretic medications and diuretic resistance may result from similar mechanisms. Diuretic adaptations can be classified as those that occur during the duration of diuretic action, those that cause sodium retention in the short term (causing "postdiuretic NaCl retention"), and those that increase sodium retention in the long term (the "braking phenomenon"). The kidneys adapt to chronic diuretic therapy in the following ways: First, nephron segments downstream of the site of diuretic action increase NaCl reabsorption during diuretic administration because of the increased NaCl load delivered. Second, as diuretic concentrations in the tubules decrease, the tubules act to retain sodium until the next dose of diuretics is administered. Third, the ability of diuretics to increase renal NaCl excretion decreases over time, resulting from both a decrease in extracellular fluid volume and structural and functional changes in the tubules themselves. These adaptations all increase the rate of NaCl reabsorption and diminish the effectiveness of diuretic therapy. For a review, see Ellison, 1999, Semin Nephrol.19(6):581-97 and De Bruyne, 2003, Postgrad MedJ79:268–271 .
[0297] Although difficult to quantify, diuretic resistance is believed to occur in one-third of patients with congestive HF. Heart failure represents the most common clinical setting in which diuretic resistance is observed. In mild congestive HF, diuretic resistance is uncommon as long as renal function is preserved. However, in patients with moderate and severe congestive HF, diuretic resistance occurs more frequently and often becomes a clinical problem ( Brater, 1985, Drugs 30:427-443; Taylor, 2000, Cardiol Rev.8:104-114 ).
[0298] The subject matter of the present invention is a pharmaceutical preparation for treatment or prevention comprising:
[0299] Prior to drug administration, determining the level of a pro-adrenomedullin precursor fragment selected from mid-region pro-adrenomedullin (MR-proADM), C-terminal pro-adrenomedullin (CT-proADM), Bio-ADM, ADM-gly, or pro-adrenomedullin N-terminal 20 peptide (PAMP) or a fragment thereof in a body fluid obtained from the subject; and
[0300] comparing the level of said pro-adrenomedullin fragment selected from MR-proADM, CT-proADM, PAMP, Bio-ADM or ADM-gly to a predefined threshold or a previously determined level of said fragment, and
[0301] ●Wherein, for relevance, the level of pro-adrenomedullin fragment selected from MR-proADM, CT-proADM, PAMP, Bio-ADM or ADM-gly or fragments thereof above a certain threshold or an increased level above a previously determined level is used for stratification of patients for therapeutic use according to the present invention.
[0302] As used herein, the term "PAMP" includes two circulating forms of PAMP, namely, a biologically inactive C-terminal glycine-extended PAMP (PAMP-Gly) and a biologically active C-terminal amidated PAMP (PAMP-Amide).
[0303] As used herein, the terms "Bio-ADM" and "ADM-NH2" shall be used synonymously and both refer to circulating bioactive adrenomedullin.
[0304] In another embodiment of the present application, the pro-adrenomedullin precursor fragment that can be measured in the body fluid is selected from:
[0305] SEQ ID No.10 (Pro-adrenomedullin N-terminal 20 peptide, PAMP): amino acids 22-41 of preproADM
[0306] ARLDVASEF RKKWNKWALS R
[0307] SEQ ID No. 11 (Middle Pro-Adrenomedullin, MR-proADM): amino acids 45-92 of preproADM
[0308] ELRMSS SYPTGLADVK AGPAQTLIRP QDMKGASRSP EDSSPDAARI RV
[0309] SEQ ID No. 12 (C-terminal pro-adrenomedullin, CT-proADM): amino acids 148-185 of preproADM
[0310] RRR RRSLPEAGPG RTLVSSKPQA HGAPAPPSGS APHFL
[0311] SEQ ID No.13 (mature human adrenomedullin (mature ADM); amidated ADM; bio-ADM; ADM-NH2): amino acids 1-52 or 95-146 of pro-ADM
[0312] YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVA PRSKISPQGY-CONH2
[0313] SEQ ID No.: 14 (Adrenomedullin 1-52-Gly (ADM 1-52-G1y): amino acids 95-147 of preproADM)
[0314] YRQSMN NFQGLRSFGC RFGTCTVQKL AHQIYQFTDK DKDNVAPRSK ISPQGYG
[0315] In another embodiment of the present application, the fragment of pro-Adrenomedullin precursor having at least 5 amino acids is selected from MR-proADM (SEQ ID No. 11), CT-proADM (SEQ ID No. 12) and / or PAMP (SEQ ID No. 10).
[0316] In one embodiment of the present application, the level of said pre-proADM and / or fragments thereof is determined by using at least one binding agent, wherein said binding agent binds to a region comprised within the sequence of MR-proADM (SEQ ID No. 11).
[0317] In another embodiment of the present application, the level of pre-pro-ADM and / or fragments thereof is determined by using at least one binding agent, wherein the binding agent binds to a region contained within the sequence of CT-proADM (SEQ ID No. 12).
[0318] In another embodiment of the present application, the level of pre-proADM and / or fragments thereof is determined by using at least one binding agent, wherein the binding agent binds to a region contained within the sequence of PAMP (SEQ ID No. 10).
[0319] In a particular embodiment of the present application, the subject matter is a method, wherein the fragment can be selected from MR-proADM according to SEQ ID No.: 11 and / or CT-proADM according to SEQ ID No.: 12 and / or PAMP according to SEQ ID No.: 10.
[0320] In a specific embodiment of the diagnostic method, the proADM and / or a fragment thereof having at least 5 amino acids is selected from the group consisting of mature ADM-NH 2(SEQ ID No. 13), ADM 1-52-Gly (SEQ ID No. 14), MR-proADM (SEQ ID No. 11) and CT-proADM (SEQ ID No. 12).
[0321] In a specific embodiment of the diagnostic method, the mature ADM-NH 2 (SEQ ID No. 13) and / or ADM1-52-Gly (SEQ ID No. 14) immunoreactivity or MR-proADM (SEQ ID No. 11) immunoreactivity or CT-proADM (SEQ ID No. 12) immunoreactivity, and correlating it with the patient's need for therapy or intervention, wherein if the mature ADM-NH 2 (SEQ ID No.13) and / or ADM 1-52-Gly (SEQ ID No.14) immunoreactivity or the level of MR-proADM (SEQ ID No.11) immunoreactivity or the level of CT-proADM (SEQ ID No.12) immunoreactivity is above a threshold value, the patient is identified as having such a need.
[0322] In a particular embodiment of the diagnostic method, the level of proADM and / or its fragments is determined by using at least one binding agent selected from: 2 (SEQ ID No. 13) and / or ADM1-52-Gly (SEQ ID No. 14), and binders that bind to regions within the sequence of mature ADM-NH 2 (SEQ ID NO. 13) and / or ADM 1-52-Gly (SEQ ID No. 14).
[0323] In a specific embodiment of the diagnostic method, the level of proADM and / or its fragments is determined by using at least one binding agent selected from: a binding agent that binds to a region contained within the sequence of MR-proADM (SEQ ID No.11), and a second binding agent that binds to a region contained within the sequence of MR-proADM (SEQ ID No.11).
[0324] In a particular embodiment of the diagnostic method, the level of proADM and / or its fragments is determined by using at least one binding agent selected from: a binding agent that binds to a region contained within the sequence of CT-proADM (SEQ ID No. 12), and a second binding agent that binds to a region contained within the sequence of CT-proADM (SEQ ID No. 12).
[0325] In a particular embodiment of the diagnostic method of the invention, the subject matter is a method according to the invention, wherein the fragment can be selected from MR-proADM according to SEQ ID No.: 11 or mature ADM-NH according to SEQ ID No.: 13. 2 .
[0326] In a specific embodiment of the invention, the threshold value is within the threshold range of plasma MR-proADM, which is between 0.5 and 1.5 nmol / L, preferably between 0.7 and 1 nmol / L, and most preferably a threshold value of 0.8 nmol / L is applied.
[0327] In a specific embodiment of the present invention, the predetermined threshold value of Bio-ADM in the body fluid sample of the subject is between 40 and 100 pg / mL, more preferably between 50 and 90 pg / mL, even more preferably between 60 and 80 pg / mL, and most preferably the threshold value is 70 pg / mL.
[0328] In a specific embodiment of the invention, the threshold value is within the threshold range of plasma CT-proADM, which is between 85 and 350 pmol / L, preferably between 100 and 250 pmol / L, most preferably a threshold value of 150 pmol / L is applied.
[0329] In a specific embodiment of the invention, the threshold value of plasma PAMP-amide is between 0.3 and 1.2 pmol / L, preferably between 0.4 and 1.0 pmol / L, most preferably a threshold value of 0.8 pmol / L is applied.
[0330] In a specific embodiment of the invention, the threshold value of the plasma PAMP-glycine is between 0.5 and 2.0 pmol / L, preferably between 0.7 and 1.8 pmol / L, most preferably a threshold value of 1.5 pmol / L is applied.
[0331] In a specific embodiment of the invention, the threshold is in plasma ADM-NH 2 The threshold value range is between 50 and 100 pg / ml, preferably between 60 and 90 pg / ml, and most preferably a threshold value of 70 pg / ml is applied.
[0332] In a specific embodiment of the present invention, the threshold value of plasma Bio-ADM is 5 times the median concentration of normal healthy people, preferably 4 times the median concentration, more preferably 3 times the median concentration, most preferably 2 times the median concentration.
[0333] In a specific embodiment of the present invention, the threshold value of plasma MR-proADM is 5 times the median concentration of normal healthy people, preferably 4 times the median concentration, more preferably 3 times the median concentration, most preferably 2 times the median concentration.
[0334] In a specific embodiment of the present invention, the threshold value of plasma CT-proADM is 5 times the median concentration of normal healthy people, preferably 4 times the median concentration, more preferably 3 times the median concentration, most preferably 2 times the median concentration.
[0335] In a specific embodiment of the present invention, the threshold value of plasma ADM-Gly is 5 times the median concentration of normal healthy people, preferably 4 times the median concentration, more preferably 3 times the median concentration, most preferably 2 times the median concentration.
[0336] In a specific embodiment of the present invention, the threshold value of plasma PAMP is 5 times the median concentration of normal healthy people, preferably 4 times the median concentration, more preferably 3 times the median concentration, most preferably 2 times the median concentration.
[0337] Threshold levels can be obtained, for example, from Kaplan-Meier analysis, in which the occurrence of the disease is associated with the quartiles of biomarkers in the population. According to this analysis, subjects with biomarker levels above the 75th percentile have a significantly increased risk of suffering from a disease according to the present invention. This result is further supported by Cox regression analysis and full adjustment for classical risk factors: the highest quartile is significantly associated with a high risk height of suffering from a disease according to the present invention compared to all other subjects.
[0338] Other preferred cutoff values are, for example, the 90th, 95th or 99th percentiles of the normal population. By using a percentile higher than the 75th percentile, one reduces the number of false positive subjects identified, but may miss identifying subjects with moderate risk (but risk still increases). Therefore, one may adopt a cutoff value based on whether it is more appropriate to identify most risky subjects at the expense of also identifying "false positives", or whether it is more appropriate to identify mainly high-risk subjects at the expense of missing a few subjects at moderate risk.
[0339] The above thresholds may be different in other assays if they have been calibrated differently from the assay system used in the present invention. Therefore, the above thresholds should be applied to such differently calibrated assays, taking into account the differences in calibration. One possibility for quantifying calibration differences is to perform a method comparison analysis (correlation) between the assay in question (e.g., bio-ADM assay) and the corresponding biomarker assay used in the present invention by measuring the corresponding biomarker in the sample using two methods (e.g., bio-ADM). Another possibility is to determine the median level of the biomarkers in a representative normal population using the assay in question (given that this test has sufficient analytical sensitivity), and compare the results with the median levels of the biomarkers described in the literature (e.g., Weber et al., 2017, JALM 2(2): 222-233), and recalculate the calibration based on the differences obtained by this comparison. Using the calibration used in the present invention, samples from normal (healthy) subjects have been measured: plasma bio-ADM (mature ADM-NH 2 ) with a median of 13.7 pg / ml (interquartile range [IQR] 9.6-18.7 pg / ml) (Weber et al., 2017, JALM2(2):222-233 ).
[0340] Subject matter of the diagnostic method of the invention is a method according to the diagnostic method of the invention, wherein the level of ProAdrenomedullin or a fragment of at least 5 amino acids thereof is determined by using a binding agent directed against ProAdrenomedullin or a fragment of at least 5 amino acids thereof.
[0341] The subject matter of the present invention is a pharmaceutical preparation for treatment or prevention, for treating a patient suffering from shock, in particular septic shock, wherein the patient:
[0342] Suffering from shock, in particular septic shock, for no longer than 8.4 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, and / or
[0343] Has been admitted to the ICU for no more than 8.4 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, and / or
[0344] is completely not receiving organ support or has been receiving organ support for no more than 8.4 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, and
[0345] Wherein the antibody or fragment binds to the N-terminal part (aa 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1).
[0346] The term "ICU admission" as used herein refers to a patient admitted to an intensive care unit who suffers or may suffer from one or more acute, immediately life-threatening functional disorders requiring the use of organ support methods. Criteria for accepting patients to an intensive care unit have been developed and are well documented in the art (Nates et al., (2016), Critical care medicine 44: 1553-1602). The term "ICU admission" should include admission according to these criteria.
[0347] Types of organ support include:
[0348] Respiratory support therapy:
[0349] -Including advanced respiratory support therapies such as endotracheal intubation and mechanical ventilation support
[0350] -Basic respiratory support therapy, such as the use of supplemental oxygen, use of an incentive ventilator, chest percussion nebulization, etc.
[0351] Circulatory support therapies, such as mechanical circulatory support (e.g., using intra-aortic balloon pumps and ventricular assist devices) and drug therapy, including the use of angiotensin-converting enzyme, beta-blockers, etc.
[0352] · Kidney support therapy, such as hemodialysis and peritoneal dialysis,
[0353] Hemodynamic monitoring or supportive therapy, such as measuring blood pressure, flow, and oxygen content, fluid resuscitation or blood transfusion, and the use of vasoactive drugs (e.g., nitroglycerin, nitric oxide, etc.),
[0354] Neurological monitoring or support, such as intraventricular catheters.
[0355] Extracorporeal organ support is described in detail in, for example, ICU Management & Practice, Volume 18–Issue 1, 2018.
[0356] In a preferred embodiment, an adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold is used to treat a patient suffering from shock, particularly septic shock, wherein the patient:
[0357] Suffering from shock, in particular septic shock, for no longer than 10 hours at the start of treatment with said anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, and / or
[0358] Has been admitted to the ICU for no more than 10 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, and / or
[0359] is completely not receiving organ support or has been receiving organ support for no more than 10 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, and
[0360] wherein the antibody or fragment or scaffold binds to the N-terminal portion (aa 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1), and
[0361] Wherein, when the patient has suffered from shock, especially septic shock, for a) no more than 10 hours and has been admitted to the ICU b) no more than 10 hours, the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is the shortest of a) and b).
[0362] In another embodiment, when the patient has been admitted to the ICU a) for no more than 10 hours and c) has received organ support for no more than 10 hours, the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is the shortest of a) and c).
[0363] In another embodiment, when the patient has suffered shock, in particular septic shock, for b) no longer than 10 hours and has received organ support for c) no longer than 10 hours, the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is the shortest of b) and c).
[0364] In another embodiment, when the patient has suffered from shock, in particular septic shock, for a) no longer than 10 hours and the patient has been in shock b) no longer than 10 hours and has received organ support for c) no longer than 10 hours, the starting point for treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is the shortest of a), b) and c).
[0365] In another embodiment, the present invention relates to an adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in treating a patient suffering from shock, particularly septic shock, wherein the patient:
[0366] Has been in shock for no more than 10 hours at the time of initiation of treatment with said anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, and / or
[0367] Has been admitted to the ICU for no more than 10 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, and / or
[0368] is completely not receiving organ support or has been receiving organ support for no more than 10 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, and
[0369] Wherein the antibody or fragment or scaffold binds to the N-terminal part (aa 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1).
[0370] In a preferred embodiment, at the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, the patient has suffered from shock, in particular septic shock, for no more than 9, preferably 8.4, preferably 8.26 (0.344 days), preferably 8, preferably 7, preferably 6, preferably 5.76 (0.25 days), preferably 5.75 (0.24 days), preferably 5, preferably 4, preferably 3 hours.
[0371] In a preferred embodiment, at the start point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, the patient has suffered from shock, in particular septic shock, for no more than 8.4, preferably 8.26 hours (0.344 days).
[0372] In a preferred embodiment, at the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, the patient has been in the ICU for no more than 9, preferably 8.4, preferably 8.26 (0.344 days), preferably 8, preferably 7, preferably 6, preferably 5.76 (0.25 days), preferably 5.75 (0.24 days), preferably 5, preferably 4, preferably 3 hours.
[0373] In a preferred embodiment, at the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, the patient has been in the ICU for no more than 8.4 hours, preferably no more than 8.26 hours (0.344 days).
[0374] In a preferred embodiment, at the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, the patient has been receiving organ support for no more than 9, preferably 8.4, preferably 8.26 (0.344 days), preferably 8, preferably 7, preferably 6, preferably 5.76 (0.25 days), preferably 5.75 (0.24 days), preferably 5, preferably 4, preferably 3 hours.
[0375] In a preferred embodiment, at the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, the patient has been receiving organ support for no more than 8.4 hours, preferably no more than 8.26 hours (0.344 days).
[0376] In another embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is used to treat patients suffering from shock, particularly septic shock, wherein the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold:
[0377] Administered within 10 hours of onset of shock in said patient, and / or
[0378] Administered within 10 hours of the patient's admission to the ICU, and / or
[0379] Administered before the patient receives organ support or for no more than 10 hours of organ support, and
[0380] Wherein the antibody or fragment or scaffold binds to the N-terminal part (aa 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1).
[0381] In another embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is used to treat patients suffering from shock, particularly septic shock, wherein the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold:
[0382] Administered within 8.4 hours of onset of shock in said patient, and / or
[0383] Administered within 8.4 hours of the patient's admission to the ICU, and / or
[0384] Administered before the patient receives organ support or for no more than 10 hours of organ support, and
[0385] Wherein the antibody or fragment or scaffold binds to the N-terminal part (aa 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1).
[0386] In a preferred embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is used to treat patients suffering from shock, especially septic shock, wherein the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold:
[0387] Administered within 10 hours of onset of shock in said patient, and / or
[0388] Administered within 10 hours of the patient's admission to the ICU, and / or
[0389] Administered before the patient receives organ support or for no more than 10 hours of organ support, and
[0390] wherein the antibody or fragment or scaffold binds to the N-terminal portion (aa 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1), and
[0391] Wherein when the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold can be administered a) within 10 hours after the occurrence of shock in the patient and b) within 10 hours after the patient is admitted to the ICU, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered at the shortest of a) and b).
[0392] In another embodiment, when the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold can be administered a) within 10 hours after the onset of shock in the patient and c) before the patient receives organ support or no more than 10 hours of organ support, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered at the shortest of a) and c).
[0393] In another embodiment, when the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold can be administered b) within 10 hours after the patient is admitted to the ICU and c) before the patient receives organ support or no more than 10 hours of organ support, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered at the shortest of b) and c).
[0394] In another embodiment, when the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold can be administered a) within 10 hours after the onset of shock in the patient and b) within 10 hours after the patient is admitted to the ICU and c) before the patient receives organ support or no more than 10 hours of organ support, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered at the shortest of a), b) and c).
[0395] In another embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is used to treat patients suffering from shock, particularly septic shock, wherein the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold:
[0396] Administered within 10 hours of onset of shock in said patient, and / or
[0397] Administered within 10 hours of the patient's admission to the ICU, and / or
[0398] Administered before the patient received organ support or for no more than 10 hours of organ support, and
[0399] Wherein the antibody or fragment or scaffold binds to the N-terminal part (aa 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1).
[0400] In a preferred embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered within 9, preferably 8.4, preferably 8.26 (0.344 days), preferably 8, preferably 7, preferably 6, preferably 5.76 (0.25 days), preferably 5.75 (0.25 days), preferably 5, preferably 4, preferably 3 hours after the onset of shock and / or sepsis in the patient.
[0401] In a preferred embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered within 8.4, preferably 8.26 hours (0.344 days) after the onset of shock and / or sepsis in the patient.
[0402] In a preferred embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered within 9, preferably 8.4, preferably 8.26 (0.344 days), preferably 8, preferably 7, preferably 6, preferably 5.76 (0.25 days), preferably 5.75 (0.25 days), preferably 5, preferably 4, preferably 3 hours after the patient is admitted to the ICU.
[0403] In a preferred embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered within 8.4, preferably 8.26 hours (0.344 days) hours after the patient is admitted to the ICU.
[0404] In a preferred embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered within 9, preferably 8.4, preferably 8.26 (0.344 days), preferably 8, preferably 7, preferably 6, preferably 5.76 (0.25 days), preferably 5.75 (0.25 days), preferably 5, preferably 4, preferably 3 hours after the patient has received organ support at the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold.
[0405] In a preferred embodiment, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is administered within 8.4, preferably 8.26 hours (0.344 days) after the patient has received organ support at the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold.
[0406] In another specific embodiment of the present invention, the shock is selected from the group consisting of shock caused by hypovolemia, cardiogenic shock, obstructive shock and distributive shock, in particular cardiogenic or septic shock.
[0407] In a specific embodiment of the invention, the shock is selected from:
[0408] In the case of cardiogenic shock, the patient has acute coronary syndrome (e.g., acute myocardial infarction) or heart failure (e.g., acute decompensated heart failure), myocarditis, arrhythmia, cardiomyopathy, valvular heart disease, aortic dissection with acute aortic stenosis, traumatic chordal rupture, or massive pulmonary embolism, or
[0409] In the case of hypovolemic shock, the patient may have a bleeding disorder, including gastrointestinal bleeding, trauma, vascular etiologies (e.g., ruptured abdominal aortic aneurysm, tumor erosion into a major vessel), and spontaneous bleeding in the setting of anticoagulants, or a non-bleeding disorder, including vomiting, diarrhea, loss of renal function, skin loss / loss of consciousness (e.g., burns, heat stroke), or loss of third space fluid in the setting of pancreatitis, cirrhosis, intestinal obstruction, trauma, or
[0410] In the case of obstructive shock, the patient may have cardiac tamponade, tension pneumothorax, pulmonary embolism, or aortic stenosis, or
[0411] In the case of distributive shock, the patient suffers from septic shock, neurogenic shock, anaphylactic shock, or shock caused by adrenal crisis.
[0412] In a more preferred embodiment, the shock is septic shock, shock caused by Covid-19, shock caused by burns, or traumatic shock.
[0413] In another embodiment, the present invention relates to an anti-ADM antibody or an anti-ADM antibody fragment or an anti-ADM non-Ig scaffold for treating a patient in shock, in particular septic shock, wherein the patient has been in shock for no more than 10 hours at the starting point of treatment with the anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold, and / or has been in an ICU for no more than 10 hours at the starting point of treatment, and / or has not received any organ support or has received organ support for no more than 10 hours at the starting point of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold, wherein a body fluid sample obtained from the patient exhibits a bioADM level >70pg / mL, and wherein the body fluid is selected from whole blood, plasma, serum.
[0414] The subject matter of the present invention is a pharmaceutical preparation for treatment or prevention, for use in a therapy in which the patient suffers from shock selected from shock caused by hypovolemia, cardiogenic shock, obstructive shock and distributive shock, in particular cardiogenic shock, septic shock, shock caused by Covid-19, shock caused by burns and traumatic shock. Another embodiment of the present invention is a pharmaceutical preparation for treatment or prevention, for use in a therapy in which the patient suffers from shock caused by chemical contamination with acidic, alkaline or oxidizing agents and chemicals in solid, liquid or gaseous form.
[0415] The term "shock" as used herein is characterized by decreased oxygen delivery and / or increased oxygen consumption or inadequate oxygen utilization, resulting in cellular and tissue hypoxia. It is a life-threatening condition of circulatory failure, most commonly manifested by hypotension (systolic blood pressure less than 90 mmHg or MAP less than 65 mmHg). Shock is divided into four main types based on the underlying cause: hypovolemic shock, cardiogenic shock, obstructive shock, and distributive shock ( Vincent and De Backer, 2014, N. Engl. J. Med. 370(6):583 ).
[0416] The term "cardiogenic shock" refers to shock in which the patient may suffer from an acute coronary syndrome (e.g., acute myocardial infarction) or in which the patient suffers from heart failure (e.g., acute decompensated heart failure), myocarditis, arrhythmias, cardiomyopathy, valvular heart disease, aortic dissection with acute aortic stenosis, traumatic chordal rupture, or massive pulmonary embolism. Cardiogenic shock (CS) is defined as a state of severe end-organ hypoperfusion caused by reduced cardiac output. It is noteworthy that CS forms a spectrum of conditions from mild hypoperfusion to severe shock. Established criteria for diagnosing CS are: (i) systolic blood pressure ≤ 90 mmHg for > 30 min or the need for vasopressors to achieve a blood pressure ≥ 90 mmHg; (ii) pulmonary congestion or elevated left ventricular filling pressures; (iii) signs of impaired organ perfusion, as evidenced by at least one of the following criteria: (a) altered mental status; (b) cool, clammy skin; (c) oliguria (< 0.5 mL / kg / h or < 30 mL / h); (d) elevated serum lactate ( Reynolds and Hochman, 2008, Circulation 117: 686–697 ). Acute myocardial infarction (AMI) with subsequent ventricular dysfunction is the most common cause of CS, accounting for approximately 80% of cases. Mechanical complications such as ventricular septal defect (4%) or free wall rupture (2%) and acute severe mitral regurgitation (7%) are less common causes of CS after AMI. ( Hochman et al., 2000, J Am Coll Cardiol 36:1063–1070 ). Non-AMI-related CS can be caused by decompensated valvular heart disease, acute myocarditis, arrhythmias, etc., and treatment options are varied. This represents 40,000 to 50,000 patients per year in the United States and 60,000 to 70,000 patients per year in Europe. Despite therapeutic advances, mainly through early revascularization, and subsequent reductions in mortality, CS remains the leading cause of death in AMI, with a mortality rate still approaching 40-50% according to recent registries and randomized trials (Goldberg et al., 2009, Circulation 119:1211–1219).
[0417] The term "hypovolemic shock" refers to shock in which the patient may have a hemorrhagic disorder, including gastrointestinal bleeding, trauma, vascular causes (e.g., ruptured abdominal aortic aneurysm, tumor erosion into major vessels), and spontaneous bleeding in the setting of anticoagulants, or a non-hemorrhagic disorder, including vomiting, diarrhea, loss of renal function, skin loss / insensitivity (e.g., burns, heat stroke), or loss of third space fluid in the setting of pancreatitis, cirrhosis, intestinal obstruction, trauma. Hypovolemic shock is characterized by a decrease in intravascular volume and can be divided into two major subtypes: hemorrhagic and non-hemorrhagic. Common causes of hemorrhagic hypovolemic shock include gastrointestinal bleeding, trauma, vascular causes (e.g., ruptured abdominal aortic aneurysm, tumor erosion into major vessels), and spontaneous bleeding in the setting of anticoagulants. Common causes of non-hemorrhagic hypovolemic shock include vomiting, diarrhea, loss of renal function, skin loss / insensitivity (e.g., burns, heat stroke), or loss of third space fluid in the setting of pancreatitis, cirrhosis, intestinal obstruction, trauma. For a review, see Koya and Paul, 2018, Shock.StatPearls [Internet]. TreasureIsland(FL): StatPearls Publishing; 2019- 2018Oct 27 .
[0418] The term "obstructive shock" refers to shock in which the patient may have cardiac tamponade, tension pneumothorax, pulmonary embolism, or aortic stenosis. Obstructive shock is caused by a physical blockage of a large blood vessel or the heart itself. Several conditions can lead to this form of shock (e.g., cardiac tamponade, tension pneumothorax, pulmonary embolism, aortic stenosis). For a review, see Koya and Paul, 2018, Shock. StatPearls[Internet]. Treasure Island(FL): StatPearls Publishing;2019-2018Oct27 .
[0419] The term "distributive shock" refers to shock in which the patient may have septic shock, neurogenic shock, anaphylactic shock, or shock caused by adrenal crisis. There are four types of distributive shock, based on etiology: neurogenic shock (decreased sympathetic nerve stimulation leading to decreased vascular tone), anaphylactic shock, septic shock, and shock caused by adrenal crisis. In addition to sepsis, systemic inflammatory response syndrome (SIRS) caused by conditions other than infection, such as pancreatitis, burns, or trauma, can also lead to distributive shock. Other causes include toxic shock syndrome (TSS), anaphylaxis (sudden severe allergic reaction), adrenal insufficiency (acute exacerbation of chronic adrenal insufficiency, destruction or removal of the adrenal glands, adrenal suppression due to exogenous steroids, hypopituitarism, and metabolic failure of hormone production), reactions to drugs or toxins, heavy metal poisoning, liver dysfunction, and central nervous system injury. For a review, see Koya and Paul, 2018, Shock. StatPearls[Internet].TreasureIsland(FL):StatPearlsPublishing; 2019-2018Oct27 .
[0420] Refractory shock is defined as the requirement for norepinephrine infusion > 0.5 μg / kg / min despite adequate volume resuscitation. Mortality in these patients can be as high as 94%, and the evaluation and management of these patients requires a much more aggressive approach to survival. The term "refractory shock" is used when tissue perfusion cannot be restored with initial corrective measures (eg, vasopressors), and it may therefore be referred to as "high vasopressor-dependent" or "vasopressor-resistant" shock ( Udupa and Shetty, 2018, Indian J RespirCare7:67-72 ). Patients with refractory shock can have features of hypoperfusion such as hypotension (mean arterial pressure <65 mmHg), tachycardia, peripheral coolness, prolonged capillary refill time, and tachypnea caused by hypoxia and acidosis. Fever may be observed in septic shock. Other signs of hypoperfusion may also be observed, such as altered sensorium, hyperlactatemia, and oliguria. These well-known signs of shock do not help determine whether the problem lies with the pump (heart) or the circuit (vascular and tissue). Different types of shock can coexist, and all forms of shock can become refractory, as demonstrated by lack of response to high doses of vasopressors ( Udupa and Shetty, 2018, IndianJRespirCare7:67-72 ).
[0421] The subject matter of the present invention is a pharmaceutical formulation for treatment or prevention, which is used in a therapy wherein the patient suffers from shock, wherein the patient is characterized by a dipeptidyl peptidase 3 (DPP3) level in a body fluid sample prior to drug administration that is below a threshold, and wherein the anti-ADM antibody or anti-ADM fragment or anti-ADM non-Ig scaffold binds to the N-terminal portion of ADM (amino acids 1-21): YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1).
[0422] The subject matter of the present invention is a pharmaceutical preparation for treatment or prevention, wherein the threshold value of DPP3 in the patient's body fluid sample is between 20 and 120 ng / mL, more preferably between 30 and 80 ng / mL, even more preferably between 40 and 60 ng / mL, and most preferably the threshold value is 50 ng / mL.
[0423] The subject matter of the present invention is a pharmaceutical preparation for use in treatment or prevention, wherein the level of DPP3 is determined by contacting the body fluid sample with a capture binding agent that specifically binds to DPP3.
[0424] One embodiment of the present application relates to an anti-ADM antibody or an anti-ADM antibody fragment or an anti-ADM non-Ig scaffold for treating or preventing shock in a patient, wherein the shock is selected from shock caused by hypovolemia, cardiogenic shock, obstructive shock and distributive shock, in particular cardiogenic shock or septic shock.
[0425] Another embodiment of the present application relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for treating or preventing shock in a patient, wherein
[0426] in the case of cardiogenic shock, the patient suffers from an acute coronary syndrome (e.g., acute myocardial infarction), or wherein the patient suffers from heart failure (e.g., acute decompensated heart failure), myocarditis, arrhythmia, cardiomyopathy, valvular heart disease, aortic dissection with acute aortic stenosis, traumatic chordal rupture, or massive pulmonary embolism, or
[0427] In the case of hypovolemic shock, the patient may have a bleeding disorder, including gastrointestinal bleeding, trauma, vascular etiologies (e.g., ruptured abdominal aortic aneurysm, tumor erosion into a major vessel), and spontaneous bleeding in the setting of anticoagulants, or a non-bleeding disorder, including vomiting, diarrhea, loss of renal function, skin loss / loss of consciousness (e.g., burns, heat stroke), or loss of third space fluid in the setting of pancreatitis, cirrhosis, intestinal obstruction, trauma, or
[0428] In the case of obstructive shock, the patient may have cardiac tamponade, tension pneumothorax, pulmonary embolism, or aortic stenosis, or
[0429] - In the case of distributive shock, the patient may be suffering from septic shock, neurogenic shock, anaphylactic shock, or shock caused by adrenal crisis.
[0430] A preferred embodiment of the present application relates to an anti-ADM antibody or an anti-ADM antibody fragment or an anti-ADM non-Ig scaffold for treating or preventing shock in a patient, wherein the threshold value of DPP3 in the patient's body fluid sample is between 20 and 120 ng / mL, more preferably between 30 and 80 ng / mL, more preferably between 40 and 90 ng / mL, even more preferably between 40 and 60 ng / mL, and most preferably the threshold value is 50 ng / mL.
[0431] A specific embodiment of the present application relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for treating or preventing shock in a patient, wherein the level of DPP3 is determined by contacting the body fluid sample with a capture binding agent that specifically binds to DPP3.
[0432] Another embodiment of the present application relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for treating or preventing shock in a patient, wherein the level of DPP3 protein and / or the level of active DPP3 is determined and compared with a predetermined threshold.
[0433] One embodiment of the present application relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for treating or preventing shock in a patient, wherein the patient is additionally characterized by ADM-NH 2 Level is above threshold.
[0434] To identify patients in shock, ADM–NH2 levels were measured.
[0435] A preferred embodiment of the present application relates to an anti-ADM antibody or an anti-ADM antibody fragment or an anti-ADM non-Ig scaffold for treating or preventing shock in a patient, wherein the ADM-NH 2 The threshold value is between 40 and 100 pg / mL, more preferably between 50 and 90 pg / mL, even more preferably between 60 and 80 pg / mL, and most preferably the threshold value is 70 pg / mL.
[0436] Another embodiment of the present application relates to an anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for treating or preventing shock in a patient, wherein the ADM-NH 2 The level of ADM-NH 2 The assay is performed by contacting the capture binding agent with the capture binding agent.
[0437] Another preferred embodiment of the present application relates to an anti-ADM antibody or an anti-ADM antibody fragment or an anti-ADM non-Ig scaffold for treating or preventing shock in a patient, wherein the patient's body fluid sample is selected from blood, serum, plasma, urine, cerebrospinal fluid (CSF) and saliva.
[0438] Another embodiment of the present application relates to a method for treating or preventing shock in a patient, the method comprising administering to the patient an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold, the method comprising the following steps:
[0439] Determining the level of DPP3 in a body fluid sample of the subject,
[0440] comparing said determined DPP3 level to a predetermined threshold value, and
[0441] wherein if the determined DPP3 level is below the predetermined threshold, the patient is treated, and
[0442] Wherein the anti-ADM antibody or anti-ADM fragment or anti-ADM non-Ig scaffold binds to the N-terminal portion (aa 1-21) of ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1).
[0443] Another specific embodiment of the present application relates to a method for treating or preventing shock in a patient, the method comprising administering to the patient an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold, the method further comprising the following steps:
[0444] Determine the ADM-NH 2 level,
[0445] · The ADM-NH 2 The level is compared with a predetermined threshold,
[0446] If the ADM-NH 2 If the level is below the predetermined threshold, the patient is treated.
[0447] In one embodiment of the invention, the level of DPP3 protein and / or the level of active DPP3 is determined and compared to a threshold level.
[0448] In a specific embodiment of the present invention, the threshold value of DPP3 in the patient's body fluid sample is between 20 and 120 ng / mL, more preferably between 40 and 90 ng / mL, more preferably between 30 and 80 ng / mL, even more preferably between 40 and 60 ng / mL, and most preferably the threshold value is 50 ng / mL.
[0449] In a specific embodiment of the present invention, the threshold value of the DPP3 level is 5 times the median concentration of a normal healthy population, preferably 4 times the median concentration, more preferably 3 times the median concentration, and most preferably 2 times the median concentration.
[0450] The level of DPP3 as the amount of DPP3 protein and / or DPP3 activity in the body fluid sample of the subject can be determined by various methods, such as immunoassay, activity assay, mass spectrometry, and the like.
[0451] According to the present invention, any type of binding assay (immunoassays and similar assays using other types of antigen-specific binding agents instead of antibodies) and DPP3 enzyme activity assays (which are specific for DPP3 by specifically capturing DPP3 from a sample using a specific binding agent (anti-DPP3 antibodies or other types of binding agents) prior to assaying the enzyme activity) can be used.
[0452] DPP3 activity can be measured by detecting the cleavage products of DPP3-specific substrates. Known peptide hormone substrates include Leu-enkephalin, Met-enkephalin, endomorphins 1 and 2, valorphin, β-casomorphin, dynorphin, protoenterin, ACTH (adrenocorticotropic hormone) and MSH (melanocyte stimulating hormone; et al., 2000, et al., 2007, Dhanda et al., 2008 ). The peptide hormones and other unlabeled oligopeptides (e.g., Ala-Ala-Ala-Ala, Dhanda et al., 2008 ) can be monitored by detecting the corresponding cleavage products. Detection methods include, but are not limited to, HPLC analysis (e.g. Lee and Snyder, 1982 ), mass spectrometry (e.g. et al., 2000 ), H1-NMR analysis (e.g. Vandenberg et al., 1985 ), capillary zone electrophoresis (CE; e.g. et al., 2007 ), thin layer chromatography (e.g. Dhanda et al., 2008 ) or reverse phase chromatography (e.g. Mazocco et al., 2006).
[0453] Detection of fluorescence generated by the hydrolysis of fluorogenic substrates by DPP3 is a standard procedure for monitoring DPP3 activity. These substrates are specific dipeptides or tripeptides (Arg-Arg, Ala-Ala, Ala-Arg, Ala-Phe, Asp-Arg, Gly-Ala, Gly-Arg, Gly-Phe, Leu-Ala, Leu-Gly, Lys-Ala, Phe-Arg, Suc-Ala-Ala-Phe) coupled to fluorophores. Fluorophores include, but are not limited to, β-naphthylamide (2-naphthylamide, βNA, 2NA), 4-methoxy-β-naphthylamide (4-methoxy-2-naphthylamide), and 7-amido-4-methylcoumarin (AMC, MCA; et al., 2000, Ohkubo et al., 1999 ). Cleavage of these fluorogenic substrates results in the release of fluorescent β-naphthylamine or 7-amino-4-methylcoumarin, respectively. In a liquid phase assay, the ECA substrate and DPP3 are incubated in, for example, a 96-well plate format, and fluorescence is measured using a fluorescence detector ( Ellis and Nuenke, 1967 ). In addition, samples carrying DPP3 can be immobilized and separated on a gel by electrophoresis, the gel can be stained with a fluorogenic substrate (e.g., Arg-Arg-βNA) and Fast Garnet GBC, and the fluorescent protein bands can be detected by a fluorescence reader ( Ohkubo et al., 1999The same peptide (Arg-Arg, Ala-Ala, Ala-Arg, Ala-Phe, Asp-Arg, Gly-Ala, Gly-Arg, Gly-Phe, Leu-Ala, Leu-Gly, Lys-Ala, Phe-Arg, Suc-Ala-Ala-Phe) can be coupled to a chromophore such as p-nitroaniline diacetate. Detection of the color change caused by hydrolysis of the chromogenic substrate can be used to monitor DPP3 activity.
[0454] Another option for detecting DPP3 activity is Protease-Glo TM Determination method (commercially available from Promega). In this embodiment of the method, DPP3 specific dipeptide or tripeptide (Arg-Arg, Ala-Ala, Ala-Arg, Ala-Phe, Asp-Arg, Gly-Ala, Gly-Arg, Gly-Phe, Leu-Ala, Leu-Gly, Lys-Ala, Phe-Arg, Suc-Ala-Ala-Phe) is coupled to aminoluciferin. After being cut by DPP3, aminoluciferin is released and serves as a substrate for a coupled luciferase reaction that emits detectable luminescence.
[0455] In a preferred embodiment, DPP3 activity is measured by adding the fluorogenic substrate Arg-Arg-βNA and monitoring fluorescence in real time.
[0456] In a specific embodiment of the method for determining active DPP3 in a body fluid sample of a subject, the capture binding agent reactive with DPP3 is immobilized on a solid phase.
[0457] The test sample is passed over the immobilized binding agent, to which DPP3 (if present) binds and itself becomes immobilized for detection. A substrate may then be added, and the reaction product may be detected to indicate the presence or amount of DPP3 in the test sample. For the purposes of this specification, the term "solid phase" may be used to include any material or container in or on which an assay may be performed, including but not limited to porous materials, non-porous materials, test tubes, wells, slides, agarose resins (e.g., Sepharose from GE Healthcare Life Sciences), magnetic particles (e.g., Dynabeads from ThermoFisher Scientific), TM or Pierce TM Magnetic beads) etc.
[0458] In another embodiment of the present invention, the level of DPP3 is determined by contacting the body fluid sample with a capture binding agent that specifically binds to DPP3.
[0459] In another preferred embodiment of the present invention, the capture binding agent used to determine the level of DPP3 may be selected from antibodies, antibody fragments or non-IgG scaffolds.
[0460] In a specific embodiment of the invention, the capture binding agent is an antibody.
[0461] The amount of DPP3 protein and / or DPP3 activity in the subject's body fluid sample can be determined, for example, by one of the following methods:
[0462] 1. Luminescent Immunoassay (LIA) for Quantification of DPP3 Protein Concentration ( Rehfeld et al., 2019 JALM3(6): 943-953 ).
[0463] The LIA is a one-step chemiluminescent sandwich immunoassay using a white high-binding polystyrene microtiter plate as a solid phase. These plates are coated with monoclonal anti-DPP3 antibody AK2555 (capture antibody). The tracer anti-DPP3 antibody AK2553 is labeled with MA70-acridinium-NHS ester and used at a concentration of 20ng per well. 20 microliters of sample (e.g., serum, heparin plasma, citrate plasma or EDTA plasma derived from patient blood) and calibrators are pipetted into the coated white microtiter plate. After adding the tracer antibody AK2553, the microtiter plate is incubated at room temperature and 600rpm for 3h. Unbound tracers are then removed by 4 washing steps (350 μL per well). The remaining chemiluminescence is measured using a microtiter plate photometer, 1s per well. The concentration of DPP3 is determined using a 6-point calibration curve. Calibrators and samples are preferably run in duplicate.
[0464] 2. Enzyme capture activity assay (ECA) for quantification of DPP3 activity ( Rehfeld et al., 2019 JALM 3(6): 943-953 ).
[0465] The ECA is a DPP3-specific activity assay using black high-binding polystyrene microtiter plates as a solid phase. These plates are coated with monoclonal anti-DPP3 antibody AK2555 (capture antibody). 20 microliters of sample (e.g., serum, heparin plasma, citrate plasma, EDTA plasma, cerebrospinal fluid, and urine) and calibrators are pipetted into the coated black microtiter plates. After adding the assay buffer (200 μL), the microtiter plates are incubated at 22° C. and 600 rpm for 2 h. The DPP3 present in the sample is fixed by binding to the capture antibody. Unbound sample components are removed by 4 washing steps (350 μL per well). The specific activity of immobilized DPP3 is measured by adding the fluorogenic substrate Arg-Arg-β-naphthylamide (Arg2-βNA) to the reaction buffer and then incubating at 37° C. for 1 h. DPP3 specifically cuts Arg2-βNA into Arg-Arg dipeptide and fluorescent β-naphthylamine. Fluorescence was measured with a fluorimeter using an excitation wavelength of 340 nm and emission detected at 410 nm. The activity of DPP3 was determined using a 6-point calibration curve. Calibrators and samples were preferably run in duplicate.
[0466] 3. Liquid phase assay (LAA) for quantification of DPP3 activity (according to Jones et al., Analytical Biochemistry, 1982 Revise).
[0467] The LAA is a liquid phase assay that uses a black non-binding polystyrene microtiter plate to measure DPP3 activity. 20 microliters of sample (e.g., serum, heparin plasma, citrate plasma) and calibrator are pipetted into a non-binding black microtiter plate. After adding the fluorogenic substrate Arg2-βNA in the assay buffer (200 μL), the initial βNA fluorescence (T=0) is measured using an excitation wavelength of 340 nm in a fluorometer, and the emission is detected at 410 nm. The plate is then incubated at 37° C. for 1 hour. The final fluorescence of (T=60) is measured. The difference between the final fluorescence and the initial fluorescence is calculated. The activity of DPP3 is determined using a 6-point calibration curve. Calibrators and samples are preferably run in duplicate.
[0468] In a specific embodiment, an assay is used to determine the level of DPP3, wherein the assay sensitivity of the assay is capable of quantifying DPP3 in healthy subjects and is <20 ng / ml, preferably <30 ng / ml, more preferably <40 ng / ml.
[0469] 4. Another immunoassay method for measuring DPP3 in plasma from whole blood samples is available, namely IB10 DPP3( https: / / www.nexus-dx.com / wp-content / uploads / 2020 / 11 / DPP3- 022-00072-IFU-REV-B_8x11.pdf ).
[0470] The IB10 DPP3 is a rapid point-of-care (POC) immunoassay for the in vitro quantitative determination of dipeptidyl peptidase 3 (DPP3) in human EDTA whole blood and plasma. The Nexus IB10 immunochemistry system combines chemistry with microfluidics and centrifugal flow to rapidly prepare cell-free plasma from whole blood, which can then be moved through channels for rehydration, dissolution, and mixing with freeze-dried immunoconjugates.
[0471] In a specific embodiment, the binding agent exhibits at least 10 7 M -1 , preferably 10 8 M -1 More preferably, the affinity is greater than 10 9 M -1 , most preferably greater than 10 10 M -1 A person skilled in the art will appreciate that it is conceivable to compensate for the lower affinity by applying a higher dose of the compound and that such measures would not lead to exceeding the scope of the present invention.
[0472] In another embodiment of the present invention, the body fluid sample is selected from the group consisting of whole blood, plasma and serum.
[0473] Mature ADM, bio-ADM and ADM-NH 2 are used synonymously throughout this application and are the molecule according to SEQ ID No.: 13.
[0474] In a particular embodiment, the body fluid according to the present invention is a blood sample. The blood sample can be selected from whole blood, serum and plasma. In a particular embodiment of the method, the sample is selected from human citrate plasma, heparin plasma and EDTA plasma.
[0475] In a specific embodiment, an assay is used to determine ADM-NH 2 The assay is sensitive enough to quantify the mature ADM-NH in healthy subjects. 2 , and <70pg / ml, preferably <40pg / ml, more preferably <10pg / ml.
[0476] In a specific embodiment of the present invention, ADM-NH 2 The threshold value is between 40 and 100 pg / mL, more preferably between 50 and 90 pg / mL, even more preferably between 60 and 80 pg / mL, most preferably a threshold value of 70 pg / ml is applied.
[0477] In a specific embodiment of the invention, plasma ADM-NH2 The threshold value is 5 times the median concentration of normal healthy people, preferably 4 times the median concentration, more preferably 3 times the median concentration, and most preferably 2 times the median concentration.
[0478] In a specific embodiment, the binding agent is ADM-NH 2 Show at least 10 7 M -1 , preferably 10 8 M -1 The binding affinity is preferably greater than 10 9 M -1 , most preferably greater than 10 10 M -1 A person skilled in the art will appreciate that it is conceivable to compensate for the lower affinity by applying a higher dose of the compound and that such measures would not lead to exceeding the scope of the present invention.
[0479] To determine the affinity of the antibody for adrenomedullin, the binding kinetics of adrenomedullin to the immobilized antibody were determined using label-free surface plasmon resonance using a Biacore 2000 system (GE Healthcare Europe GmbH, Freiburg, Germany). Reversible immobilization of the antibody was performed using an anti-mouse Fc antibody covalently coupled to the surface of a CM5 sensor at high density according to the manufacturer's instructions (Mouse Antibody Capture Kit; GE Healthcare). Lorenz et al., 2011, Antimicrob Agents Chemother. 55(1): 165–173 ).
[0480] The term "binding affinity" as used herein refers to the affinity of the protein described in the present invention for its binding target, and is numerically expressed using a "Kd" value. The term "Kd" as used herein means the dissociation constant of an antibody-antigen interaction. If two or more proteins are indicated to have comparable binding affinities for their binding targets, the Kd values for the binding of the corresponding proteins to their binding targets are within ±2 times of each other. If two or more proteins are indicated to have comparable binding affinities for a single binding target, the Kd values for the binding of the corresponding proteins to the single binding target are within ±2 times of each other. If a protein is indicated to bind two or more targets with comparable binding affinities, the Kd values for the binding of the protein to the two or more targets are within ±2 times of each other. In general, a higher Kd value corresponds to a weaker binding. In some embodiments, the Kd values for the binding of the protein to the two or more targets are determined by radiolabeled antigen binding assay (MA) or using BIAcore TM -2000 or BIAcore TM "Kd" was measured by surface plasmon resonance assay using a BIAcore-3000 (BIAcore, Inc., Piscataway, NJ).
[0481] In a specific embodiment, the binding agent is selected from ADM-NH 2 Conjugated antibodies or antibody fragments or non-Ig scaffolds.
[0482] In a specific embodiment, an assay is used to measure ADM-NH 2 The assay is a sandwich assay, preferably a fully automated assay.
[0483] In one embodiment, the method for determining the biomarkers (DPP3 and / or ADM-NH 2 ) is a sandwich immunoassay using any type of detection technology, including but not limited to enzyme markers, chemiluminescent markers, electrochemiluminescent markers, preferably a fully automated assay. In one embodiment of the diagnostic method, the assay is an enzyme-labeled sandwich assay. Examples of automated or fully automated assays include assays that can be used in one of the following systems: Roche Abbott Siemens Brahms Alere
[0484] Various immunoassays are known and can be used in the assays and methods of the present invention, including: radioimmunoassay ("RIA"), homogeneous enzyme multiplication immunoassay ("EMIT"), enzyme-linked immunosorbent assay ("ELISA"), apoenzyme reactivation immunoassay ("ARIS"), test strip immunoassays, and immunochromatographic assays.
[0485] In one embodiment of the invention, the assay is a sandwich immunoassay using any type of detection technology, including but not limited to enzyme labels, chemiluminescent labels, electrochemiluminescent labels, preferably a fully automated assay. In one embodiment of the invention, the assay is an enzyme-labeled sandwich assay. Examples of automated or fully automated assays include assays that can be used with one of the following systems: Roche Abbott Siemens Brahms Alere
[0486] In one embodiment of the invention, it may be a so-called POC test (point-of-care), which is a testing technology that allows testing to be performed near the patient in less than 1 hour without the need for a fully automated assay system. An example of such a technology is the immunochromatographic testing technology.
[0487] In a preferred embodiment, the label is selected from chemiluminescent labels, enzyme labels, fluorescent labels, and radioactive iodine labels.
[0488] The assay can be a homogeneous or heterogeneous assay, a competitive and non-competitive assay. In one embodiment, the assay takes the form of a sandwich assay, which is a non-competitive immunoassay in which the molecule to be detected and / or quantified is bound to a first antibody and to a second antibody. The first antibody can be bound to a solid phase, such as a bead, a surface of a well or other container, a chip or a strip, and the second antibody is an antibody labeled, for example, with a dye, a radioisotope or a reactive or catalytically active portion. The amount of labeled antibody bound to the analyte is then measured by a suitable method. The general composition and procedures of the "sandwich assay" are well-known and known to the skilled person ( "immunity The Immunoassay Handbook, edited by David Wild, Elsevier LTD, Oxford; Edition (May 2005), ISBN-13:978-0080445267; Hultschig C et al., Curr Opin Chem Biol. 2006 Feb;10(1):4-10. PMID: 16376134 ).
[0489] In another embodiment, the assay comprises two capture molecules, preferably antibodies, both present as dispersed systems in a liquid reaction mixture, wherein a first labeling component is attached to the first capture molecule, wherein the first labeling component is part of a labeling system based on fluorescence or chemiluminescence quenching or amplification, and a second labeling component of the labeling system is attached to a second capture molecule, such that a measurable signal is generated upon binding of the two capture molecules to the analyte, allowing detection of the formed sandwich complex in a solution containing the sample.
[0490] In another embodiment, the labeling system comprises a rare earth cryptate or rare earth chelate in combination with a fluorescent dye or a chemiluminescent dye, in particular a dye of the cyanine type.
[0491] In the context of the present invention, fluorescence-based assays include the use of dyes which may be selected, for example, from FAM (5- or 6-carboxyfluorescein), VIC, NED, fluorescein, fluorescein isothiocyanate (FITC), IRD-700 / 800, cyanine dyes such as CY3, CY5, CY3.5, CY5.5, Cy7, xanthene, 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), TET, 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxy-X-rhodamine (ROX), 5-carboxyrhodamine-6G (R6G5), 6-carboxyrhodamine-6G (RG6), rhodamine, rhodamine green, rhodamine red, rhodamine 110, BODIPY dyes such as BODIPY TMR, Oregon Green, coumarins such as umbelliferone, benzimides such as Hoechst 33258, phenanthridines such as Texas Red, yakima yellow, Alexa Fluor, PET, ethidium bromide, acridine dyes, carbazole dyes, phenoxazine dyes, porphyrin dyes, polymethine dyes, etc.
[0492] In the context of the present invention, chemiluminescence-based assays involve the use of dyes based on the physical principles described for chemiluminescent materials in the literature ( Kirk-Othmer, Encyclopedia of Chemical Technology Chemical Technology), 4th edition, Executive Editor JIKroschwitz; Editor-in-Chief M.Howe-Grant, John Wiley & Sons, 1993, vol. 15, p. 518-562, incorporated herein by reference, including the citations on pages 511-562. arts ). Preferred chemiluminescent dyes are acridinium esters.
[0493] As used herein, an "assay" or "diagnostic assay" may be of any type used in the field of diagnostics. Such an assay may be based on the binding of an analyte to be detected to one or more capture probes having a certain affinity. With respect to the interaction between the capture molecule and the target molecule or molecule of interest, the affinity constant is preferably greater than 10 8 M -1 .
[0494] In a specific embodiment, at least one of the two binding agents is labeled for detection.
[0495] The ADM-NH of the present invention 2 The levels have been described for ADM-NH 2 Determination method Weber et al., 2017. JALM2 (2):1-4 The DPP3 levels of the present invention have been determined using the described DPP3 assay as outlined in the Examples ( Rehfeld et al., 2019.JALM3(6):943-953). The above thresholds may be different in other assays if they have been calibrated differently from the assay system used in the present invention. Therefore, the above cutoff values should be applied to such differently calibrated assays, taking into account the differences in calibration. One possibility for quantifying calibration differences is to perform a method comparison analysis (correlation) between the assay in question and the corresponding biomarker assay used in the present invention by measuring the corresponding biomarker in the sample (e.g., bio-ADM, DPP3) using both methods. Another possibility is to determine the median level of the biomarkers of a representative normal population using the assay in question (given that this test has sufficient analytical sensitivity), and to compare the results with the median levels of the biomarkers described in the literature, and to recalculate the calibration based on the differences obtained by this comparison. Using the calibration used in the present invention, samples from normal (healthy) subjects have been measured: plasma bio-ADM (mature ADM-NH 2 ) The median value was 24.7pg / ml, the lowest value was 11pg / ml, and the 99th percentile was 43pg / ml ( Marino et al. 2014.CriticalCare18:R34) With the calibration used in the present invention, samples from 5400 normal (healthy) subjects (Swedish Single Center Prospective Population Study (MPP-RES)) were measured: the median (interquartile range) of plasma DPP3 was 14.5 ng / ml (11.3 ng / ml-19 ng / ml).
[0496] Therefore, in the present invention ADM-NH2 levels were measured in order to identify patients at increased risk of developing shock.
[0497] As used herein, the term "prevention" or any grammatical variation thereof includes, but is not limited to, delaying the onset of symptoms, preventing recurrence of the disease, increasing the latency period between symptom onset periods, or a combination thereof. As used herein, prevention does not require the complete absence of symptoms.
[0498] In a survival study in CLP-induced septic mice, the efficacy of a non-neutralizing antibody targeting the N-terminus of ADM was investigated. Pre-treatment with the non-neutralizing antibody resulted in a reduction in catecholamine infusion rates, renal dysfunction, and ultimately improved survival ( Struck et al., 2013. Intensive Care Med Exp 1(1):22; Wagner et al., 2013.IntensiveCareMed Exp 1(1):21 ).
[0499] As a result of these positive results, an N-terminally humanized version of the anti-ADM antibody, named Adrecizumab, was developed for further clinical development. The beneficial effects of Adrecizumab on vascular barrier function and survival were recently demonstrated in preclinical models of systemic inflammation and sepsis ( Geven et al., 2018. Shock 50(6):648-654). In this study, pretreatment with Adrecizumab attenuated renal vascular leakage in endotoxemic rats and CLP-induced septic mice, which coincided with increased renal expression of the protective peptide Ang-1 and reduced expression of the harmful peptide vascular endothelial growth factor. In addition, pretreatment with Adrecizumab increased the 7-day survival rate from 10% to 50% (single dose administration) and from 0% to 40% (repeated dose administration) in CLP-induced septic mice. In addition, in a Phase I study, excellent safety and tolerability were demonstrated (see Example 6): no serious adverse events were observed, no signals of more frequent adverse events were detected in Adrecizumab-treated subjects, and no relevant changes in other safety parameters were found ( Geven et al., 2017. Intensive Care Med Exp 5(Suppl 2):0427 ). Of particular interest is the proposed mechanism of action of Adrecizumab. Both animal and human data reveal a strong dose-dependent increase in circulating ADM following administration of the antibody. Based on pharmacokinetic data and the absence of an increase in MR-proADM (an inactive peptide fragment derived from the same prohormone as ADM), the higher circulating ADM levels cannot be explained by increased production.
[0500] A mechanistic explanation for this increase may be that the excess of circulating antibodies may expel ADM from the interstitium into the circulation, because ADM is small enough to cross the endothelial barrier, while antibodies cannot (Geven et al., 2018. Shock. 50(2): 132-140; and Voors et al. (J. Eur J Heart Fail. 2019 Feb; 21(2): 163-171)). In addition, the binding of antibodies to ADM results in an extension of the half-life of ADM. Although NT-ADM antibodies partially inhibit ADM-mediated signaling, the significant increase in circulating ADM leads to an overall "net" increase in ADM activity in the blood compartment, where it has a beneficial effect on EC (mainly barrier stabilization), while ADM's deleterious effects on VSMC in the interstitium (vasodilation) are reduced.
[0501] The present invention is not specifically limited to the use of Adrecizumab. There is no reason to doubt that the case of Adrecizumab also applies to antibodies that share the main basic characteristics (especially affinity and epitope specificity). Antibodies targeting the same area are expected to have the same technical effect, provided that they have the same affinity and the same or very comparable structural characteristics (size, shape...).
[0502] The term "antibody" generally includes monoclonal and polyclonal antibodies and binding fragments thereof, in particular Fc fragments and so-called "single-chain antibodies" (Bird et al., 1988), chimeric, humanized (in particular CDR-grafted) antibodies and diabodies or tetrabodies (Holliger et al., 1993). Also included are immunoglobulin-like proteins that specifically bind to a molecule of interest contained in a sample, selected by techniques including, for example, phage display. In this context, the term "specific binding" refers to antibodies raised against a molecule of interest or a fragment thereof. An antibody is considered specific if its affinity for the molecule of interest or its above-mentioned fragment is at least preferably 50 times higher, more preferably 100 times higher, and most preferably at least 1000 times higher than its affinity for other molecules contained in the sample containing the molecule of interest. How to prepare antibodies and select antibodies with a given specificity is well known in the art.
[0503] In one embodiment of the present invention, the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold is monospecific.
[0504] A monospecific anti-Adrenomedullin (ADM) antibody or monospecific anti-Adrenomedullin antibody fragment or monospecific anti-ADM non-Ig scaffold refers to an antibody or antibody fragment or non-Ig scaffold that binds to a specific region within the target ADM covering at least 5 amino acids. A monospecific anti-Adrenomedullin (ADM) antibody or monospecific anti-Adrenomedullin antibody fragment or monospecific anti-ADM non-Ig scaffold is an anti-Adrenomedullin (ADM) antibody or anti-Adrenomedullin antibody fragment or anti-ADM non-Ig scaffold that all have affinity for the same antigen. Monoclonal antibodies are monospecific, but monospecific antibodies can also be produced by other means besides being produced from a common germ cell.
[0505] The anti-ADM antibody or antibody fragment binding to ADM or the non-Ig scaffold binding to ADM may be a non-neutralizing anti-ADM antibody or antibody fragment binding to ADM or the non-Ig scaffold binding to ADM.
[0506] In a specific embodiment, the anti-ADM antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold is a non-neutralizing antibody, fragment or non-Ig scaffold. Neutralizing anti-ADM antibodies, anti-ADM antibody fragments or anti-ADM non-Ig scaffolds will block the biological activity of ADM to nearly 100%, at least more than 90%, preferably at least more than 95%.
[0507] In contrast, non-neutralizing anti-ADM antibodies or anti-ADM antibody fragments or anti-ADM non-Ig scaffolds block the biological activity of ADM to less than 100%, preferably less than 95%, preferably less than 90%, more preferably less than 80%, and even more preferably less than 50%. This means that the biological activity of ADM is reduced to less than 100%, 95% or less but not greater, 90% or less but not greater, 80% or less but not greater, 50% or less but not greater. This means that the residual biological activity of ADM bound to non-neutralizing anti-ADM antibodies or anti-ADM antibody fragments or anti-ADM non-Ig scaffolds will exceed 0%, preferably exceed 5%, preferably exceed 10%, more preferably exceed 20%, and more preferably exceed 50%.
[0508] In this context, molecules (whether antibodies, antibody fragments or non-Ig scaffolds) with "non-neutralizing anti-ADM activity" are collectively referred to herein for simplicity as "non-neutralizing" anti-ADM antibodies, antibody fragments or non-Ig scaffolds (which, for example, block the biological activity of ADM to less than 80%) and are defined as
[0509] - One or more molecules that bind to ADM, which, after being added to a culture of a eukaryotic cell line expressing a functional human recombinant ADM receptor composed of CRLR (calcitonin receptor-like receptor) and RAMP3 (receptor activity modifying protein 3), reduce the amount of cAMP produced by the cell line through the action of a human synthetic ADM peptide added in parallel, wherein the added human synthetic ADM is added in an amount that causes a half-maximal stimulation of cAMP synthesis in the absence of the non-neutralizing antibody to be analyzed, and wherein the degree of reduction of cAMP by the molecule that binds to ADM does not exceed 80% even when the non-neutralizing molecule that binds to ADM to be analyzed is added in an amount that is 10 times the amount required to obtain the maximum reduction in cAMP synthesis that can be obtained using the non-neutralizing antibody to be analyzed.
[0510] The same definition applies to other ranges: 95%, 90%, 50%, etc.
[0511] The antibodies or fragments according to the present invention are proteins that specifically bind to an antigen and include one or more polypeptides that are substantially encoded by immunoglobulin genes. Recognized immunoglobulin genes include kappa, lambda, alpha (IgA), gamma (IgG 1 IgG 2 IgG 3 IgG 4 ), delta (IgD), epsilon (IgE), and mu (IgM) constant region genes, as well as numerous immunoglobulin variable region genes. A full-length immunoglobulin light chain is typically about 25Kd or 214 amino acids long.
[0512] A full-length immunoglobulin heavy chain is usually about 50 Kd or 446 amino acids long. 2 The heavy chain is encoded by a variable region gene (about 110 amino acids in length) at the COOH-terminus and a kappa or lambda constant region gene at the COOH-terminus. The heavy chain is also encoded by a variable region gene (about 116 amino acids in length) and one of the other constant region genes.
[0513] The basic structural unit of an antibody is usually a tetramer composed of two identical pairs of immunoglobulin chains, each pair having one light chain and one heavy chain. In each pair, the light and heavy chain variable regions bind to the antigen, and the constant regions mediate effector functions. Immunoglobulins also exist in various other forms, including, for example, Fv, Fab, and (Fab') 2 , as well as bifunctional hybrid antibodies and single chains (e.g. Lanzavecchia et al., 1987. Eur. J. Immunol. 17:105; Huston et al., 1988. Proc. Natl. Acad. Sci. USA, 85: 5879-5883; Bird et al., 1988. Science 242: 423-426; Hood et al., 1984, Immunology, Benjamin, NY, 2nd ed.; Hunkapiller and Hood, 1986.Nature323:15-16 The immunoglobulin light or heavy chain variable region includes a framework region interrupted by three hypervariable regions, also called complementarity determining regions (CDRs) (see Sequences of Proteins Related to Immune Function of Immunological Interest), E. Kabat et al., 1983, USDDepartment of Health and Human Services As mentioned above, CDR is mainly responsible for binding to the epitope of the antigen. The immune complex is an antibody such as a monoclonal antibody, a chimeric antibody, a humanized antibody or a human antibody or a functional antibody fragment that specifically binds to the antigen.
[0514] Chimeric antibodies are antibodies whose light chain and heavy chain genes are usually constructed from immunoglobulin variable and constant region genes belonging to different species by genetic engineering. For example, the variable segment of the gene from a mouse monoclonal antibody can be connected to a human constant segment, such as κ and γ1 or γ3. Therefore, in one example, a therapeutic chimeric antibody is a hybrid protein composed of a variable or antigen-binding domain from a mouse antibody and a constant or effector domain from a human antibody, but other mammalian species can also be used, or the variable region can be produced by molecular technology. Methods for preparing chimeric antibodies are well known in the art, for example, see U.S. Patent No. 5,807,715. "Humanized" immunoglobulins are immunoglobulins including human framework regions and one or more CDRs from non-human (e.g., mouse, rat or synthetic) immunoglobulins. The non-human immunoglobulins providing CDRs are referred to as "donors", and the human immunoglobulins providing frameworks are referred to as "acceptors". In one embodiment, all CDRs in humanized immunoglobulins are from donor immunoglobulins. Constant regions need not be present, but if present, they must be substantially identical to human immunoglobulin constant regions, i.e., the identity is at least about 85-90%, such as about 95% or higher. Thus, all parts of a humanized immunoglobulin, except possibly the CDRs, are substantially identical to corresponding parts of natural human immunoglobulin sequences. A "humanized antibody" is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. A humanized antibody binds to the same antigen as a donor antibody providing the CDRs. The acceptor framework of a humanized immunoglobulin or antibody may have a limited number of amino acid substitutions obtained from a donor framework. Humanized or other monoclonal antibodies may have additional conservative amino acid substitutions that have little effect on antigen binding or other immunoglobulin functions. Exemplary conservative substitutions are, for example, substitutions of gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr. Humanized immunoglobulins can be constructed by genetic engineering means (see, for example, U.S. Patent No. 5,585,089). Human antibodies are antibodies in which the light chain and heavy chain genes are derived from humans. Human antibodies can be produced using methods known in the art. Human antibodies can be produced by immortalizing human B cells that secrete the antibody of interest. For example, immortalization can be achieved by EBV infection or by fusing human B cells with myeloma or hybridoma cells to produce tri-hybridoma cells. Human antibodies can also be produced by phage display methods (see, e.g., WO91 / 17271; WO92 / 001047; WO92 / 20791 ), or selected from a human combinatorial monoclonal antibody library (see the Morphosys website). Human antibodies can also be prepared by using transgenic animals carrying human immunoglobulin genes (see, for example, WO93 / 12227; WO 91 / 10741 ).
[0515] Thus, the anti-ADM antibody may have a format known in the art. Examples are human antibodies, monoclonal antibodies, humanized antibodies, chimeric antibodies, CDR-grafted antibodies. In a preferred embodiment, the antibody according to the invention is a recombinantly produced antibody, such as a typical full-length immunoglobulin, IgG, or an antibody fragment containing at least the F variable domain of a heavy chain and / or a light chain, such as a chemically coupled antibody (antigen binding fragment), including but not limited to a Fab fragment, including a Fab minibody, a single-chain Fab antibody, a monovalent Fab antibody with an epitope tag, such as Fab-V5Sx2; a divalent Fab (minibody) dimerized with a CH3 domain; a divalent Fab or a multivalent Fab, for example, formed by multimerization with the help of a heterologous domain, such as by dimerization of a dHLX domain, such as Fab-dHLX-FSx2; a F(ab') 2 fragments, scFv fragments, multimerized multivalent and / or multispecific scFv fragments, bivalent and / or bispecific diabodies, (bispecific T cell engagers), triabodies, multivalent antibodies e.g. from a class different from G; single domain antibodies e.g. nanobodies derived from camelid or fish immunoglobulins and many others.
[0516] In addition to anti-ADM antibodies, other biopolymer scaffolds are known in the art to complex target molecules and have been used to generate highly target-specific biopolymers. Examples are aptamers, spiegelmers, anticalins, and conotoxins. See Figures 1a, 1b, and 1c for illustrations of antibody formats.
[0517] In a preferred embodiment, the anti-ADM antibody format is selected from the group consisting of Fv fragment, scFv fragment, Fab fragment, scFab fragment, F(ab) 2 In another preferred embodiment, the antibody format is selected from the group consisting of scFab fragments, Fab fragments, scFv fragments and bioavailability-optimized conjugates thereof, such as PEGylated fragments. One of the most preferred formats is the scFab format.
[0518] The non-Ig scaffolds may be protein scaffolds and may be used as antibody mimics because they are able to bind to ligands or antigens. The non-Ig scaffolds may be selected from tetranectin-based non-Ig scaffolds (e.g., US2010 / 0028995 ), fibronectin scaffolds (e.g., EP 1 266025 ), lipocalin-based scaffolds (e.g., WO 2011 / 154420 ), ubiquitin scaffolds (e.g., WO 2011 / 073214 ), transferrin scaffolds (e.g., US2004 / 0023334), Protein A scaffolds (e.g., EP 2 231 860 ), ankyrin repeat-based scaffolds (e.g., WO 2010 / 060748 ), microprotein (preferably cysteine knot forming microprotein) scaffolds (e.g. EP2314308 ), Fyn SH3 domain-based scaffolds (e.g., WO 2011 / 023685 ), EGFR-A domain-based scaffolds (e.g., WO 2005 / 040229 ) and Kunitz domain-based scaffolds (e.g., in EP 1 941 867 described in ).
[0519] In one embodiment of the present invention, anti-ADM antibodies according to the present invention can be prepared by synthesizing fragments of ADM as antigens as outlined in Example 1. Subsequently, binding agents of the fragments are identified using the methods described below or other methods known in the art.
[0520] Humanization of mouse antibodies can be performed according to the following procedure:
[0521] For the humanization of antibodies of murine origin, the structural interactions of the framework regions (FR) and complementary determining regions (CDR) of the antibody sequences with the antigen are analyzed. Based on structural modeling, suitable FRs of human origin are selected, and the murine CDR sequences are transplanted into human FRs. Variations in the amino acid sequences of the CDRs or FRs can be introduced to regain the structural interactions eliminated by species conversion of the FR sequences. The restoration of this structural interaction can be achieved by random methods using phage display libraries or by directed methods guided by molecular modeling ( Almagro and Fransson, 2008, Human origin of antibodies Humanization of antibodies, Front Biosci.2008Jan1;13:1619-33 ).
[0522] In a preferred embodiment, the ADM antibody format is selected from the group consisting of Fv fragment, scFv fragment, Fab fragment, scFab fragment, F(ab) 2 In another preferred embodiment, the antibody format is selected from the group consisting of scFab fragments, Fab fragments, scFv fragments and bioavailability-optimized conjugates thereof such as PEGylated fragments. One of the most preferred formats is the scFab format.
[0523] In another preferred embodiment, the anti-ADM antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold is a full-length antibody, antibody fragment or non-Ig scaffold.
[0524] In a preferred embodiment, the anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold is directed against an epitope of at least 5 amino acids in length contained in ADM and can bind to the epitope.
[0525] In a more preferred embodiment, the anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold is directed against an epitope of at least 4 amino acids in length contained in ADM and can bind to the epitope.
[0526] In a specific embodiment of the present invention, an anti-ADM antibody or anti-ADM antibody fragment that binds to adrenomedullin or an anti-ADM non-Ig scaffold that binds to adrenomedullin is provided for use in treating or preventing shock in a patient, wherein the antibody or fragment or scaffold is not ADM binding protein-1 (complement factor H).
[0527] In a specific embodiment of the present invention, an anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold binding to adrenomedullin is provided for treating or preventing shock in a patient, wherein the antibody or fragment or scaffold binds to a region of preferably at least 4 or at least 5 amino acids within the amino acid sequence 1-21 of mature human ADM: YRQSMNNFQGLRSFGCRFGTC SEQ ID No.: 1.
[0528] In a preferred embodiment of the present invention, the anti-ADM antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold binds to a region or epitope of ADM located in the N-terminal portion of adrenomedullin (amino acids 1-21).
[0529] In another preferred embodiment, the anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold recognizes and binds to the region or epitope within amino acids 1-14 of adrenomedullin: YRQSMNNFQGLRSF (SEQ ID No.: 15) (i.e., the N-terminal part of adrenomedullin (amino acids 1-14)).
[0530] In another preferred embodiment, the anti-ADM antibody or anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold recognizes and binds to the region or epitope within amino acids 1-10 of adrenomedullin: YRQSMNNFQG (SEQ ID No.: 16) (i.e., the N-terminal portion of adrenomedullin (amino acids 1-10)).
[0531] In another preferred embodiment, the anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold recognizes and binds to the region or epitope within amino acids 1-6 of adrenomedullin: YRQSMN (SEQ ID No.: 17) (i.e., the N-terminal portion of adrenomedullin (amino acids 1-6)). As described above, the region or epitope preferably comprises at least 4 or at least 5 amino acids in length.
[0532] In another preferred embodiment, the anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold recognizes and binds to the N-terminal end (amino acid position 1) of adrenomedullin. The N-terminal end means the amino acid position 1, which is "Y" of SEQ ID No. 13 or 18 (SEQ ID No.: 18 (1-42 of human ADM): YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVA), respectively, and is essential for binding. The antibody or fragment or scaffold binds neither to adrenomedullin with N-terminal extension or N-terminal modification, nor to adrenomedullin with N-terminal degradation. This means that in another preferred embodiment, if the N-terminal end of ADM is free, the anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold only binds to a region within the sequence of mature ADM. In such embodiments, the anti-ADM antibody or anti-ADM antibody fragment or non-Ig scaffold does not bind to a region within the sequence of mature ADM, if such sequence is contained, for example, within pro-ADM.
[0533] For the sake of clarity, the numbers in brackets in specific regions of ADM, such as "N-terminal portion (amino acids 1-21)" are understood by those skilled in the art to mean that the N-terminal portion of ADM consists of amino acids 1-21 of the mature ADM sequence.
[0534] In another specific embodiment according to the present invention, the anti-ADM antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold provided herein does not bind to the C-terminal portion of ADM, i.e., amino acids 43-52 of ADM: PRSKISPQGY-NH 2 (SEQ ID No.: 19) binding.
[0535] Epitopes, also known as antigenic determinants, are the parts of an antigen that are recognized by the immune system, especially antibodies. For example, an epitope is a specific fragment of an antigen that is bound by an antibody. The part of an antibody that binds to an epitope is called a paratope. Epitopes of protein antigens are divided into two categories, conformational epitopes and linear epitopes, based on their structure and interaction with the paratope.
[0536] Conformational and linear epitopes interact with the complement on the basis of the 3-D conformation adopted by the epitope, which is determined by the surface features of the epitope residues involved and the shape or tertiary structure of other segments of the antigen. Conformational epitopes are formed by the 3-D conformation adopted by the interaction of discontinuous amino acid residues. Linear or sequential epitopes are epitopes whose linear amino acid sequence or primary structure is recognized by antibodies and are formed by the 3-D conformation adopted by the interaction of consecutive amino acid residues.
[0537] In a specific embodiment, it is preferred to use an anti-ADM antibody or an anti-ADM antibody fragment or an anti-ADM non-Ig scaffold according to the present invention, wherein the anti-ADM antibody or the anti-ADM antibody fragment or the anti-ADM non-Ig scaffold causes an increase in ADM levels or ADM immunoreactivity in serum, blood, or plasma by at least 10%, preferably at least 50%, more preferably >50%, and most preferably >100%.
[0538] In a specific embodiment, it is preferred to use an anti-ADM antibody or an anti-ADM antibody fragment or an anti-ADM non-Ig scaffold according to the present invention, wherein the anti-ADM antibody or the anti-ADM antibody fragment or the anti-ADM non-Ig scaffold is an ADM stable antibody or an ADM stable antibody fragment or an ADM stable non-Ig scaffold, which reduces the half-life (t 1 / 2 ; half retention time) is increased by at least 10%, preferably at least 50%, more preferably >50%, most preferably >100%.
[0539] The half-life (half-retention time) of ADM can be determined in human serum, blood or plasma using an immunoassay for ADM quantification in the presence and absence of ADM stabilizing antibodies or ADM stabilizing antibody fragments or ADM stabilizing non-Ig scaffolds, respectively.
[0540] You can perform the following steps:
[0541] - ADM can be diluted in human citrated plasma in the absence and presence of ADM stabilizing antibodies or adrenomedullin stabilizing antibody fragments or adrenomedullin stabilizing non-Ig scaffolds, respectively, and can be incubated at 24°C.
[0542] - Aliquots are taken at selected time points (eg within 24 hours) and degradation of ADM in the aliquots can be stopped by freezing at -20°C.
[0543] - If the chosen assay is not affected by the stabilizing antibody, the amount of ADM can be determined directly by hADM immunoassay. Alternatively, an aliquot can be treated with a denaturant such as HCl and after clarifying the sample (e.g. by centrifugation), the pH can be neutralized and ADM quantification can be performed by ADM immunoassay. Alternatively, ADM quantification can be performed using non-immunoassay techniques such as RP-HPLC.
[0544] - Calculation of the ADM half-life of ADM incubated in the absence and presence of ADM stabilizing antibodies or adrenomedullin stabilizing antibody fragments or adrenomedullin stabilizing non-Ig scaffolds, respectively.
[0545] - The half-life enhancement of the stabilized ADM was calculated compared to ADM incubated in the absence of ADM stabilizing antibody or adrenomedullin stabilizing antibody fragment or adrenomedullin stabilizing non-Ig scaffold.
[0546] A two-fold increase in the half-life of ADM is a 100% enhancement of the half-life.
[0547] Half-life (half retention time) is defined as the length of time it takes for the concentration of a particular chemical or drug in a particular fluid or blood to decrease to half of its baseline concentration.
[0548] Example 3 describes an assay that can be used to determine the half-life (half-retention time) of adrenomedullin in serum, blood, or plasma.
[0549] In a preferred embodiment, the anti-ADM antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold is a non-neutralizing antibody, fragment or scaffold. Neutralizing anti-ADM antibodies, anti-ADM antibody fragments or anti-ADM non-Ig scaffolds will block the biological activity of ADM to nearly 100%, at least more than 90%, preferably at least more than 95%. In other words, this means that the non-neutralizing anti-ADM antibodies, anti-ADM antibody fragments or anti-ADM non-Ig scaffolds will block the biological activity of ADM to less than 100%, preferably less than 95%, preferably less than 90%. In embodiments where the non-neutralizing anti-ADM antibodies, anti-ADM antibody fragments or anti-ADM non-Ig scaffolds block the biological activity of ADM to less than 95%, anti-ADM antibodies, anti-ADM antibody fragments or anti-ADM non-Ig scaffolds that block the biological activity of ADM to more than 95% will be outside the scope of the embodiments. This means that in one embodiment, the biological activity is reduced to 95% or less rather than more, preferably 90% or less, more preferably 80% or less, more preferably 50% or less rather than more.
[0550] In one embodiment of the present invention, the non-neutralizing antibody is an antibody that binds to a region of at least 5 amino acids within the amino acid sequence at positions 1 to 21 of mature human ADM (SEQ ID No.: 1).
[0551] In another preferred embodiment of the present invention, the non-neutralizing antibody is an antibody that binds to a region of at least 4 amino acids within the amino acid sequence at positions 1 to 21 of mature human ADM (SEQ ID No.: 1).
[0552] In a specific embodiment according to the present invention, a non-neutralizing anti-ADM antibody or anti-ADM antibody fragment or ADM non-Ig scaffold is used, wherein the anti-ADM antibody or anti-ADM antibody fragment blocks the biological activity of ADM to less than 80% (of the baseline value), preferably less than 50%. It must be understood that the defined blocking of the biological activity of ADM (meaning the reduction of the biological activity) occurs even at an excess concentration of the antibody, fragment or scaffold (meaning that the antibody, fragment or scaffold is in excess relative to ADM). In the specific embodiment, the defined blocking is an inherent property of the ADM binder itself. This means that the antibody, fragment or scaffold has a maximum inhibition of 80% or 50%, respectively. In a preferred embodiment, the anti-ADM antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold will block the biological activity of the anti-ADM antibody / reduce its biological activity to at least 5%. The above situation means that there is about 20% or 50% or even 95% residual ADM biological activity, respectively.
[0553] Thus, according to the present invention, provided anti-ADM antibodies, anti-ADM antibody fragments and anti-ADM non-Ig scaffolds do not neutralize the corresponding ADM biological activity.
[0554] Described biological activity is defined as the effect that material shows to living organism or tissue or organ or functional unit after interaction in vivo or in vitro (for example in assay method).In the case of ADM biological activity, this can be the effect of ADM in human recombinant ADM receptor cAMP functional assay method.Therefore, according to the present invention, biological activity is defined by ADM receptor cAMP functional assay method.In order to measure the biological activity of ADM in this assay method, following steps can be performed:
[0555] - Perform dose response curves with ADM in the human recombinant ADM receptor cAMP functional assay.
[0556] - The ADM concentration for half-maximal cAMP stimulation can be calculated.
[0557] - Dose response curves were performed with ADM stabilized antibodies or ADM stabilized antibody fragments or ADM stabilized non-Ig scaffolds, respectively, at a constant half-maximal cAMP stimulating ADM concentration (final concentration up to 100 μg / ml).
[0558] A maximum inhibition of 50% in the ADM bioassay means that the anti-ADM antibody or the anti-ADM antibody fragment or the anti-ADM non-Ig scaffold blocks the bioactivity of ADM to 50% of the baseline value, respectively. A maximum inhibition of 50% in the ADM bioassay means that the anti-ADM antibody or the anti-adrenomedullin antibody fragment or the anti-adrenomedullin non-Ig scaffold blocks the bioactivity of ADM to 80%, respectively. This means that the bioactivity of ADM is blocked to no more than 80%. This means that there is still about 20% residual ADM bioactivity.
[0559] However, according to the present specification and the above background, the expression "blocking the biological activity of ADM" in connection with the anti-ADM antibodies, anti-ADM antibody fragments and anti-ADM non-Ig scaffolds disclosed herein should be understood as only reducing the biological activity of ADM from 100% to a maximum of 20% of the ADM biological activity remaining, preferably reducing the ADM biological activity from 100% to 50% of the ADM biological activity remaining; but in any case, there is still remaining ADM biological activity that can be measured as described above.
[0560] The biological activity of ADM can be determined according to Example 2 in the human recombinant adrenomedullin receptor cAMP functional assay (adrenomedullin bioassay).
[0561] In a preferred embodiment, the regulatory anti-ADM antibody or regulatory anti-ADM antibody fragment or regulatory anti-ADM non-Ig scaffold is used to treat or prevent shock in a patient.
[0562] A "modulatory" anti-ADM antibody or a modulatory anti-ADM antibody fragment or a modulatory anti-ADM non-Ig scaffold is an antibody or antibody fragment or non-Ig scaffold that increases the half-life (t 1 / 2 , half-retention time) is increased by at least 10%, preferably at least 50%, more preferably>50%, most preferably>100%, and the biological activity of ADM is blocked to less than 80%, preferably less than 50%, and the anti-ADM antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold will block the biological activity of ADM to at least 5%. These values related to half-life and blocking of biological activity must be understood in conjunction with the above-mentioned assays in order to determine these values. This means that the blocking of ADM biological activity does not exceed 80% or does not exceed 50%, respectively.
[0563] Such regulatory anti-ADM antibodies or regulatory anti-ADM antibody fragments or regulatory anti-ADM non-Ig scaffolds provide the advantage of convenient administration. The combination of partially blocking or partially reducing the biological activity of ADM and increasing the half-life in vivo (increasing the biological activity of ADM) leads to a beneficial simplification of the administration of anti-ADM antibodies or anti-ADM antibody fragments or anti-ADM non-Ig scaffolds. In the case of excessive endogenous ADM (maximum stimulation, late sepsis, shock, low power period), the activity reduction effect is the main effect of the antibody or fragment or scaffold, limiting the (negative) effect of ADM. In the case of low or normal endogenous ADM concentration, the biological effect of anti-ADM antibodies or anti-ADM antibody fragments or anti-ADM non-Ig scaffolds is a combination of reducing (by partially blocking) the biological activity of ADM and increasing (by increasing) the half-life of ADM. Therefore, the non-neutralizing and regulatory anti-ADM antibodies or anti-ADM antibody fragments or anti-ADM non-Ig scaffolds act like ADM bioactive buffers to keep the biological activity of ADM within a certain physiological range.
[0564] As used herein, the term "pharmaceutical formulation" refers to a preparation that is in a form that permits the biological activity of the active ingredients contained therein to be effective, and that contains no other components that are unacceptably toxic to a subject to which the formulation is administered.
[0565] The present invention also relates to a pharmaceutical preparation comprising a therapeutically effective dose of an active ingredient in combination with at least one pharmaceutically acceptable excipient.
[0566] "Pharmaceutically acceptable excipient" refers to an excipient that does not produce adverse, allergic or other untoward reactions when administered to a subject. In addition to the therapeutic protein, it also includes carriers, various diluents, fillers, salts, buffers, stabilizers, solubilizers and other materials known in the art. The characteristics of the carrier will depend on the route of administration.
[0567] In some embodiments, the preparation of the present invention can be directly administered to the patient's bloodstream, muscle, tissue, fat or internal organs. Suitable parenteral administration methods include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intraosseous, intradermal and subcutaneous. Suitable devices for parenteral administration include needles (including microneedles, microprotrusions, soluble needles and other micropore formation technologies) syringes, needleless syringes and infusion techniques. In some embodiments, the preparation of the present invention is subcutaneously administered to a subject.
[0568] In another embodiment, the aqueous pharmaceutical composition can be administered to a subject in need of treatment according to known administration methods. Examples of administration methods may further include injection or infusion of shock doses over a period of time, intracerebrospinal, transdermal, oral, topical application or inhalation.
[0569] In some embodiments, the mode of administration of the aqueous formulation according to the present invention comprises administering a dose of the formulation once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, once every fifteen weeks, once every twenty weeks, or once every twenty-four weeks. In some embodiments, the aqueous formulation according to the present invention is administered once a month, once every two months, once every three months, once every four months, once every five months, or once every six months.
[0570] In some embodiments, the volume of the agent in the formulation is less than or equal to about 20 ml, about 15 ml, about 10 ml, about 5 ml, about 2.5 ml, about 1.5 ml, about 1.0 ml, about 0.75 ml, about 0.5 ml, about 0.25 ml, or about 0.01 ml.
[0571] In some embodiments, the volume of the agent in the formulation is about 20 ml, about 19 ml, about 18 ml, about 17 ml, about 16 ml, about 15 ml, about 14 ml, about 13 ml, about 12 ml, about 11 ml, about 10 ml, about 9 ml, about 8 ml, about 7 ml, about 6 ml, about 5 ml, about 4 ml, about 3 ml, about 2 ml, or about 1 ml. Or about 20.5 ml, about 19.5 ml, about 18.5 ml, about 17.5 ml, about 16.5 ml, about 15.5 ml, about 14.5 ml, about 13.5 ml, about 12.5 ml, about 11.5 ml, about 10.5 ml, about 9.5 ml, about 8.5 ml, about 7.5 ml, about 6.5 ml, about 5.5 ml, about 4.5 ml, about 3.5 ml, about 2.5 ml, about 1.5 ml, or about 0.5 ml. Or about 900 microliters, about 800 microliters, about 700 microliters, about 600 microliters, about 500 microliters, about 400 microliters, about 300 microliters, about 200 microliters or about 100 microliters, or about 950 microliters, about 850 microliters, about 750 microliters, about 650 microliters, about 550 microliters, about 450 microliters, about 350 microliters, about 250 microliters, about 150 microliters or about 50 microliters. In some embodiments, the volume of the agent in the preparation is about 1.0 ml.
[0572] Dosage regimen can depend on the pharmacokinetic decay pattern that the doctor wishes to achieve. For example, in some embodiments, it is envisioned that one to four times of weekly administration is given. Even less frequent administration can be used. In some embodiments, the medicament is administered once every 1 week, every 2 weeks, every 3 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, every 10 weeks, every 15 weeks, every 20 weeks, every 25 weeks or longer. In some embodiments, the medicament is administered once every 1 month, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months or longer. The progress of this therapy is easily monitored by traditional techniques and assays. The dosage regimen can change over time. For example, in some embodiments, the medicament of the preparation of the present invention is administered with 1-10mg / kg body weight every other week (for example, by intravenous injection). In some embodiments, the medicament of the preparation of the present invention is administered with 1-10mg / kg body weight every other week (for example, by intravenous injection). In some embodiments, the medicament of the preparation of the present invention is administered with an initial dose of 1-10 mg / kg body weight four times intravenous injection in one day (the 1st day) or 1-10 mg / kg body weight injection twice a day for two consecutive days (the 1st and 2nd day), and then the second dose is administered with 1-10 mg / kg body weight after two weeks (the 15th day), and then the maintenance dose of 1-10 mg / kg body weight is administered every other week. In some embodiments, the medicament of the preparation of the present invention is administered with an initial dose of 1-10 mg / kg body weight (e.g., intravenous injection), and then 1-10 mg / kg body weight is administered every other week starting from one week after the initial dose. For the purposes of the present invention, the suitable dose of the drug will depend on the antibody used, the type and severity of the disorder to be treated, whether the administration of the drug is for prevention or treatment purposes, previous therapy, the patient's clinical history and the response to the drug, and the judgment of the attending physician. Typically, the clinician will administer the drug until the dosage for achieving the desired result is reached. The dosage can be determined empirically. For example, an individual increasing dose is given to evaluate the efficacy of the drug, and blood glucose levels can be tracked.
[0573] The dosage and / or frequency may vary over the course of treatment. Empirical considerations such as antibody half-life generally help determine dosage. The frequency of administration may be determined and adjusted over the course of treatment, generally but not necessarily based on the treatment and / or suppression and / or improvement and / or delay of one or more symptoms of the autoimmune disease. In some individuals, more than one dose of the agent may be required. The frequency of administration may be determined and adjusted over the course of treatment. For example, but not limited to, for repeated administration over several days or longer, depending on the disease and its severity, treatment continues until the desired symptom suppression occurs or a sufficient therapeutic level is reached.
[0574] The administration of the preparation of the present invention can be continuous or intermittent, depending on, for example, the physiological condition of the recipient, whether the purpose of administration is treatment or prevention, and other factors known to professional practitioners. The administration of the preparation of the present invention can be substantially continuous over a preselected time period, or it can be a series of interval administrations.
[0575] Preferably, the administration of the medicament is parenteral administration, preferably selected from intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intraosseous, intradermal and subcutaneous. Preferably, the preparation is in a unit dose sterile form for parenteral administration (e.g., subcutaneous administration).
[0576] The following embodiments are also subject matter of the present invention:
[0577] 1. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the antibody or fragment binds to the N-terminal portion of ADM (aa 1-21): YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1), wherein the antibody or antibody fragment is present in a concentration of 1 mg / ml to 100 mg / ml, preferably 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, most preferably 20 mg / ml, and wherein the aqueous pharmaceutical formulation further comprises:
[0578] Arginine in the range of 1 g / L to 100 g / L, and
[0579] Trehalose in the range of 1 g / L to 100 g / L, and
[0580] - a surfactant selected from polysorbates and poloxamers in the range of 0.01 g / L to 5 g / L, and
[0581] Histidine in the range of 0.1 g / L to 6.4 g / L, and
[0582] wherein the pH of the formulation is in the range of 4.0 to 8.0.
[0583] 2. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment according to embodiment 1, wherein the antibody or fragment is a human monoclonal antibody or fragment thereof that binds to the N-terminal region (aa 1-21) of ADM (SEQ ID No. 1), wherein the heavy chain comprises the following sequence:
[0584] CDR1: SEQ ID NO: 2
[0585] GYTFSRYW
[0586] CDR2: SEQ ID NO: 3
[0587] ILPGSGST
[0588] CDR3: SEQ ID NO: 4
[0589] TEGYEYDGFDY
[0590] and wherein the light chain comprises the sequence "
[0591] CDR1: SEQ ID NO: 5
[0592] QSIVYSNGNTY
[0593] CDR2: SEQ ID NO: 6
[0594] RVS
[0595] CDR3: SEQ ID NO: 7
[0596] FQGSHIPYT.
[0597] 3. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 2, comprising an anti-adrenomedullin antibody directed against the N-terminal end of adrenomedullin, said antibody comprising as a heavy chain the following sequence or a sequence having >95% identity thereto:
[0598] SEQ ID NO: 8
[0599] QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0600] and comprising as a light chain the following sequence or a sequence having >95% identity thereto:
[0601] SEQ ID NO: 9
[0602] DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLE IKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
[0603] 4. An aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment according to any one of embodiments 1 to 3, wherein the surfactant is a poloxamer.
[0604] 5. An aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment according to any one of embodiments 1 to 4, wherein the formulation is substantially free of NaCl and / or glycine.
[0605] 6. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 5, wherein arginine is present in the range of 1 g / L to 100 g / L, preferably 15 g / L to 60 g / L, preferably 13.1 g / L to 52.2 g / L, preferably 11.2 g / L to 44.4 g / L, more preferably 26.1 g / L.
[0606] 7. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 6, wherein trehalose is present in the range of 1 g / L to 100 g / L, preferably 32.6 g / L to 97.8 g / L, preferably 28.4 g / L to 85.1 g / L, preferably 24.1 g / L to 72.4 g / L, more preferably 56.7 g / L.
[0607] 8. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 7, wherein the poloxamer is present in the range of 0.01 g / L to 5 g / L, preferably 0.115 g / L to 1.15 g / L, preferably 0.1 g / L to 1.0 g / L, preferably 0.085 g / L to 0.85 g / L, more preferably 0.5 g / L.
[0608] 9. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 8, wherein histidine is present in the range of 0.1 g / L to 6.4 g / L, preferably 0.22 g / L to 6.88 g / L, preferably 0.8 g / L to 3.2 g / L, preferably 0.68 g / L to 3.68 g / L, more preferably 1.6 g / L.
[0609] 10. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 9, wherein the pH of the formulation is in the range of 4.0 to 8.0, preferably 5.0 to 7.0, and more preferably 6.0.
[0610] 11. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 10, wherein the formulation comprises an anti-adrenomedullin antibody comprising the N-terminal end of the sequence SEQ ID No. 1 to adrenomedullin, arginine at a concentration of 26.1 g / L, trehalose at a concentration of 56.7 g / L, poloxamer at a concentration of 0.5 g / L, and histidine at a concentration of 1.6 g / L, and wherein the formulation exhibits a pH of 6.0.
[0611] 12. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 11, an aqueous pharmaceutical formulation, wherein the formulation is stable after storage at 2 to 8°C for at least 4 weeks, and wherein less than 5 wt / wt-%, preferably 4 wt / wt-%, more preferably 3 wt / wt-%, more preferably 2 wt / wt-%, more preferably 1 wt / wt-%, more preferably 0.05%-mol or most preferably 0.01 wt / wt-% of total antibody aggregation when measured by size exclusion high performance liquid chromatography (SEC-HPLC), and wherein the antibody is present in a concentration of 1 mg / ml to 100 mg / ml, preferably 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, most preferably 20 mg / ml.
[0612] 13. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 12, wherein the formulation is stable after storage at 2 to 8°C for at least 4 weeks, and wherein stable means that the formulation remains free of visible particles.
[0613] 14. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 13, wherein the formulation is stable after storage at 2 to 8°C for at least 4 weeks, and wherein stable means that the formulation remains free of subvisible particles.
[0614] 15. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 14, wherein the activity of the antibody or antibody fragment in the formulation is stable after stress, and wherein the stress is induced by storing the formulation at 45°C, preferably 42°C, more preferably 38°C, more preferably 36°C, most preferably 40°C and 85% rH, preferably 80 rH, preferably 70% rH, most preferably 75% rH for at least 4 weeks, and / or by storing the formulation at 29°C, preferably 27°C, more preferably 22°C, more preferably 36°C, most preferably 40°C and 85% rH, preferably 80 rH, preferably 70% rH, most preferably 75% rH. Preferably, the formulation is stored at 20°C, most preferably at 25°C and / or 70% rH, preferably 65% rH, preferably 55% rH, more preferably 50% rH, most preferably 60% rH for at least 3 months, and / or by storing the formulation at 9°C, preferably 7°C, more preferably 2°C, more preferably 0°C, most preferably 5°C for at least 6 months, and / or by subjecting the formulation to at least 1 freeze-thaw cycle, and / or by subjecting the formulation to mechanical stress including orbital shaking and overhead rotation, and wherein the stability is determined by evaluating the visual appearance of the formulation after stress, including color, clarity and visible particles.
[0615] 16. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of embodiments 1 to 15, wherein the antibody is present in a concentration of 1 mg / ml to 100 mg / ml, preferably 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, most preferably 20 mg / ml.
[0616] 17. A lyophilized pharmaceutical preparation obtainable from the aqueous pharmaceutical preparation according to any one of embodiments 1 to 16.
[0617] 18. A method for preparing a ready-to-use solution, the method comprising the steps of:
[0618] a. Providing an aqueous pharmaceutical formulation according to any one of embodiments 1 to 16;
[0619] b. conditioning the aqueous pharmaceutical preparation from step a) in a physiologically acceptable solution by optionally diluting the volume of the pharmaceutical preparation from step a) with a physiologically acceptable solution and by optionally dividing the pharmaceutical preparation from step a) into aliquots, wherein the diluted or adjusted aqueous pharmaceutical preparation is suitable for administration in a patient.
[0620] 19. A method for preparing a ready-to-use solution, the method comprising the steps of:
[0621] a. providing a lyophilized formulation obtained from an aqueous formulation according to any one of embodiments 1 to 16 by freeze drying and optionally without adding any other bulking agent;
[0622] b. reconstitute the lyophilisate from step a) in water and / or a physiologically acceptable solution for injection;
[0623] c. conditioning the reconstituted formulation from step b) in a physiologically acceptable solution by optionally diluting the volume of the reconstituted formulation from step b) with a physiologically acceptable solution and by optionally dividing the reconstituted formulation from step b) into aliquots, wherein the diluted or conditioned aqueous pharmaceutical formulation is suitable for administration in a patient.
[0624] 20. A ready-to-use aqueous pharmaceutical formulation obtainable by the method according to embodiment 18 or 19, comprising a dose of 1 to 10 mg / kg body weight of the human or humanized anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment.
[0625] 21. A ready-to-use aqueous pharmaceutical formulation obtainable by the method according to embodiment 18 or 19, comprising a dose of 2 to 8 mg / kg body weight, preferably 2 or 4 or 8 mg / kg body weight of the human or humanized anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment.
[0626] 22. A pharmaceutical formulation according to any one of embodiments 1 to 16, 20 and 21 for the treatment or prevention of an acute disease or acute condition selected from the following: SIRS, severe infection, sepsis, shock selected from shock caused by hypovolemia, cardiogenic shock, obstructive shock and distributive shock, in particular cardiogenic shock, septic shock, shock caused by Covid-19, shock caused by burns and traumatic shock, acute vascular diseases such as heart failure, congestion, in particular diuretic-resistant congestion, inflammatory disorders, autoimmune diseases, metabolic diseases, brain diseases, cardiovascular diseases and drug-induced diseases. Symptoms of illness or illness characterized by such symptoms, wherein the symptoms of illness are selected from nausea, headache, muscle pain, back pain, tremors and / or vomiting and migraine.
[0627] 23. A pharmaceutical formulation according to any one of embodiments 1 to 16, 20 and 21, for use in treating or preventing an acute disease or acute condition in a patient to prevent or alleviate organ dysfunction or prevent organ failure in the patient, wherein the acute disease or acute condition is selected from, for example, severe infection, diabetes, cancer, acute and chronic vascular diseases such as heart failure, myocardial infarction, stroke, atherosclerosis, shock and organ dysfunction, renal dysfunction, liver dysfunction, burns, surgery, trauma, poisoning and injury caused by chemotherapy, and wherein the disease is not SIRS, sepsis or septic shock.
[0628] 24. The pharmaceutical formulation according to any one of embodiments 1 to 16, 20 and 21, for use in treating or preventing an acute disease or acute condition in a patient to stabilize the patient's systemic circulation, wherein the patient suffers from a disease selected from SIRS, sepsis, diabetes, cancer, acute vascular disease such as heart failure, shock such as septic shock, and organ dysfunction such as renal dysfunction.
[0629] 25. The pharmaceutical preparation according to any one of embodiments 1 to 16, 20 and 21, wherein
[0630] a) for the treatment of an acute disease or acute condition in a patient in order to stabilize the patient's systemic circulation, wherein the patient requires systemic circulation stabilization and exhibits a heart rate > 100 beats / min and / or a mean arterial pressure < 65 mmHg, and wherein stabilization of systemic circulation means increasing the mean arterial pressure to more than 65 mmHg, or
[0631] b) For prophylactic use in the treatment of an acute disease or acute condition in a patient to prevent an increase in heart rate to >100 beats / min and / or a decrease in mean arterial pressure to <65 mmHg.
[0632] 26. A pharmaceutical formulation according to any one of embodiments 1 to 16, 20 and 21, for use in treating or preventing an acute disease or acute condition in a patient to regulate fluid balance, wherein the patient is a patient in need of regulating fluid balance and suffers from a disease selected from systemic inflammatory response syndrome (SIRS), sepsis, diabetes, cancer, heart failure, shock and renal dysfunction.
[0633] 27. A pharmaceutical formulation according to any one of embodiments 1 to 16, 20 and 21 for use in treating or preventing congestion in a patient, wherein the patient suffers from a disease or condition selected from the group consisting of congestive hypertension, swelling or water retention (edema), heart failure, in particular acute heart failure, kidney disease or liver disease.
[0634] 28. A pharmaceutical preparation for treatment or prevention according to any one of embodiments 1 to 16 and 20 to 27, comprising:
[0635] Determining the level of a pro-adrenomedullin precursor fragment selected from mid-region pro-adrenomedullin (MR-proADM), C-terminal pro-adrenomedullin (CT-proADM), Bio-ADM, ADM-gly, or pro-adrenomedullin N-terminal 20 peptide (PAMP) or a fragment thereof in a body fluid obtained from the subject prior to drug administration; and
[0636] comparing the level of said pro-adrenomedullin fragment selected from MR-proADM, CT-proADM, PAMP, Bio-ADM or ADM-gly to a predefined threshold or a previously determined level of said fragment, and
[0637] Wherein for relevance said pro-adrenomedullin fragment selected from MR-proADM, CT-proADM, PAMP, Bio-ADM or ADM-gly or fragments thereof above a certain threshold or an increased level above a previously determined level is used for stratification of patients for therapeutic use according to the invention.
[0638] 29. A pharmaceutical preparation for treatment or prevention according to any one of embodiments 1 to 16, 20 to 28, for treating a patient with shock, in particular septic shock, wherein the patient:
[0639] ● Suffering from shock, in particular septic shock, for no longer than 8.4 hours at the time of initiation of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, and / or
[0640] ● ICU stay of no more than 8.4 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, and / or
[0641] • Not receiving any organ support or receiving organ support for no more than 8.4 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment.
[0642] 30. A pharmaceutical formulation for treatment or prevention according to any one of embodiments 1 to 17, 20 to 29, wherein the patient is characterized in that the level of dipeptidyl peptidase 3 (DPP3) in a body fluid sample of the patient is below a threshold value before drug administration.
[0643] 31. A pharmaceutical preparation for treatment or prevention according to embodiment 30, wherein the threshold value of DPP3 in the patient's body fluid sample is between 20 and 120 ng / mL, more preferably between 30 and 80 ng / mL, even more preferably between 40 and 60 ng / mL, and most preferably the threshold value is 50 ng / mL.
[0644] 32. A pharmaceutical formulation for treatment or prevention according to embodiment 30 or 31, wherein the level of DPP3 is determined by contacting the body fluid sample with a capture binding agent that specifically binds to DPP3.
[0645] 33. A pharmaceutical preparation for use in treatment or prevention according to embodiments 30 to 32, wherein the level of DPP3 protein and / or the level of active DPP3 is determined and compared to a predetermined threshold value. BRIEF DESCRIPTION OF THE DRAWINGS
[0646] Figure 1A - C: Relative areas [%] of the main peak (A), HMWS (B) and LMWS (C) of unstressed and stressed anti-ADM antibody (HAM8101) samples determined by SEC-HPLC. The graph shows the average of two replicates each measured twice.
[0647] Figure 2A -C: Relative areas [%] of the main peak (A), HMWS (B) and LMWS (C) of anti-ADM antibody (HAM8101) samples determined by SEC-HPLC: untreated (t=0), freeze-thaw (5 cycles of F / T at -80°C / 25°C) and mechanical stress (overhead rotation and orbital shaking). The graph shows the average of two replicates each measured twice.
[0648] Figure 3A - C: Relative areas [%] of the main peak (A), acidic peak (B) and basic peak (C) of unstressed and stressed anti-ADM antibody (HAM8101) samples determined by CEX-HPLC. The graph shows the average of two replicates each measured twice.
[0649] Figure 4A -C: Relative areas [%] of the main peak (A), acidic peak (B) and basic peak (C) of anti-ADM antibody (Ham80101) samples determined by CEX-HPLC: untreated (t=0), freeze-thaw (5 cycles of F / T at -80°C / 25°C) and mechanical stress (overhead rotation and orbital shaking). The graph shows the average of two replicates each measured twice.
[0650] Figure 5: Results of DLS measurements of non-stressed and stressed anti-ADM antibody (HAM8101) samples.
[0651] Fig. 6A - B: Results of non-reduced CE SDS after accelerated aging (A), mechanical stress (B) and freeze-thaw. Mean and SD of two replicates each measured twice are shown.
[0652] Fig. 7A - B: Results of CE SDS reduction after accelerated aging (A), mechanical stress (B) and freeze-thaw show the mean and SD of two replicates each measured twice.
[0653] Figure 8 : DLS results of formulations 1-5 after storage at 40°C and after mechanical stress.
[0654] Fig. 9 : DLS results of formulations 6-11 after storage at 40°C and after mechanical stress.
[0655] Fig.10 : DLS results of formulations 11-15 after storage at 40°C and after mechanical stress.
[0656] Fig.11 : DLS results of formulations 16-21 after storage at 40°C and after mechanical stress.
[0657] Fig. 12A -B: Relative area [%] of monomers by SEC-HPLC of formulated anti-ADM antibody (HAM8101) stored at 40°C±2°C / 75% rH±5% rH for up to 2 weeks (A) and after mechanical stress and freeze-thaw (B), the graph shows the mean and SD of two replicates measured twice each.
[0658] Fig.13A -B: Relative area [%] of HMWS by SEC-HPLC of formulated anti-ADM antibody (HAM8101) stored at 40°C±2°C / 75% rH±5% rH for up to 2 weeks (A) and after mechanical stress and freeze-thaw (B), the graph shows the mean and SD of two replicates measured twice each.
[0659] Fig.14A -B: Relative area [%] of LMWS by SEC-HPLC of formulated anti-ADM antibody (HAM8101) stored at 40°C±2°C / 75% rH±5% rH for up to 2 weeks (A) and after mechanical stress and freeze-thaw (B), the graph shows the mean and SD of two replicates measured twice each.
[0660] Fig.15A- D: content of particles smaller than 5 μm (A), 5 to 10 μm (B), greater than or equal to 10 μm (C) and greater than or equal to 25 μm (D) after storage at 40° C. for 2 weeks.
[0661] Fig.16A - D: content of subvisible particles less than 5 μm (A), between 5 and 10 μm (B), greater than or equal to 10 μm (C) and greater than or equal to 25 μm (D) after mechanical stress.
[0662] Fig.17A - C: Relative areas [%] of monomer (A), HMWS (B) and LMWS (C) contents by SEC-HPLC of formulated anti-ADM antibody (HAM8101) stored at 40°C ± 2°C / 75% rH ± 5% rH for up to 4 weeks. The graph shows the mean and SD of two replicates each measured twice.
[0663] Fig.18A - C: Relative areas [%] of monomer (A), HMWS (B) and LMWS (C) contents by SEC-HPLC of formulated anti-ADM antibody (HAM8101) after mechanical stress and 5 freeze-thaw cycles. The graph shows the mean and SD of two replicates each measured twice.
[0664] Fig.19 : Relative monomer content after external analysis by analytical ultracentrifugation.
[0665] Fig. 20A - B: DLS results after storage at 40°C (A) and after mechanical stress (B).
[0666] Fig.21A -D: particles after thermal stress, content of particles less than 5 μm (A), 5 to 10 μm (B), greater than or equal to 10 μm (C) and greater than or equal to 25 μm (D) after storage at 40°C for 2 weeks.
[0667] Fig.22A - D: particles after mechanical stress, content of particles less than 5 μm (A), 5 to 10 μm (B), greater than or equal to 10 μm (C) and greater than or equal to 25 μm (D) after mechanical stress.
[0668] Fig.23A - C: Relative areas [%] of major (A), acidic (B) and basic (C) species of formulated anti-ADM antibody (HAM8101) stored at 40°C ± 2°C / 75% rH ± 5% rH for up to 3.5 weeks by CEX-HPLC. The graph shows the mean and SD of two replicates each measured twice.
[0669] Fig.24A- C: Relative areas [%] of the main (A), acidic (B) and basic (C) species of CEX-HPLC of formulated anti-ADM antibody (HAM8101) after mechanical stress and 5 freeze-thaw cycles. The graph shows the mean and SD of two replicates each measured twice. Example
[0670] Example 1 - Basic characteristics of anti-ADM antibody (HAM8101): Methods
[0671] 1. Materials
[0672] The sources of all excipients used to prepare HAM8101 are all in accordance with the quality of the United States Pharmacopoeia (USP) and / or the European Pharmacopoeia (Ph.Eur.). The sources of all chemicals used for analytical methods are all sufficient for the quality (e.g., pa) of a single method. The HAM8101 bulk drug (DS) samples in the basic buffer and the present application preparations are provided by the manufacturer. All samples are stored at -80 ° C and monitored internally.
[0673] Except for HPLC analysis, the water used throughout the project was sterile water of WFI quality (Aqua B. Braun Water for Injection, Braun, Cat. No. 0082479E).
[0674] 2. pH adjustment
[0675] The final pH adjustment of all formulations and buffers was performed at a temperature between 23°C and 25°C using a calibrated pH electrode (VWR) connected to a SevenExcellence pH meter (Mettler Toledo) (in compliance with Ph.Eur. and USP). The pH value was always adjusted to the desired target value ± 0.03. For pH measurement of the formulated DS, the samples were measured at a temperature between 23°C and 25°C using a calibrated pH electrode (Mettler Toledo) connected to a SevenExcellence pH meter (Mettler Toledo) (in compliance with Ph.Eur. and USP).
[0676] 3. Determination of osmotic pressure molar concentration
[0677] Osmolality was determined in an osmometer (Osmomat 030-D RS, Gonotec) by freezing point depression. Each measurement was performed in a 15 μl aliquot after calibration with a sodium chloride standard (600 mOsmol / kg) and purified water.
[0678] 4. Dialysis for Buffer Exchange
[0679] Buffer exchange for reconstituted DS was performed by dialysis in a Slide-A-Lyzer cassette (Thermo) with a nominal cutoff of 20 kDa. The sample was dialyzed three times for at least 2 hours each time with slow stirring at 2-8°C in a refrigerator, followed by a step overnight (>12 hours). After dialysis, if necessary, the HAM8101 concentration was adjusted to a target value of 20 g / L ± 2 g / L using the corresponding buffer.
[0680] 5. Concentration measurement
[0681] The concentration of the drug substance was measured by absorbance at 280 nm using a Spark plate reader (Tecan, Schweiz). For this purpose, placebo and DS samples were measured in a 96-well plate under identical conditions. The absorbance of the placebo was then subtracted from the corresponding DS sample.
[0682] 6. Vial filling
[0683] Before filling the vials, the samples were sterile filtered using a 0.1 μm PES filter. For liquid storage in steps 3 and 4, a volume of 2 ml of each formulation containing 20 mg / ml ± 2 mg / mL DS was inserted into a sterile, particle-free 2R vial (supplied by Rentschler) under laminar air flow. The vials were closed with sterile stoppers (supplied by Rentschler) and crimped with a suitable aluminum cap.
[0684] 7. Sample Storage
[0685] Samples stored at 5 ± 3 °C were kept in a refrigerator with external temperature monitoring. DS in original formulation was stored at -80 °C in a refrigerator with internal temperature monitoring.
[0686] The samples undergoing accelerated aging are stored in an ICH cabinet (Memmert) with controlled humidity, at 25 ± 2 ° C / 60 ± 5% rH, 30 ± 2 ° C / 65 ± 5% rH and 40 ± 2 ° C / 75 ± 5% rH, respectively. During the entire storage period, the temperature is also monitored separately. Freeze-thaw stress is carried out in a cooling chamber, alternately stored at -80 ° C and + 25 ° C, and each temperature is at least 2 hours. The freeze-thaw results are visually controlled and adjusted accordingly. At uncontrolled room temperature, shear stress is applied by rotating the overhead (overhead shaker, Hei-Mix Reax 2, Heidolph / VWR) at 30 rpm for 24 h or by shaking the specified time period at 400 rpm orbital (double plate shaker PSU-2T, Kisker). For all storage time points up to one month, the sample is taken out within + / - 1 day of the target take-out date, and for the stability time of two months, three months and six months, it is taken out within + / - 3 days of the target take-out date.
[0687] 8. Size Exclusion Chromatography (SE-HLPC)
[0688] The SE-HPLC method is based on the SOP that manufacturers provide for HAM8101. In size exclusion chromatography, using ThermoUltimate 3000HPLC system, using the isocratic flow rate (50mM sodium phosphate, 300mM sodium chloride, pH 7.0) of 0.5ml / min at 20 ± 5 ℃, the sample (20 ± 2mg / ml HAM8101) stored is separated on TSKgel G3000SWXL posts (5 μm, 7.8x300mm, Tosoh Bioscience, numbering 0008541). Record data at 214 and 280nm by UV detector. Each injection is loaded with 20 μg DS diluted in 20 μl mobile phases. Use Chromeleon 7.2.6.10049 software to perform data analysis. For column performance checks, molecular weight markers (1511901; Bio-Rad) were used before and after each set of reference standards and 10 samples, including thyroglobulin, γ-globulin, ovalbumin, myoglobin and vitamin B12. To prevent high pressure, all turbid samples before Example 3 (WP4a) (e.g., FT samples, F01 and F06) and all samples from Example 4 (WP4b) and all placebos were filtered with a 0.1 PES filter (Sartorius, 16553).
[0689] 9. Cation exchange chromatography (CEX-HLPC)
[0690] The CEX-HPLC method is based on the SOP provided by Rentschler for HAM8101. In the cation exchange chromatography, the stored sample (20 ± 2mg / ml HAM8101) is separated on the MAbPac SCX-10 column (5μm, 4mm x 150mm; Thermo Scientific, No. 085198) on the Thermo Ultimate 3000HPLC system. The gradient (see Table 1) of diluent A: 100% 20mM 2-(N-morpholinyl) ethanesulfonic acid (MES) and diluent B: 100% 20mmol MES and 200mM sodium chloride (pH6.0) is used in 40 minutes to separate the variants with antibodies at a constant flow rate of 0.5ml / min at 25 ± 5°C. Each injection is loaded with 60μg DS diluted in 30μl eluent A. Data are recorded at 280nm and 214nm by UV detector. Data analysis was performed using Chromeleon 7.2.6.10049 software.
[0691] To prevent high pressure, all turbid samples before Example 3 (WP4a) (eg FT and 2w 40°C samples, F01 and F06) as well as all samples from Example 4 (WP4b) onwards and all placebos were filtered with a 0.1 PES filter (Sartorius, 16553).
[0692] 10.CE-SDS / reduction / non-reduction
[0693] Rentschler provided a CE-SDS method SOP with an accessory for the analysis of HAM8101 for the quantitative determination of low molecular weight substances (LMWS) using non-reduced CE-SDS analysis. However, it was agreed that CE-SDS would be performed on all samples (reduced and non-reduced) during this project. Therefore, a standard instrument setup in accordance with the instrument supplier's recommendations and a standard sample buffer (pH 6.8) for CE-SDS were used. The samples were diluted with water to a concentration of 3 mg / mL, but were not subsequently concentrated by zentricons as described in the manufacturer's SOP. The eluents were prepared according to the SOP, the samples were diluted, and the sequence run was performed according to the SOP, but the results using the sample buffer at pH 6.8 were not comparable to those provided by the manufacturer. Therefore, the samples were diluted with a sample buffer at pH 9.0 and the sequence run was repeated. Using a sample buffer at pH 9.0, the results were comparable and the described instrument setup and sample preparation were used for the other WPs in this project.
[0694] 11. Dynamic Light Scattering (DLS) for Aggregate Testing
[0695] Dynamic light scattering was performed at 25°C in a 384-well plate (Aurora) in a DynaPro plate reader III (Wyatt). In order to implement the method, samples were measured with undiluted 20 mg / ml and diluted to different concentrations (0.25 mg / ml, 0.5 mg / ml, 0.75 mg / ml and 1 mg / ml), and placebo was measured together with the sample. All subsequent measurements were performed using 35 μL undiluted samples and 35 μL all placebos measured under the same conditions. After sample filling, the plate was sealed with sealing tape and centrifuged briefly, then placed in a DLS plate reader at 25°C. Dynamics 7.9.14 version was used for analysis. For each parallel sample, 10 separate acquisitions were recorded, each lasting 5 seconds, as shown in Figure 1.
[0696] The results are reported as the average value of three technical parallel samples of two biological parallel samples. All measurement results are reported as intensity weighted results. In DLS, the monitoring hydrodynamic radius is nanometer-level particles. Degradation products can be fragments with a radius less than the DS radius of the monomer, or aggregates with a larger radius that is manifested as an additional population. The result can be visualized as a histogram of, for example, a particle size population. The category type diagram of the DLS peak containing the combination of D50 value and peak radius and intensity weighting based on the histogram is applied. For stability studies, DLS data are presented as the D50 value on the radius scatter plot of all measured peaks with intensity weighted symbol size, to allow easier comparison of different formulations during storage. The radius (x-axis) of each population measured each time and the D50 value (y-axis) of all particles measured are plotted in a log-log scatter plot.
[0697] The size of the depiction symbol at each peak is directly proportional to the relative intensity (% of weighted intensity) of the corresponding peak. In addition, the superposition of parallel sample measurements is carried out using transparent colors, and the repeatability of each signal can be assessed by the color intensity useful in the main peak determination. Unless otherwise described, each measurement result is composed of at least 2x100 single measurements. Parameters are derived from volume distribution and intensity distribution, and the intensity distribution itself is obtained from the correlation function. In general, the D50 value on the peak radius diagram with the intensity weighted symbol size is used for qualitative comparison of the preparations at the application time point in the different research arms of the stability study.
[0698] 12. Turbidity
[0699] The turbidity of the samples was analyzed by turbidimetry or by measuring the absorbance at 350 nm, 510 nm and 550 nm. Turbidity was measured by absorbance at 350 nm, 510 nm and 550 nm using a Spark plate reader (Tecan, Schweiz). For this purpose, placebo and DS samples were measured in a 96-well plate under the same conditions. If sufficient sample volume (minimum 1.5 mL) was available, the turbidity of the formulated drug substance was measured in a cuvette with an inner diameter of 11 mm (HACH Lange) on a calibrated turbidimeter LAB 2100AN (HACH Lange) by comparing the measured turbidity with standards of known turbidity (<0.1, 3, 6, 18, 20 and 30 NTU according to European Pharmacopoeia 6.0, as As described in the kit user manual; HACHLanger).
[0700] 13. Subvisible particles (SVP)
[0701] Micron-sized protein aggregates and particles (subvisible particles, SVPs) are important quality attributes for therapeutic protein formulations as they pose a risk of enhancing immunogenic responses. Therefore, pharmacopoeias require quantification of subvisible particles larger than 10 μm and 25 μm and are typically performed using light obscuration (LO) techniques. Currently, the acceptance criteria for SVPs are 6000 NMT ≥ 10 μm / container and 600 NMT ≥ 25 μm / container. SVPs < 10 μm must be monitored and the acceptance criteria have not yet been determined. However, the quantification and characterization of particles with a size below 10 μm is of increasing interest and is also a regulatory expectation. In this study, measurements were performed by microfluidic imaging using FlowCam (Fluid Imaging Technologies) according to the software settings described below. Analysis was performed using the software visual spreadsheet (version 4.12.3, Fluid Imaging Technologies). According to Ph.Eur. / USP, the data are grouped by size into sub-visible particles (SVP) less than 5 μm, 5-10 μm, greater than or equal to 10 μm and greater than or equal to 25 μm. Sample and placebo measurements were performed undiluted. After each technical replicate, at least one cleaning and washing step was performed with 4% Hellmanex III (Sigma-Aldrich) and water. Sample measurements were performed only if the SST measurement using water showed no particle contamination.
[0702] It must be emphasized that according to the literature, MFI should provide higher particle counts if compared to LO, due to its higher sensitivity for particles with a refractive index close to that of the solvent (Huang et al., 2009). This is especially true for protein particles.
[0703] 14. Visual color inspection
[0704] The formulated DS was tested for appearance regarding colour according to Ph.Eur. method 2.2.2. Visible particles (Ph.Eur. method 2.9.20), clarity and opalescence (Ph.Eur. method 2.2.1) were analysed according to Ph.Eur. methods 2.9.20 and 2.2.1, respectively. The above evaluations were performed using an inspection light box equipped with a flicker-free fluorescent lamp and a black and white background plate. For colour evaluation, the samples were compared with a Ph.Eur. reference solution and freshly prepared water. The samples were evaluated for 5 s without magnification to assess the number and shape of visible particles and clarity in front of a black and white background.
[0705] 15. Analytical Ultracentrifugation
[0706] Selected samples for analysis by analytical ultracentrifugation (AUC) were sent for external analysis. At Zentriforce Pharma Research GmbH, the sedimentation curves of the samples were detected by an optical detection system. Thus, the shape, conformational changes and size distribution of the molecules could be determined.
[0707] Example 2: Basic characteristics of anti-ADM antibody (HAM8101)
[0708] As summarized in Table 2 below, the response of anti-ADM antibody (HAM8101) to different stress modes in the current buffer (20 mM His / HCL, 300 mM glycine, pH 6.0) was studied in a forced degradation study including temperature, mechanical and freeze-thaw stress. Samples were tested by SE-HPLC, CEX-HPLC / CiEF, CE-SDS (reduced / non-reduced), appearance, turbidimetry, DLS and SvP after storage for 3, 7, 14 and 21 days.
[0709] 1. Size Exclusion Chromatography (SE-HPLC)
[0710] The results of SEC-HPLC were analyzed as relative peak areas [%], the average of two replicates each measured twice was calculated, and is shown in Figure 1. In addition to storage at elevated temperatures, the samples were also stressed by overhead rotation, orbital shaking, and 5 freeze-thaw (F / T) cycles at room temperature. The SEC-HPLC results for mechanical and freeze-thaw stress are shown in Figure 2. The key results of the SEC analysis are: 1. Temperature-dependent increase in LMWS during hot storage (strongest increase at 40°C). 2. Increase in HMWS in SEC after 5 F&T cycles.
[0711] 2. Cation Exchange Chromatography (CEX-HPLC)
[0712] The results of CEX-HPLC are expressed as the average relative peak area derived from two parallel samples measured in duplicate. The results are shown in Figure 3. In addition to storage at high temperature, the samples were also stressed by overhead rotation, orbital shaking and 5 freeze-thaw (F / T) cycles at room temperature. These results are depicted in Figure 4. The CEX analysis concluded that CEX-HPLC revealed a significant increase in acidic substances during storage, especially in samples stored at 40°C. A possible explanation is "deamidation".
[0713] 3. Dynamic Light Scattering (DLS)
[0714] The DLS analysis results of the original formulation are shown in Figure 5Medium. Blue dots shifting to the right (some populations with larger particle sizes) and upwards (higher average particle size) indicate aggregation. Shifting to the left indicates fragmentation. A large number of dots indicates that the sample contains various populations with different particle sizes, i.e. hydrodynamic radii; the graph shows the average of 2 technical replicates, each evaluated for 3x100 1s acquisitions. Overall, no significant effect of stress was visible. Higher particle sizes were detected in all samples, as expected.
[0715] 4. Appearance
[0716] The results of visual appearance after stress and subsequent freezing at -80°C (Table 3), followed by another cycle of aliquoting and freezing at -80°C (Table 4) are shown below. It is noteworthy that after overnight incubation at 5°C, the visible particle burden appears to be less than a few hours after thawing the previous day. Therefore, freeze-thaw stress appears to be important.
[0717] 5.CE-SDS (reduced / non-reduced)
[0718] The results of CE-SDS are expressed as the average relative peak areas derived from two replicates measured in duplicate (see Figures 6 and 7). The key results of the CE-SDS analysis are: 1. LMWS increased after 7 days and longer at 40°C. 2. No effect of mechanical stress was detected. 3. CE-SDS data matched the SEC data.
[0719] Example 3: Design, testing and optimization of formulations to stabilize anti-ADM antibody (HAM8101) and reduce particle formation in liquid formulations during two rounds of accelerated aging - Screening DoE design
[0720] The implementation of the first round of accelerated aging and the corresponding results are presented here. The purpose of this round of screening was to investigate the impact of different parameters of the screening DoE, as shown in Table 5. The reference of anti-ADM antibody (HAM8101) was formulated in the current buffer (20mM His / HCL, 300mM glycine, pH 6.0).
[0721] The following stress conditions were selected based on the results shown in Example 2:
[0722] ·Store at 40℃±2℃ / 75±5%rH for 2 weeks
[0723] 5 freeze-thaw cycles (-80°C / +25°C) (1°C / min; plateau phase 2 hours)
[0724] Mechanical stress: orbital shaking and overhead rotation as described above.
[0725] The analytical methods employed are shown in Table 2, while the compositions of the different formulations are shown in Table 6. 1. Osmolality and Concentration
[0726] First the osmolality and concentration of the samples are described. The measured data are shown in Table 7.
[0727] 2. Dynamic Light Scattering (DLS)
[0728] The DLS analysis results of WP4a preparation are shown in Figure 8-Figure 11 The results show that for large radii (≤x6) the sensitivity is very high, early shifts are observed, and the D50 values (~5nm) confirm that most particles are within the size range of the API.
[0729] 3. Size Exclusion HPLC
[0730] The results of SEC-HPLC are expressed as the average relative peak area [%] derived from two replicates measured in duplicate and are shown in FIGS. 12 to 14 .
[0731] 4. Subvisible particles (SVP)
[0732] Here, the amount of subvisible particles of the samples was determined and the results are shown in Figures 15 and 16. In detail, the content of particles less than 5 μm, 5 to 10 μm, greater than or equal to 10 μm and greater than or equal to 25 μm was evaluated after storage for 2 weeks at 40°C or after mechanical stress.
[0733] 5. Visual Appearance
[0734] In addition, the visual appearance after mechanical stress, freeze-thaw and storage for 2 weeks at 40° C. was evaluated. The results are described in Table 8.
[0735] 6. Summary
[0736] The main focus of the formulation development was to prevent visible particles. In the screening DoE, the stressed formulations 4, 10, 11, 16, 18, 19 and 20 contained no visible particles. Most of these formulations also showed low sub-visible particle counts. In SE-HPLC and DLS analysis, no significant effect was observed. However, formulation 6 and reference formulation 21 showed significantly higher HMWS content after 5 freeze-thaw cycles. Both formulations do not contain arginine and poloxamer and have high glycine content. Based on the observed results, the following potential effects are further explored in Example 4.
[0737] Example 4: Design, testing and optimization of formulations to stabilize anti-ADM antibody (HAM8101) and reduce particle formation in liquid formulations during two rounds of accelerated aging - Screening DoE design - Optimization rounds
[0738] Based on the results of Example 3, 10 formulations were selected in addition to the current formulation (F11) and subjected to a second round of forced degradation. The stress conditions of Example 4 were the same as those used for Example 3. The compositions of the different formulations are shown in Table 9.
[0739] 1. Osmolality and concentration
[0740] First, the osmolality and concentration of the samples in Example 4 are described. The measured data are shown in Table 10.
[0741] 2. Size Exclusion HPLC
[0742] The results of SEC-HPLC are expressed as the average relative peak area [%] derived from two replicates measured in duplicate and are shown in Figures 17 and 18. Overall, significant fragmentation was detected after 4 weeks at 40°C and an effect of increased HMW levels in Formulation 11 was detected after 5 freeze-thaw cycles.
[0743] 3. AUC of pre-selected samples (1, 2, 3, 4, 10, 11)
[0744] After 3.5 weeks at 40°C, the AUC results for selected samples confirmed the results of SE-HPLC. Overall, no significant aggregation was detected, and formulation WP4b-2 showed the lowest amount (%) of LMWS and HMWS. The results are depicted in Table 11. The relative monomer content after external analysis by analytical ultracentrifugation is shown in Fig.19 middle.
[0745] 4.CE-SDS (reduced / non-reduced)
[0746] The results of non-reduced (Table 12) and reduced (Table 13) CE-SDS are expressed as the average relative peak areas of two parallel samples derived from duplicate measurements and are shown in Tables 12 and 13, respectively. The results of CE-SDS (non-reduced) showed that no obvious aggregation effect was detected after 3.5 weeks at 40°C, but obvious fragmentation was visible. In addition, the lowest fragmentation levels were observed for F01 and F02, while the highest fragmentation levels were observed for F08 and F11. It is worth noting that the results of CE-SDS (reduced) showed that there were no detectable obvious aggregation and fragmentation effects. In detail, obvious fragmentation was detected after 3.5 weeks at 40°C, and the lowest fragmentation levels were observed for F02, F03 and F09.
[0747] 5. Dynamic Light Scattering (DLS)
[0748] The DLS results after storage at 40°C and after mechanical stress are shown in FIG. 20 .
[0749] 6. Sub-visible particle analysis by FlowCam
[0750] Here, the particles were analyzed after thermal and mechanical stress. The results are shown in Figures 21 and 22.
[0751] 7. Visual Appearance
[0752] In addition, the visual appearance after mechanical stress, freeze-thaw and storage for 2 weeks at 40° C. was evaluated. The results are described in Table 14 (clear: milky white water; NVP: no visible particles; turbid: too many particles to count).
[0753] 8. Cation Exchange HPLC
[0754] The relative areas [%] of the main (upper), acidic (middle) and basic (lower) species of CEX-HPLC of formulated HAM8101 stored at 40°C ± 2°C / 75% rH ± 5% rH for up to 3.5 weeks or after mechanical stress and 5 freeze-thaw cycles were evaluated. The results are shown in Figures 23 and 24.
[0755] sheet
[0756] Table 1: Gradients used for CEX analysis
[0757] Time [min] Eluent A[%] Eluent B[%] 0 100 0 5 100 0 10 70 30 25 35 65 27 0 100 32 0 100 35 100 0 40 100 0
[0758] Table 2: Storage conditions
[0759]
[0760] Table 3: Visual appearance (color, clarity and visible particles) after stress and subsequent freezing at -80°C
[0761]
[0762] Table 4: Visual appearance (color, clarity and visible particles) after stress and subsequent freezing at -80°C, followed by aliquoting for analysis and further freezing cycles at -80°C
[0763]
[0764] Table 5: DoE excipient concentrations
[0765]
[0766] Table 6: Composition of formulations based on DoE
[0767]
[0768] Table 7: Measured osmolality in mOsmol / L (in vials A, B and placebo) and concentrations in g / L after preparation and storage (mean + SD)
[0769]
[0770]
[0771] Table 9: Formulation Matrix
[0772]
[0773] Table 10: Measured osmolality in mOsmol / L (in vials A, B) and concentrations in g / L (mean + SD) after preparation and storage
[0774]
[0775] Table 11: Results of analytical ultracentrifugation
[0776]
[0777] Table 12: Relative results of non-reduced CE SDS analysis
[0778]
[0779] Table 13: Relative results of reduced CE SDS analysis
[0780]
[0781] Table 14: Visual Appearance
[0782]
Claims
1. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment, wherein the antibody or fragment binds to the N-terminal portion of ADM (aa 1-21): YRQSMNNFQGLRSFGCRFGTC (SEQ ID No. 1), wherein the antibody or antibody fragment is present in a concentration of 1 mg / ml to 100 mg / ml, preferably 2 mg / ml to 50 mg / ml, more preferably 10 mg / ml to 30 mg / ml, more preferably 15 mg / ml to 25 mg / ml, most preferably 20 mg / ml, and wherein the aqueous pharmaceutical formulation further comprises: Arginine in the range of 1 g / L to 100 g / L, and Trehalose in the range of 1 g / L to 100 g / L, and - a surfactant selected from polysorbates and poloxamers in the range of 0.01 g / L to 5 g / L, and Histidine in the range of 0.1 g / L to 6.4 g / L, and wherein the pH of the formulation is in the range of 4.0 to 8.
0.
2. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment according to claim 1, wherein the antibody or fragment is a human monoclonal antibody or fragment thereof that binds to the N-terminal region (aa 1-21) of ADM (SEQ ID No. 1), wherein the heavy chain comprises the following sequence: CDR1: SEQ ID NO: 2 GYTFSRYW CDR2: SEQ ID NO: 3 ILPGSGST CDR3: SEQ ID NO: 4 TEGYEYDGFDY And wherein the light chain comprises the following sequence " CDR1: SEQ ID NO: 5 QSIVYSNGNTY CDR2: SEQ ID NO: 6 RVS CDR3: SEQ ID NO: 7 FQGSHIPYT.
3. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of claims 1 to 2, comprising an anti-adrenomedullin antibody directed against the N-terminal end of adrenomedullin, the antibody comprising as a heavy chain the following sequence or a sequence having >95% identity thereto: SEQ ID NO: 8 QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK and comprising as a light chain the following sequence or a sequence having >95% identity thereto: SEQ ID NO: 9 DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLE IKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
4. An aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment according to any one of claims 1 to 3, wherein the surfactant is a poloxamer.
5. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of claims 1 to 4, wherein arginine is present in the range of 1 g / L to 100 g / L, preferably 15 g / L to 60 g / L, preferably 13.1 g / L to 52.2 g / L, preferably 11.2 g / L to 44.4 g / L, more preferably 26.1 g / L.
6. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of claims 1 to 5, wherein trehalose is present in the range of 1 g / L to 100 g / L, preferably 32.6 g / L to 97.8 g / L, preferably 28.4 g / L to 85.1 g / L, preferably 24.1 g / L to 72.4 g / L, more preferably 56.7 g / L.
7. An aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment according to any one of claims 1 to 6, wherein the poloxamer is present in the range of 0.01 g / L to 5 g / L, preferably 0.115 g / L to 1.15 g / L, preferably 0.1 g / L to 1.0 g / L, preferably 0.085 g / L to 0.85 g / L, more preferably 0.5 g / L.
8. An aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment according to any one of claims 1 to 7, wherein histidine is present in the range of 0.1 g / L to 6.4 g / L, preferably 0.22 g / L to 6.88 g / L, preferably 0.8 g / L to 3.2 g / L, preferably 0.68 g / L to 3.68 g / L, more preferably 1.6 g / L.
9. An aqueous pharmaceutical formulation comprising a human or humanized anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment according to any one of claims 1 to 8, wherein the pH of the formulation is in the range of 4.0 to 8.0, preferably 5.0 to 7.0, more preferably 6.
0.
10. An aqueous pharmaceutical formulation comprising a human or humanized anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment according to any one of claims 1 to 9, wherein the formulation comprises an anti-adrenomedullin antibody comprising the N-terminal end of the sequence SEQ ID No. 1 to adrenomedullin, arginine at a concentration of 26.1 g / L, trehalose at a concentration of 56.7 g / L, poloxamer at a concentration of 0.5 g / L, histidine at a concentration of 1.6 g / L, and wherein the formulation exhibits a pH of 6.
0.
11. A lyophilized pharmaceutical preparation obtainable from the aqueous pharmaceutical preparation according to any one of claims 1 to 10.
12. A method for preparing a ready-to-use solution, the method comprising the steps of: a. Providing an aqueous pharmaceutical formulation according to any one of claims 1 to 10; b. conditioning the aqueous pharmaceutical preparation from step a) in a physiologically acceptable solution by optionally diluting the volume of the pharmaceutical preparation from step a) with a physiologically acceptable solution and by optionally dividing the pharmaceutical preparation from step a) into aliquots, wherein the diluted or adjusted aqueous pharmaceutical preparation is suitable for administration in a patient.
13. A method for preparing a ready-to-use solution, the method comprising the steps of: a. providing a lyophilized formulation obtained from an aqueous formulation according to any one of claims 1 to 10 by freeze drying and optionally without adding any other bulking agent; b. reconstitute the lyophilisate from step a) in water and / or a physiologically acceptable solution for injection; c. conditioning the reconstituted formulation from step b) in a physiologically acceptable solution by optionally diluting the volume of the reconstituted formulation from step b) with a physiologically acceptable solution and by optionally dividing the reconstituted formulation from step b) into aliquots, wherein the diluted or conditioned aqueous pharmaceutical formulation is suitable for administration in a patient.
14. A ready-to-use aqueous pharmaceutical formulation obtainable by the method according to claim 12 or 13, comprising the human or humanized anti-Adrenomedullin (ADM) antibody or anti-Adrenomedullin antibody fragment in a dose of 1 to 10 mg / kg body weight.
15. A pharmaceutical preparation according to any one of claims 1 to 10 and 14 for the treatment or prevention of an acute disease or acute condition selected from the group consisting of SIRS, severe infection, sepsis, shock selected from shock caused by hypovolemia, cardiogenic shock, obstructive shock and distributive shock, in particular cardiogenic shock, septic shock, shock caused by Covid-19, shock caused by burns and traumatic shock, acute vascular diseases such as heart failure, congestion, in particular diuretic-resistant congestion, inflammatory disorders, autoimmune diseases, metabolic diseases, brain diseases, cardiovascular diseases and drug-induced diseases, symptoms of illness or illness characterized by such symptoms, wherein the symptoms of illness are selected from nausea, headache, muscle pain, back pain, tremors and / or vomiting and migraine.
16. A pharmaceutical preparation according to any one of claims 1 to 10 and 14 for use in the treatment or prevention of an acute disease or acute condition in a patient to prevent or alleviate organ dysfunction or prevent organ failure in the patient, wherein the acute disease or acute condition is selected from, for example, severe infection, diabetes, cancer, acute and chronic vascular diseases such as heart failure, myocardial infarction, stroke, atherosclerosis, shock and organ dysfunction, renal dysfunction, liver dysfunction, burns, surgery, trauma, poisoning and injury caused by chemotherapy, and wherein the disease is not SIRS, sepsis or septic shock.
17. A pharmaceutical preparation according to any one of claims 1 to 10 and 14, for use in treating or preventing an acute disease or acute condition in a patient to regulate fluid balance, wherein the patient is a patient in need of regulating fluid balance and suffers from a disease selected from systemic inflammatory response syndrome (SIRS), sepsis, diabetes, cancer, heart failure, shock and renal dysfunction.
18. A pharmaceutical formulation according to any one of claims 1 to 10 and 14 for use in treating or preventing congestion in a patient, wherein the patient suffers from a disease or condition selected from the group consisting of congestive hypertension, swelling or water retention (edema), heart failure, in particular acute heart failure, kidney disease or liver disease.
19. A pharmaceutical preparation for treatment or prevention according to any one of claims 1 to 10 and 14 to 18, comprising: Determining the level of a pro-adrenomedullin precursor fragment selected from mid-region pro-adrenomedullin (MR-proADM), C-terminal pro-adrenomedullin (CT-proADM), Bio-ADM, ADM-gly, or pro-adrenomedullin N-terminal 20 peptide (PAMP) or a fragment thereof in a body fluid obtained from the subject prior to drug administration; and comparing the level of said pro-adrenomedullin fragment selected from MR-proADM, CT-proADM, PAMP, Bio-ADM or ADM-gly to a predefined threshold or a previously determined level of said fragment, and Wherein for relevance said pro-adrenomedullin fragment selected from MR-proADM, CT-proADM, PAMP, Bio-ADM or ADM-gly or fragments thereof above a certain threshold or an increased level above a previously determined level is used for stratification of patients for therapeutic use according to the invention.
20. A pharmaceutical preparation for treatment or prevention according to any one of claims 1 to 10, 14 to 19, for treating a patient with shock, in particular septic shock, wherein the patient: ● Suffering from shock, in particular septic shock, for no longer than 8.4 hours at the time of initiation of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, and / or ● ICU stay of no more than 8.4 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment, and / or • Not receiving any organ support or receiving organ support for no more than 8.4 hours at the start of treatment with the anti-adrenomedullin (ADM) antibody or anti-adrenomedullin antibody fragment.
21. A pharmaceutical preparation for treatment or prevention according to any one of claims 1 to 10, 14 to 20, wherein the patient is characterized in that the level of dipeptidyl peptidase 3 (DPP3) in a body fluid sample of the patient is below a threshold value before drug administration.
